var title_f31_16_32000="OUCHER pain scale";
var content_f31_16_32000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    OUCHER pain scale",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 197px; height: 600px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The OUCHER pain scale uses both pictures and numbers. The pictures can be used for preschool children, while older children can also use the numerical scale. The scales include pictures of Caucasian, African-American, Hispanic, Asian, and First Nation children. The example here depicts a Caucasian child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     The Caucasian version of the Oucher was developed and copyrighted in 1983 by Judith E Beyer, Ph.D., RN, (University of Missouri-Kansas City School of Nursing, Retired), USA. For more information, please visit",
"     <a href=\"file://www.oucher.org\" target=\"_blank\">",
"      file://www.oucher.org",
"     </a>",
"     . Reproduced with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32000=[""].join("\n");
var outline_f31_16_32000=null;
var title_f31_16_32001="Nonhormonal treatments for menopausal symptoms";
var content_f31_16_32001=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?31/16/32001/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32001/contributors\" id=\"au5618\">",
"       Richard J Santen, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?31/16/32001/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32001/contributors\" id=\"se5918\">",
"       Peter J Snyder, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32001/contributors\" id=\"se3550\">",
"       William F Crowley, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?31/16/32001/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32001/contributors\" id=\"de5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?31/16/32001?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     During a woman's reproductive years, the ovaries produce estrogen and progesterone. Estrogen is important for normal menstrual periods and fertility, and it promotes bone strength. Estrogen and progesterone levels fall at the time of menopause, causing well-known symptoms such as hot flashes.",
"    </p>",
"    <p>",
"     Postmenopausal hormone therapy is the term used to describe the two hormones, estrogen and progestin, that are the most effective treatments available to relieve bothersome symptoms of menopause. However, some women cannot take estrogen, for example, women with breast cancer. Other women choose not to take hormone therapy. Fortunately, there are some alternatives to hormone therapy to treat menopausal symptoms. Although they may not be as effective as estrogen, they do provide some relief.",
"    </p>",
"    <p>",
"     This article discusses alternatives to postmenopausal hormone therapy. A separate article discusses the risks, benefits, and options for hormone therapy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"      \"Patient information: Postmenopausal hormone therapy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      CONTROLLING HOT FLASHES",
"     </span>",
"    </p>",
"    <p>",
"     Non-estrogen treatments for hot flashes are effective in many women. None work as well as estrogen, but they are better than placebo (sugar pills). Not all women need treatment for hot flashes since they are mild in some women. Options include:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H229312250\">",
"     <span class=\"h2\">",
"      Gabapentin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gabapentin (Neurontin&reg;) is a drug that is primarily used to treat seizures. It also relieves hot flashes in some women, when given as a single bedtime dose.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Antidepressants",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antidepressant medications are recommended as a first line treatment for hot flashes in women who cannot take estrogen.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Venlafaxine (brand name Effexor&reg;), citalopram (brand name Celexa&reg;), and escitalopram (brand name Lexapro&reg;) were developed to treat depression, but studies show that they are an effective treatment for hot flashes. Paroxetine (brand name Paxil&reg;) is also effective for hot flashes, but you should not take paroxetine if you have breast cancer and are taking tamoxifen. The concern is that paroxetine can interfere with tamoxifen and make it less effective.",
"      </li>",
"      <li>",
"       Fluoxetine (brand name Prozac&reg;) is also effective, but might not work as well as venlafaxine, citalopram, escitalopram, and paroxetine. Sertraline (Zoloft&reg;) is not helpful for treating hot flashes.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Other antidepressant side effects and interactions are discussed in detail in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Progesterone",
"     </span>",
"     &nbsp;&mdash;&nbsp;The injectable progestin birth control hormone, medroxyprogesterone acetate (Depo-Provera&reg;) helps to reduce hot flashes. This option is not used as often as gabapentin or antidepressants.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Plant-derived estrogens (phytoestrogens)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Plant-derived estrogens have been marketed as a \"natural\" or \"safer\" alternative to hormones for women with menopausal symptoms. Phytoestrogens are found in many foods, including soybeans, chickpeas, lentils, flaxseed, lentils, grains, fruits, vegetables, and red clover. Isoflavone supplements, a type of phytoestrogen, can be purchased in health food stores.",
"    </p>",
"    <p>",
"     However, there is no convincing evidence that phytoestrogens help to reduce hot flashes or night sweats. In addition, some phytoestrogens might act like estrogen in some tissues of the body. Many experts suggest that women who have a history of breast cancer should avoid phytoestrogens.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Herbal treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of herbal treatments have been promoted as a \"natural\" remedy for hot flashes. In fact, many postmenopausal women use black cohosh for hot flashes, but clinical trials have shown that it is not more effective than placebo. In addition, there are safety concerns about some herbs, including black cohosh, which might stimulate breast tissue (similar to estrogen). Herbal treatments are not recommended for hot flashes or other menopausal symptoms.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      TREATING VAGINAL DRYNESS",
"     </span>",
"    </p>",
"    <p>",
"     Vaginal estrogen is a very effective treatment for postmenopausal women with vaginal dryness or pain with intercourse. This is a treatment that women can continue for many years after menopause because it does not get into the bloodstream and increase the risk of breast cancer, heart attack, or stroke. This is discussed in more detail in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=see_link\">",
"      \"Patient information: Vaginal dryness (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804590728\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5517333\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=see_link\">",
"      Patient information: Menopause (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5517342\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"      Patient information: Bone density testing (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/62/15331?source=see_link\">",
"      Patient information: Vitamin D deficiency (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=see_link\">",
"      Patient information: Vaginal dryness (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20184?source=see_link\">",
"      Androgen production and therapy in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=see_link\">",
"      Clinical manifestations and diagnosis of vaginal atrophy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40486?source=see_link\">",
"      Continuous postmenopausal hormone therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41975?source=see_link\">",
"      Estrogen and cognitive function",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"      Menopausal hot flashes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17831?source=see_link\">",
"      Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=see_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/menopause.cfm\">",
"      www.hormone.org/public/menopause.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Center for Complementary and Alternative Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://nccam.nih.gov/health/menopause/menopausesymptoms.htm\">",
"      file://nccam.nih.gov/health/menopause/menopausesymptoms.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?31/16/32001/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?31/16/32001?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32001/abstract/1\">",
"      Nedrow A, Miller J, Walker M, et al. Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med 2006; 166:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32001/abstract/2\">",
"      Pinkerton JV, Santen R. Alternatives to the use of estrogen in postmenopausal women. Endocr Rev 1999; 20:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32001/abstract/3\">",
"      North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004; 11:11.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f31_16_32001=[""].join("\n");
var outline_f31_16_32001=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           CONTROLLING HOT FLASHES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           TREATING VAGINAL DRYNESS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f31_16_32002="Interactive diabetes case 13: Deterioration of metabolic control in a 59-year-old man with type 2 diabetes complicated by retinopathy, nephropathy, and neuropathy";
var content_f31_16_32002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interactive diabetes case 13: Deterioration of metabolic control in a 59-year-old man with type 2 diabetes complicated by retinopathy, nephropathy, and neuropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32002/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32002/contributors\">",
"     Lloyd Axelrod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32002/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32002/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32002/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32002/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/16/32002/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 59-year-old man is referred to you because of uncontrolled diabetes. Fourteen years ago the patient was found to have a blood glucose level of about 300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (16.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    on a routine examination. He was treated with a program of diet, exercise, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    . The glucose level fell to the 110 to 140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.1 to 7.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    range.",
"   </p>",
"   <p>",
"    The patient relates that for the next eight years, \"I avoided it all,\" following no regimen and taking no medication for diabetes. Three years ago his A1C was 13 percent. He developed proliferative diabetic retinopathy and had a total of 11 laser treatments to both eyes and a right vitrectomy. He also developed progressive nephropathy.",
"   </p>",
"   <p>",
"    When his vision deteriorated, he saw a clinician and resumed care of his diabetes. He followed a diet, began to exercise and started to take NPH insulin, currently 52 units every day at bedtime. The A1C fell to 7.4 percent over the next nine months.",
"   </p>",
"   <p>",
"    In the last year, the glucose values, previously predictable, became erratic, with nearly normal glucose control on some days, inexplicable hyperglycemia on others, and occasional hypoglycemia before lunch. His most recent laboratory studies include a BUN of 44",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    a serum creatinine of 2.7",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    a potassium level of 5.3",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    an A1C of 9.7 percent, and 2 + proteinuria. He has aching pain in his legs, mostly at night, from his feet to the level of the mid-calf. Light touch sensation is diminished to the thighs. Vibratory sensation is absent at the great toes and reduced at the medial malleoli and tibial tubercles. Deep tendon reflexes are absent at the ankles and the knees.",
"   </p>",
"   <p>",
"    He has had nausea, abdominal pain, and intermittent constipation in the last year.",
"   </p>",
"   <p>",
"    He was evaluated for these symptoms on two occasions. Laboratory studies revealed normal values for the white blood cell count, for liver function tests, and for amylase and lipase. Supine and upright x-rays of the abdomen revealed stool in the colon, no evidence of obstruction or perforation, and no other significant abnormality. An upper GI series revealed only mild esophageal dysmotility and mild gastroesophageal reflux, but was otherwise within normal limits. There was no evidence of obstruction.",
"   </p>",
"   <p>",
"    Two years ago, after developing dyspnea while climbing stairs, he was found to have extensive coronary artery disease and had a four vessel coronary artery bypass graft. The patient's medications, in addition to insulin, include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    40 mg daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    12.5 mg daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    81 mg daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    25 mg twice a day, a multivitamin, a stool softener, and Metamucil. The patient weighs 205 pounds, is 5 feet 8 inches tall and has a body mass index of 31.2.",
"   </p>",
"   <p>",
"    How would you manage the patient?",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      You change the patient's insulin regimen from NPH 52 units every day at bedtime to glargine insulin 42 units at bedtime. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?31/16/32002-a1?source=see_link\">",
"       \"Interactive diabetes case 13: Deterioration of metabolic control in a 59-year-old man with type 2 diabetes complicated by retinopathy, nephropathy, and neuropathy - A1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      You change the patient's basal insulin regimen from NPH 52 units every day at bedtime to glargine insulin 42 units at bedtime. You also prescribe prandial (premeal) and correction doses of lispro insulin. Using the rule of 1500, you recommend a prandial dose of 1 unit for every 10 grams of carbohydrates at meals, and a correction dose of 1 unit for every elevation of 30",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      of blood glucose above 150",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      An approach to estimating the dose of short and very short-acting insulins is discussed separately. (See",
"      <a class=\"medical medical_answer\" href=\"./interactive-diabetes-case-3-hypoglycemia-in-a-patient-with-type-1-diabetes-b2?source=see_link\">",
"       \"Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - B2\"",
"      </a>",
"      and",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?31/16/32002-a2?source=see_link\">",
"       \"Interactive diabetes case 13: Deterioration of metabolic control in a 59-year-old man with type 2 diabetes complicated by retinopathy, nephropathy, and neuropathy - A2\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      You advise the patient to add a sliding scale of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      before meals and at bedtime, starting with 2 units for a blood glucose of 201 to 250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.2 to 13.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and adding 2 units for each increment of 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      (eg, 4 units for a blood glucose of 251 to 300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [13.9 to 16.7",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      up to a dose of 8 units for a blood glucose of 351 to 400",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (19.5 to 22.2",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?31/16/32002-a3?source=see_link\">",
"       \"Interactive diabetes case 13: Deterioration of metabolic control in a 59-year-old man with type 2 diabetes complicated by retinopathy, nephropathy, and neuropathy - A3\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      You advise the patient to measure the blood glucose levels seven or eight times a day, both before and after meals and at 2 or 3 am, with the intention of using a more complex insulin regimen with glargine insulin at bedtime and lispro insulin before meals. In the meantime, you recommend a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      500 mg by mouth twice a day in an effort to improve glucose control before intensifying the insulin regimen. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?31/16/32002-a4?source=see_link\">",
"       \"Interactive diabetes case 13: Deterioration of metabolic control in a 59-year-old man with type 2 diabetes complicated by retinopathy, nephropathy, and neuropathy - A4\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4175 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32002=[""].join("\n");
var outline_f31_16_32002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?31/16/32002-a1?source=related_link\">",
"      Interactive diabetes case 13: Deterioration of metabolic control in a 59-year-old man with type 2 diabetes complicated by retinopathy, nephropathy, and neuropathy - A1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?31/16/32002-a2?source=related_link\">",
"      Interactive diabetes case 13: Deterioration of metabolic control in a 59-year-old man with type 2 diabetes complicated by retinopathy, nephropathy, and neuropathy - A2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?31/16/32002-a3?source=related_link\">",
"      Interactive diabetes case 13: Deterioration of metabolic control in a 59-year-old man with type 2 diabetes complicated by retinopathy, nephropathy, and neuropathy - A3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?31/16/32002-a4?source=related_link\">",
"      Interactive diabetes case 13: Deterioration of metabolic control in a 59-year-old man with type 2 diabetes complicated by retinopathy, nephropathy, and neuropathy - A4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"./interactive-diabetes-case-3-hypoglycemia-in-a-patient-with-type-1-diabetes-b2?source=related_link\">",
"      Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - B2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_16_32003="Petit triangle nerves";
var content_f31_16_32003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Petit triangle nerves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32003=[""].join("\n");
var outline_f31_16_32003=null;
var title_f31_16_32004="Lactobacillus: Drug information";
var content_f31_16_32004=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lactobacillus: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/6/18532?source=see_link\">",
"    see \"Lactobacillus: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/5/1108?source=see_link\">",
"    see \"Lactobacillus: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bacid&reg; [OTC];",
"     </li>",
"     <li>",
"      Culturelle&reg; [OTC];",
"     </li>",
"     <li>",
"      Dofus [OTC];",
"     </li>",
"     <li>",
"      Flora-Q&trade; [OTC];",
"     </li>",
"     <li>",
"      Floranex&trade; [OTC];",
"     </li>",
"     <li>",
"      Kala&reg; [OTC];",
"     </li>",
"     <li>",
"      Lactinex&trade; [OTC];",
"     </li>",
"     <li>",
"      Lacto-Bifidus [OTC];",
"     </li>",
"     <li>",
"      Lacto-Key [OTC];",
"     </li>",
"     <li>",
"      Lacto-Pectin [OTC];",
"     </li>",
"     <li>",
"      Lacto-TriBlend [OTC];",
"     </li>",
"     <li>",
"      Megadophilus&reg; [OTC];",
"     </li>",
"     <li>",
"      MoreDophilus&reg; [OTC];",
"     </li>",
"     <li>",
"      RisaQuad&reg;-2 [OTC];",
"     </li>",
"     <li>",
"      RisaQuad&trade; [OTC];",
"     </li>",
"     <li>",
"      Superdophilus&reg; [OTC];",
"     </li>",
"     <li>",
"      VSL #3&reg; [OTC];",
"     </li>",
"     <li>",
"      VSL #3&reg;-DS",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bacid&reg;;",
"     </li>",
"     <li>",
"      Fermalac",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F186500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Dietary Supplement;",
"     </li>",
"     <li>",
"      Probiotic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F186488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement: Oral: Dosing varies by manufacturer; consult product labeling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     Bacid&reg;: 2 caplets/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Culturelle&reg;: 1 capsule daily; may increase to twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Flora-Q&trade;: 1 capsule/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lacto-Key 100 or 600: 1-2 capsules/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lactinex&trade;: 1 packet or 4 tablets 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     VSL #3&reg;: 1-8 sachets or 2-32 capsules/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     VSL #3&reg;-DS: 1-4 packets/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F186495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/5/1108?source=see_link\">",
"      see \"Lactobacillus: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement: Oral: Dosing varies by manufacturer; consult product labeling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     Culturelle&reg;: 1 capsule daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F186489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Culturelle&reg;:",
"     <i>",
"      L. rhamnosus",
"     </i>",
"     GG 10 billion colony-forming units [contains casein and whey]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dofus:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     and",
"     <i>",
"      L. bifidus",
"     </i>",
"     10:1 ratio [beet root powder base]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Flora-Q&trade;:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     and",
"     <i>",
"      L.  paracasei",
"     </i>",
"     &ge;8 billion colony-forming units [also contains",
"     <i>",
"      Bifidobacterium",
"     </i>",
"     and",
"     <i>",
"      S. thermophilus",
"     </i>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lacto-Key:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     100:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     1 billion colony-forming units [milk, soy, and yeast free; rice derived]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     600:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     6 billion colony-forming units [milk, soy, and yeast free; rice derived]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lacto-Bifidus:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     100:",
"     <i>",
"      L. bifidus",
"     </i>",
"     1 billion colony-forming units [milk, soy, and yeast free; rice derived]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     600:",
"     <i>",
"      L. bifidus",
"     </i>",
"     6 billion colony-forming units [milk, soy, and yeast free; rice derived]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lacto-Pectin:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     and",
"     <i>",
"      L.  casei",
"     </i>",
"     &ge;5 billion colony-forming units [also contains",
"     <i>",
"      Bifidobacterium lactis",
"     </i>",
"     and citrus pectin cellulose complex]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lacto-TriBlend:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     100:",
"     <i>",
"      L. acidophilus,  L. bifidus,",
"     </i>",
"     and",
"     <i>",
"      L. bulgaricus",
"     </i>",
"     1 billion colony-forming units [milk, soy and yeast free; rice derived]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     600:",
"     <i>",
"      L. acidophilus, L. bifidus,",
"     </i>",
"     and",
"     <i>",
"      L. bulgaricus",
"     </i>",
"     6 billion colony-forming units [milk, soy and yeast free; rice derived]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Megadophilus&reg;, Superdophilus&reg;:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     2 billion units [available in dairy based or dairy free formulations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     RisaQuad&trade;:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     and",
"     <i>",
"      L. paracasei",
"     </i>",
"     8 billion colony-forming units [also includes",
"     <i>",
"      Bifidobacterium",
"     </i>",
"     and",
"     <i>",
"      Streptococcus thermophilus",
"     </i>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     VSL #3&reg;:",
"     <i>",
"      L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus",
"     </i>",
"     112 billion live cells [also contains",
"     <i>",
"      Bifidobacterium breve, B. longum, B. infantis,",
"     </i>",
"     and",
"     <i>",
"      Streptococcus thermophilus",
"     </i>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, double strength:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     RisaQuad&reg;-2:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     and",
"     <i>",
"      L. paracasei",
"     </i>",
"     16 billion colony-forming units [gluten free; also includes",
"     <i>",
"      Bifidobacterium",
"     </i>",
"     and",
"     <i>",
"      Streptococcus thermophilus",
"     </i>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Capsule, softgel:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     100 active units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Caplet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Bacid&reg;:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     and",
"     <i>",
"      L. bulgaricus",
"     </i>",
"     [also contains",
"     <i>",
"      Bifidobacterium biffidum",
"     </i>",
"     and",
"     <i>",
"      Streptococcus  thermophilus",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Floranex&trade;:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     and",
"     <i>",
"      L. bulgaricus",
"     </i>",
"     100 million live cells per 1 g packet (12s) [contains milk, sodium 5 mg/packet, soy]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lactinex&trade;:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     and",
"     <i>",
"      L. bulgaricus",
"     </i>",
"     100 million live cells per 1 g packet (12s) [gluten free; contains calcium 5 mg/packet, lactose 380 mg/packet, potassium 20 mg/packet, sodium 5 mg/packet, sucrose 34 mg/packet, whey, evaporated milk, and soy peptone]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Powder:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lacto-TriBlend:",
"     <i>",
"      L. acidophilus, L. bifidus,",
"     </i>",
"     and",
"     <i>",
"      L. bulgaricus",
"     </i>",
"     10 billion colony-forming units per &frac14; teaspoon (60 g) [milk, soy, and yeast free; rice derived]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Megadophilus&reg;, Superdophilus&reg;:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     2 billion units per half-teaspoon (49 g, 70 g, 84 g, 126 g) [available in dairy based or dairy free (garbanzo bean) formulations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     MoreDophilus&reg;:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     12.4 billion units per teaspoon (30 g, 120 g) [dairy free, yeast free; soy and carrot derived]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     VSL #3&reg;:",
"     <i>",
"      L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus",
"     </i>",
"     450 billion live cells per sachet (10s, 30s) [gluten free; also contains",
"     <i>",
"      Bifidobacterium breve, B. longum, B. infantis",
"     </i>",
"     , and",
"     <i>",
"      Streptococcus thermophilus",
"     </i>",
"     ; lemon cream flavor and unflavored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     VSL #3&reg;-DS:",
"     <i>",
"      L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus",
"     </i>",
"     900 billion live cells per packet (20s,) [gluten free; also contains",
"     <i>",
"      Bifidobacterium breve, B. longum, B. infantis",
"     </i>",
"     , and",
"     <i>",
"      Streptococcus thermophilus",
"     </i>",
"     ]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Kala&reg;:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     200 million units [dairy free, yeast free; soy based]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Tablet, chewable:",
"     <i>",
"      L. reuteri",
"     </i>",
"     100 million organisms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Floranex&trade;:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     and",
"     <i>",
"      L. bulgaricus",
"     </i>",
"     1 million colony-forming units [contains lactose, nonfat dried milk, whey]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lactinex&trade;:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     and",
"     <i>",
"      L. bulgaricus",
"     </i>",
"     1 million live cells [gluten free; contains calcium 5.2 mg/4 tablets, lactose 960 mg/4 tablets, potassium 20 mg/4 tablets, sodium 5.6 mg/4 tablets, and sucrose  500 sucrose/4 tablets; contains whey, evaporated milk, and soy peptone]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Wafer:",
"     <i>",
"      L. acidophilus",
"     </i>",
"     90 mg and",
"     <i>",
"      L. bifidus",
"     </i>",
"     25 mg (100s) [provides 1 billion organisms/wafer at time of manufacture; milk free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F186474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Culturelle&reg;: Capsules may be opened and mixed in a cool beverage or sprinkled onto baby food or applesauce.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flora-Q&trade;: May be taken with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lactinex&trade;: Granules may be added to or administered with cereal, food, or milk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Megadophilus&reg;, Superdophilus&reg;: Administer on an empty stomach; powder should be mixed in unchilled water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VSL #3&reg;, VSL #3&reg;-DS: Powder may be mixed in any cold, noncarbonated beverage or mixed with any cold food such as yogurt or apple sauce.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F186473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promote normal bacterial flora of the intestinal tract",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F186498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gastrointestinal: Bloating (intestinal), flatulence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F186477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F186463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <i>",
"      Lactobacillus",
"     </i>",
"     species have been studied for various gastrointestinal disorders including diarrhea, inflammatory bowel disease, gastrointestinal infection. Effectiveness may be dependent upon actual species used; studies are ongoing. Currently, there are no FDA-approved disease-prevention or therapeutic indications for these products.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F186467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F186479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain potassium and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F186478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Culturelle Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 B cell (30): $17.32",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F186480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Lacteol Fort (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F186462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Helps re-establish normal intestinal flora; suppresses the growth of potentially pathogenic microorganisms by producing lactic acid which favors the establishment of an aciduric flora.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F186476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Local, primarily colon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9541 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-708A4DD6E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32004=[""].join("\n");
var outline_f31_16_32004=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186486\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186487\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186500\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186488\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186495\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186489\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160247\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160248\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186472\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186459\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186474\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186473\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186498\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186477\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186463\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299569\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186467\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186479\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186478\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186480\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186462\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186476\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9541\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9541|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/6/18532?source=related_link\">",
"      Lactobacillus: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/5/1108?source=related_link\">",
"      Lactobacillus: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_16_32005="Use of GnRH agonists in the treatment of hyperandrogenism and hirsutism";
var content_f31_16_32005=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of GnRH agonists in the treatment of hyperandrogenism and hirsutism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32005/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32005/contributors\">",
"     Jeffrey Chang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32005/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32005/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32005/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32005/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32005/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/16/32005/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperandrogenism and hirsutism in women are most commonly due to idiopathic hirsutism and the polycystic ovary syndrome (PCOS). The options for drug therapy for these women are oral contraceptives, anti-androgens, and gonadotropin-releasing hormone (GnRH) agonists. Consideration of GnRH agonist therapy is based upon the assumption that the hyperandrogenism is at least in part gonadotropin-dependent, because the action of chronic GnRH agonist therapy (as opposed to physiologic endogenous pulsatile GnRH secretion) is to inhibit luteinizing hormone (LH) and to a lesser extent follicle-stimulating hormone secretion, thereby leading to a decline in ovarian function and consequently ovarian androgen production (",
"    <a class=\"graphic graphic_figure graphicRef51212 \" href=\"UTD.htm?19/58/20398\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=see_link\">",
"     \"Physiology of gonadotropin-releasing hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of GnRH agonist therapy in women with hyperandrogenism and hirsutism will be reviewed here. Any therapy that decreases androgen production, such as the administration of a GnRH agonist, must be continued for at least six months before its efficacy can be judged. Decreasing androgen secretion slows the growth of new hair follicles, but has little effect on existing ones, which must complete their life span before the hair is lost. Other therapies for hirsutism are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"     \"Treatment of hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;GnRH agonist therapy should be considered for those women with ovarian hyperandrogenism who do not respond adequately to oral contraceptive therapy with or without an antiandrogen such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/17/27928?source=see_link\">",
"     \"Use of combination estrogen-progestin contraceptives in the treatment of hyperandrogenism and hirsutism\"",
"    </a>",
"    .) This situation is most likely to occur in women who have marked menstrual disturbances and signs of virilization in addition to hirsutism. Unlike women with hirsutism alone, these women usually have unequivocal increases in serum testosterone concentrations and PCOS or ovarian hyperthecosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=see_link\">",
"     \"Pathogenesis and causes of hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reasons for not using a GnRH agonist as primary therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GnRH agonist therapy alone causes severe hypoestrogenism, and therefore estrogen-progestin supplementation must be given if therapy is continued for more than a few months, as is necessary in women with hyperandrogenism.",
"     </li>",
"     <li>",
"      The agonist must be given parenterally and is therefore inconvenient.",
"     </li>",
"     <li>",
"      The cost of GnRH agonist therapy is high compared with other available therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2008, the Endocrine Society published clinical guidelines for the evaluation and treatment of hirsutism in premenopausal women. They suggested against the routine use of GnRH agonists for hirsutism, for the reasons noted above, and because there are other effective therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32005/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of GnRH agonist therapy alone in women with ovarian hyperandrogenism has been demonstrated in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32005/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. One study, as an example, evaluated eight women with PCOS, and compared their serum hormonal values in response to daily injection of a GnRH agonist for six months with the values in women who had undergone bilateral oophorectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32005/abstract/4\">",
"     4",
"    </a>",
"    ]. Serum estradiol, estrone, progesterone, androstenedione, and testosterone concentrations decreased in one month to the concentrations present in the women after oophorectomy, and remained low thereafter.",
"    <strong>",
"     Adrenal",
"    </strong>",
"    steroid production was not affected. Four of the women with PCOS had hot flashes, five had decreased hair growth, and all had a subjective reduction in skin oiliness.",
"   </p>",
"   <p>",
"    In another study, six women with hirsutism were treated with the GnRH agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26580?source=see_link\">",
"     nafarelin",
"    </a>",
"    for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32005/abstract/5\">",
"     5",
"    </a>",
"    ]. Their serum androgen concentrations decreased markedly within one month; as an example, the mean serum total testosterone concentration fell from 77 to 40",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (2.7 to 1.4",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    the mean serum free testosterone concentration decreased from 1.1 to 0.4",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (38 to 14",
"    <span class=\"nowrap\">",
"     pmol/L),",
"    </span>",
"    and the mean serum androstenedione concentration decreased from 240 to 120",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (8.4 to 4.2",
"    <span class=\"nowrap\">",
"     nmol/L);",
"    </span>",
"    the values remained low for the remainder of the treatment period. Clinically, hair growth slowed, hair texture became finer, and the Ferriman-Gallwey hirsutism score decreased in four women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COMBINED GnRH AGONIST-ESTROGEN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of GnRH agonist therapy in reducing ovarian androgen and estrogen secretion, paired with the unacceptability of severe estrogen deficiency in premenopausal women, led to studies of combined GnRH agonist and estrogen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32005/abstract/6-14\">",
"     6-14",
"    </a>",
"    ]. A progestin must also be given to ensure regular endometrial shedding and avoid endometrial hyperplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy of combined therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen does not appear to interfere with the beneficial effect of GnRH agonist therapy on excessive hair growth, and may even enhance it. As an example, a six-month study randomly assigned 22 women with hirsutism to receive the long-acting GnRH agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/11/9398?source=see_link\">",
"     triptorelin",
"    </a>",
"    (Decapeptyl) alone or with estrogen therapy (0.625",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of conjugated estrogens for 21",
"    <span class=\"nowrap\">",
"     days/month",
"    </span>",
"    and 10 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    on days 12 to 21) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32005/abstract/6\">",
"     6",
"    </a>",
"    ]. Serum androgen concentrations decreased in both groups, although the reductions in serum total and free testosterone were greater in the group receiving combined GnRH agonist-estrogen therapy. The Ferriman-Gallwey hirsutism score also decreased more in the women receiving combined therapy (4.1 versus 2.5), while vasomotor symptoms occurred only in the women receiving triptorelin alone.",
"   </p>",
"   <p>",
"    A second study found similar reductions in serum androgen concentrations in women receiving the GnRH agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    alone or with estrogen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32005/abstract/11\">",
"     11",
"    </a>",
"    ]. Bleeding and premenstrual symptoms necessitated withdrawal of therapy in 3 of 10 women treated with estrogen.",
"   </p>",
"   <p>",
"    An oral contraceptive also can be given to prevent estrogen deficiency without altering the therapeutic efficacy of the GnRH agonist [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32005/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. In one study, as an example, 33 women with hirsutism were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    alone, leuprolide plus a combination monophasic oral contraceptive, or an oral contraceptive alone [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32005/abstract/7\">",
"     7",
"    </a>",
"    ]. The fall in serum free testosterone concentrations was significantly greater in the leuprolide plus oral contraceptive group as compared with either of the other groups, because the leuprolide reduced ovarian testosterone secretion and the estrogen raised serum sex hormone-binding globulin concentrations, thereby increasing binding of the testosterone that was produced. However, the greater decrease in serum free testosterone concentrations in the combined therapy group was not associated with greater clinical benefit; the decreases in facial hair density and hirsutism score were similar in both GnRH therapy groups.",
"   </p>",
"   <p>",
"    The combination of a GnRH agonist and an oral contraceptive is somewhat less effective (and far more costly) than antiandrogen and oral contraceptive therapy. In a study of 38 women with hirsutism randomly assigned to receive an oral contraceptive and either the GnRH agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/11/9398?source=see_link\">",
"     triptorelin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    for nine months, the Ferriman-Gallwey scores decreased by 28, 33, and 47 percent in the three groups, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32005/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When GnRH agonist therapy is started, there is a transient increase in gonadotropin and therefore in estrogen secretion, which can cause bloating and breast tenderness. Thus, the initiation of estrogen replacement should be",
"    <strong>",
"     delayed",
"    </strong>",
"    until the woman begins to have hot flashes, or for six to eight weeks, whichever is sooner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prevention of side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of estrogen (add-back therapy) in any form ameliorates or prevents hot flushes and vaginal dryness in women treated with a GnRH agonist (",
"    <a class=\"graphic graphic_table graphicRef58788 \" href=\"UTD.htm?43/31/44539\">",
"     table 1",
"    </a>",
"    ). It also minimizes bone loss. Those women treated with a GnRH agonist and an oral contraceptive had no loss of bone density in two reports [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32005/abstract/12,16\">",
"     12,16",
"    </a>",
"    ], while in other studies women given a GnRH agonist and low-dose estrogen lost less bone than women given the agonist alone [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32005/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFICACY OF GnRH AGONISTS IN SPECIAL CIRCUMSTANCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of GnRH agonists in women with PCOS and hyperthecosis presents some separate challenges.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Polycystic ovary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCOS is a prime example of gonadotropin-dependent hyperandrogenism, and these women should be ideal candidates for GnRH agonist therapy. However, several factors need to be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some women with PCOS have a small increase in adrenal androgen production (",
"      <a class=\"graphic graphic_table graphicRef60049 \" href=\"UTD.htm?19/41/20123\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/0/12?source=see_link\">",
"       \"Steroid hormone metabolism in polycystic ovary syndrome\"",
"      </a>",
"      .) GnRH agonist therapy does not reduce adrenal androgen secretion.",
"     </li>",
"     <li>",
"      Depending upon the severity of hair growth, some women may not achieve their desired cosmetic goal. There are ethnic and familial traits that may render a woman more likely to develop hirsutism and less likely to have a satisfactory response to any reduction in serum androgen concentrations. As an example, women of Middle Eastern extraction tend to have more facial and body hair.",
"     </li>",
"     <li>",
"      Women with PCOS are often obese, and complete suppression of ovarian steroidogenesis during GnRH agonist therapy may not be achieved due to an inadequate dose relative to weight. This possibility is suggested by a lack of hypoestrogenic symptoms (eg, vasomotor instability or vaginal dryness) soon after the initiation of treatment, and can be confirmed by measurement of serum estradiol. If the concentration is not low, then the dose of GnRH agonist should be increased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ovarian hyperthecosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This uncommon condition of young women represents an extremely severe form of ovarian hyperandrogenism. These women characteristically have not only marked hirsutism and menstrual irregularity, but also some virilization. Most also have marked hyperinsulinemia, which probably contributes substantially to their excess androgen production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38662?source=see_link\">",
"     \"Ovarian hyperthecosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few reported studies of GnRH agonist therapy in women with hyperthecosis. In one woman, daily GnRH agonist administration for six months nearly completely inhibited ovarian steroid production [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32005/abstract/17\">",
"     17",
"    </a>",
"    ], but her hirsutism changed little, probably because it was long-standing and severe. GnRH should be effective in these women, and its use should always be considered because the only other available treatment of any efficacy is oophorectomy.",
"   </p>",
"   <p>",
"    Hyperthecosis in postmenopausal women represents a different challenge. These women develop stromal hyperplasia because of the increase in gonadotropin secretion induced by ovarian senescence. In addition, the ovaries are usually enlarged. Most of these women are treated by oophorectomy because of the possibility of ovarian tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of GnRH agonist and estrogen-progestin therapy is effective in women with ovarian hyperandrogenism. However, the complicated nature of the treatment and its expense make it suitable only for those women who have responded poorly to oral contraceptive or anti-androgen therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"     \"Treatment of hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Recommended treatment regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;When GnRH therapy is indicated, a suitable regimen is intramuscular administration of a depot preparation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    (Lupron Depot) in a dose of 3.75 mg monthly until hot flashes appear, at which time estrogen-progestin therapy should be initiated. If no vasomotor or hypoestrogenic symptoms occur by two months, then serum estradiol should be measured to determine the extent of ovarian suppression. If it is incomplete, the dose of leuprolide should be increased by 50 percent. Once a satisfactory dose has been achieved, estrogen-progestin therapy should be added. It is usually given in the form of daily conjugated estrogens (0.030 to 0.625 mg) and intermittent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (5 to 10 mg). The woman should be reevaluated at regular intervals, and if after six months of therapy there has been no improvement in hirsutism, serum testosterone should be measured to determine the extent of ovarian suppression.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/1\">",
"      Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/2\">",
"      Chang RJ, Laufer LR, Meldrum DR, et al. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab 1983; 56:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/3\">",
"      Rittmaster RS, Thompson DL. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. J Clin Endocrinol Metab 1990; 70:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/4\">",
"      Steingold K, De Ziegler D, Cedars M, et al. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. J Clin Endocrinol Metab 1987; 65:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/5\">",
"      Andreyko JL, Monroe SE, Jaffe RB. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin). J Clin Endocrinol Metab 1986; 63:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/6\">",
"      Carmina E, Janni A, Lobo RA. Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism. J Clin Endocrinol Metab 1994; 78:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/7\">",
"      Elkind-Hirsch KE, Anania C, Mack M, Malinak R. Combination gonadotropin-releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism. Fertil Steril 1995; 63:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/8\">",
"      Falsetti L, Pasinetti E. Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism. Fertil Steril 1994; 61:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/9\">",
"      Ciotta L, Cianci A, Giuffrida G, et al. Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease. Fertil Steril 1996; 65:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/10\">",
"      Azziz R, Ochoa TM, Bradley EL Jr, et al. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. J Clin Endocrinol Metab 1995; 80:3406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/11\">",
"      Tiitinen A, Simberg N, Stenman UH, Ylikorkala O. Estrogen replacement does not potentiate gonadotropin-releasing hormone agonist-induced androgen suppression in treatment of hirsutism. J Clin Endocrinol Metab 1994; 79:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/12\">",
"      Carr BR, Breslau NA, Givens C, et al. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study. J Clin Endocrinol Metab 1995; 80:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/13\">",
"      Lemay A, Faure N. Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study. J Clin Endocrinol Metab 1994; 79:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/14\">",
"      Heiner JS, Greendale GA, Kawakami AK, et al. Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism. J Clin Endocrinol Metab 1995; 80:3412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/15\">",
"      Pazos F, Escobar-Morreale HF, Balsa J, et al. Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Fertil Steril 1999; 71:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/16\">",
"      Castelo-Branco C, Mart&iacute;nez de Osaba MJ, Pons F, Fortuny A. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use. Metabolism 1997; 46:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32005/abstract/17\">",
"      Steingold KA, Judd HL, Nieberg RK, et al. Treatment of severe androgen excess due to ovarian hyperthecosis with a long-acting gonadotropin-releasing hormone agonist. Am J Obstet Gynecol 1986; 154:1241.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7388 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32005=[""].join("\n");
var outline_f31_16_32005=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COMBINED GnRH AGONIST-ESTROGEN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy of combined therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prevention of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFICACY OF GnRH AGONISTS IN SPECIAL CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ovarian hyperthecosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Recommended treatment regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7388\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7388|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/58/20398\" title=\"figure 1\">",
"      Continuous GnRH LH and FSH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7388|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/31/44539\" title=\"table 1\">",
"      GnRH add back regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/41/20123\" title=\"table 2\">",
"      Androgens in PCOS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38662?source=related_link\">",
"      Ovarian hyperthecosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=related_link\">",
"      Pathogenesis and causes of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=related_link\">",
"      Physiology of gonadotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/12?source=related_link\">",
"      Steroid hormone metabolism in polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=related_link\">",
"      Treatment of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/17/27928?source=related_link\">",
"      Use of combination estrogen-progestin contraceptives in the treatment of hyperandrogenism and hirsutism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_16_32006="Regorafenib: Drug information";
var content_f31_16_32006=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Regorafenib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/33/2582?source=see_link\">",
"    see \"Regorafenib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F15125802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15231623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Stivarga&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15125803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor;",
"     </li>",
"     <li>",
"      Vascular Endothelial Growth Factor (VEGF) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15233627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Colorectal cancer, metastatic:",
"     </b>",
"     Oral: 160 mg once daily for the first 21 days of each 28-day cycle; continue until disease progression or unacceptable toxicity (Grothey, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gastrointestinal stromal tumor (GIST), locally-advanced, unresectable, or metastatic:",
"     </b>",
"     Oral: 160 mg once daily for the first 21 days of each 28-day cycle; continue until disease progression or unacceptable toxicity (Demetri, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Missed doses:",
"     </i>",
"     Do not administer 2 doses on the same day to make up for a missed dose from the previous day.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15233628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15233629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pre-existing mild impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     60-89 mL/minute): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pre-existing moderate impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-59 mL/minute): No dosage adjustment provided in manufacturer&rsquo;s labeling (limited pharmacokinetic data available).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pre-existing severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15233630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pre-existing mild or moderate impairment (Child-Pugh Class A or B): No dosage adjustment necessary; closely monitor for adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pre-existing severe impairment (Child-Pugh Class C): Use is not recommended (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatotoxicity during treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 3 AST and/or ALT elevation: Withhold dose until recovery. If benefit of treatment outweighs toxicity risk, resume therapy at a reduced dose of 120 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AST or ALT &gt;20 times ULN: Discontinue permanently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AST or ALT &gt;3 times ULN",
"     <b>",
"      and",
"     </b>",
"     bilirubin &gt;2 times ULN: Discontinue permanently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Recurrence of AST or ALT &gt;5 times ULN despite dose reduction to 120 mg: Discontinue permanently.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F15233631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 2 hand-foot skin reaction (HFSR; palmar-plantar erythrodysesthesia [PPE]) of any duration: Reduce dose to 120 mg once daily for first occurrence. If grade 2 HFSR recurs at this dose, further reduce the dose to 80 mg once daily. Interrupt therapy for grade 2 HFSR that is recurrent or fails to improve within 7 days in spite of dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 3 HFSR: Interrupt therapy for a minimum of 7 days. Upon recovery, reduce dose to 120 mg once daily. If grade 2-3 toxicity recurs at this dose, further reduce dose to 80 mg once daily upon recovery. Interrupt therapy for grade 2-3 HFSR that is recurrent or fails to improve within 7 days in spite of dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Recurrent or persistent HFSR at 80 mg once daily: Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypertension: Grade 2 (symptomatic): Interrupt therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Other toxicity: Any grade 3 or 4 adverse reaction (other than hepatotoxicity): Interrupt therapy; upon recovery, reduce dose to 120 mg once daily. If any grade 3 or 4 adverse reaction occurs while on this reduced dose, may further reduce dose to 80 mg once daily upon recovery. For any grade 4 adverse reaction, only resume therapy if the benefit outweighs the risk. Permanently discontinue therapy if unable to tolerate 80 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal perforation/fistula: Discontinue permanently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemorrhage (severe or life-threatening): Discontinue permanently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reversible posterior leukoencephalopathy syndrome (RPLS): Discontinue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Wound dehiscence: Discontinue.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15234639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stivarga&reg;: 40 mg [contains soy lecithin]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15231624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F15800734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Regorafenib is available only through the REACH support program. Information regarding program enrollment may be found at file://www.stivarga-us.com/access_stivarga.html or by calling 1-866-639-2827.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15233633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take at the same time each day with a low-fat (&lt;30% fat) breakfast; swallow tablets whole.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15125762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic colorectal cancer in patients previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, or anti-EGFR therapy (if",
"     <i>",
"      KRAS",
"     </i>",
"     wild type); treatment of locally-advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) in patients previously treated with imatinib and sunitinib",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15231622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Regorafenib may be confused with axitinib, crizotinib, dasatinib, erlotinib, imatinib, lapatinib, nilotinib, pazopanib, ponatinib, ruxolitinib, sorafenib, sunitinib, vemurafenib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15237409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (30% to 59%; grade &ge;3: 8% to 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (52% to 64%), dysphonia (30% to 39%), pain (29%), fever (21% to 28%), headache (10% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Palmar-plantar erythrodysesthesia (45% to 67%; grade &ge;3: 17% to 22%), rash (26% to 30%; grade &ge;3: 6% to 7%), alopecia (8% to 24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypocalcemia (17% to 59%), hypophosphatemia (55% to 57%), hyponatremia (30%), hypokalemia (21% to 26%), hypothyroidism (4% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Appetite decreased (31% to 47%), lipase increased (14% to 46%), diarrhea (43% to 47%), mucositis (33% to 40%), weight loss (14% to 32%), amylase increased (26%), nausea (20%), vomiting (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (79%; grade 3: 5%; grade 4: 1%), lymphopenia (30% to 54%; grade 3: 8% to 9%), thrombocytopenia (13% to 41%; grade 3: 1% to 2%; grade 4: &lt;1%), INR increased (24%), hemorrhage (11% to 21%; grade &ge;3: 2% to 4%), neutropenia (3% to 16%; grade 3: 1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: AST increased (58% to 65%; grade 3: 3% to 5%; grade 4: 1%), ALT increased (39% to 45%; grade 3: 4% to 5%; grade 4: 1%), hyperbilirubinemia (33% to 45%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Stiffness (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Proteinuria (33% to 60%; grade 3: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (31% to 32%; grade &ge;3: 5% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Myocardial ischemia and infarction (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Taste disturbance (8%), xerostomia (5%), gastroesophageal reflux (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Tremor (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Erythema multiforme, gastrointestinal fistula, hypertensive crisis, liver injury (severe), liver failure, reversible posterior encephalopathy syndrome (RPLS), skin cancer (keratoacanthoma, squamous cell carcinoma), Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15233578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15233598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular events: Myocardial ischemia and infarction were observed at a higher incidence than placebo in a clinical trial. Interrupt therapy in patients who develop new or acute onset ischemia or infarction; resume only if the benefit of therapy outweighs the cardiovascular risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dermatological toxicity: Hand-foot skin reaction (HFSR), also known as palmar-plantar erythrodysesthesia (PPE), and rash were commonly seen in clinical trials; erythema multiforme and Stevens Johnson syndrome were also observed more frequently in regorafenib-treated patients. Toxic epidermal necrolysis occurred rarely. Onset of dermatologic toxicity typically occurs in the first cycle of treatment. Therapy interruptions, dosage reductions, and/or discontinuation may be necessary depending on the severity and persistence. Supportive treatment may be of benefit for symptomatic relief.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Gastrointestinal perforation: Gastrointestinal perforation or fistula has occurred in a small number of patients treated with regorafenib; some cases were fatal. Monitor for signs/symptoms of perforation (fever, abdominal pain with constipation, and/or nausea/vomiting); permanently discontinue if perforation or fistula develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hemorrhage: The incidence of hemorrhage was increased with regorafenib. Hemorrhage of the respiratory, gastrointestinal, or genitourinary tracts was observed in trials; some cases were fatal. Permanently discontinue in patients who experience severe or life-threatening bleeding. In patients receiving concomitant warfarin, monitor INR frequently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Severe liver toxicity and hepatic failure (sometimes resulting in death) have been observed in clinical trials; hepatocyte necrosis with lymphocyte infiltration has been demonstrated with liver biopsy. Monitor hepatic function at baseline and during treatment. Interrupt therapy for hepatotoxicity; dose reductions or discontinuation are necessary depending on the severity and persistence.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertension: Elevated blood pressure was observed in clinical trials (onset typically in the first cycle of therapy); ensure blood pressure is adequately controlled prior to initiation. Monitor blood pressure weekly for the first 6 weeks and monthly thereafter or as clinically indicated; if hypertension develops, interrupt therapy or permanently discontinue for severe or uncontrolled hypertension. Hypertensive crisis has occurred in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Reversible posterior leukoencephalopathy syndrome (RPLS): RPLS occurred very rarely in regorafenib-treated patients; evaluate promptly if symptoms (eg, seizures, headache, visual disturbances, confusion or altered mental function) occur. Discontinue if diagnosis is confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Wound healing impairment: Regorafenib inhibits vascular endothelial growth factor, which may lead to impaired wound healing. Stop therapy at least 2 weeks prior to scheduled surgery; resume regorafenib postsurgery based on clinical judgment of wound healing; discontinue if wound dehiscence occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15255943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), UGT1A9;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     BCRP, P-glycoprotein, UGT1A1, UGT1A9",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15255941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Regorafenib may increase serum concentrations of the active metabolite(s) of Irinotecan. Regorafenib may increase the serum concentration of Irinotecan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: May enhance the adverse/toxic effect of Regorafenib. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F15233600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Regorafenib serum concentrations may be altered when taken with grapefruit or grapefruit juice. Management: Avoid concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may alter the levels/effects of regorafenib. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15233558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15233559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In animal reproduction studies, teratogenic effects were observed with doses less than the equivalent human dose. Patients (male and female) should use effective contraception during therapy and for at least 2 months following treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15233560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15233561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if regorafenib is excreted into breast milk. According to the manufacturer, the decision to discontinue regorafenib or to discontinue breast-feeding during therapy should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F15233632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with a low-fat breakfast (&lt;30% fat)",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Stivarga Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (28): $3740.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15233635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for hand-foot skin reaction (HFSR)/palmar-plantar erythrodysesthesia (PPE); signs/symptoms of cardiac ischemia or infarction; bleeding; signs/symptoms of GI perforation or fistula; signs/symptoms of reversible posterior leukoencephalopathy syndrome (severe headaches, seizure, confusion, or change in vision). Monitor for impaired wound healing. Obtain liver function tests at baseline, every 2 weeks during the first 2 months of treatment, then monthly or more frequently if clinically necessary (weekly until improvement if liver function tests are elevated). Monitor blood pressure weekly for the first 6 weeks of therapy and with every subsequent cycle, or more frequently if indicated. CBC with differential and platelets and serum electrolytes (baseline and periodic). Monitor INR more frequently if receiving warfarin.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15233602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Regorafenib is a multikinase inhibitor; it targets kinases involved with tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment which results in inhibition of tumor growth. Specifically, it inhibits VEGF receptors 1-3, KIT, PDGFR-alpha, PDGFR-beta, RET, FGFR1 and 2, TIE2, DDR2, TrkA, Eph2A, RAF-1. BRAF, BRAF",
"     <sup>",
"      V600E",
"     </sup>",
"     , SAPK2, PTK5, and Abl.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15233604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: A high-fat meal increased the mean AUC of the parent drug by 48% compared to the fasted state and decreased the mean AUC of the M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl) active metabolites by 20% and 51%, respectively. A low-fat meal increased the mean AUC of regorafenib, M-2, and M-5 by 36%, 40% and 23%, respectively (as compared to the fasted state).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 99.5% (active metabolites M-2 and M-5 are also highly protein bound)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4 and UGT1A9, primarily to active metabolites M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Tablets: 69%; Oral solution: 83%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Regorafenib: 28 hours (range: 14-58 hours); M-2 metabolite: 25 hours (range: 14-32 hours); M-5 metabolite: 51 hours (range: 32-70 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (71%; 47% as parent compound; 24% as metabolites); Urine (19%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Demetri GD, Reichardt P, Kang YK, et al, &ldquo;Efficacy and Safety of Regorafenib for Advanced Gastrointestinal Stromal Tumours After Failure of Imatinib and Sunitinib (GRID): An International, Multicenter, Randomized, Placebo-Controlled, Phase 3 Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2013, 381(9863):295-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32006/abstract-text/23177515/pubmed\" id=\"23177515\" target=\"_blank\">",
"        23177515",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eisen T, Joensuu H, Nathan PD, et al, &ldquo;Regorafenib for Patients With Previously Untreated Metastatic or Unresectable Renal-Cell Carcinoma: A Single-Group Phase 2 Trial,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2012, 13(10):1055-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32006/abstract-text/22959186/pubmed\" id=\"22959186\" target=\"_blank\">",
"        22959186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      George S, Wang Q, Heinrich MC, et al, &ldquo;Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(19):2401-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32006/abstract-text/22614970/pubmed\" id=\"22614970\" target=\"_blank\">",
"        22614970",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grothey A, van Cutsem E, Sobrero A, et al, &ldquo;Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): An International, Multicenter, Randomized, Placebo-Controlled, Phase 3 Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2013,  381(9863):303-12",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32006/abstract-text/23177514/pubmed\" id=\"23177514\" target=\"_blank\">",
"        23177514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mross K, Frost A, Steinbild S, et al, \"A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients With Advanced Solid Tumors,\"",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2012, 18(9):2658-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32006/abstract-text/22421192/pubmed\" id=\"22421192\" target=\"_blank\">",
"        22421192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strumberg D, Scheulen ME, Schultheis B, et al, \"Regorafenib (BAY 73-4506) in Advanced Colorectal Cancer: A Phase I Study,\"",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2012, 106(11):1722-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32006/abstract-text/22568966/pubmed\" id=\"22568966\" target=\"_blank\">",
"        22568966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waddell T and Cunningham D, &ldquo;Evaluation of Regorafenib in Colorectal Cancer and GIST,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2013, 381(9863):273-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32006/abstract-text/23177516/pubmed\" id=\"23177516\" target=\"_blank\">",
"        23177516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86690 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-C2273CD5CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32006=[""].join("\n");
var outline_f31_16_32006=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125802\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15231623\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125803\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233627\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233628\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233629\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233630\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233631\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15234639\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15231624\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15800734\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233633\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125762\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15231622\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15237409\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233578\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233598\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15255943\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15255941\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233600\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233558\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233559\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233560\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233561\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233632\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570456\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233635\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233602\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15233604\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86690\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86690|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/33/2582?source=related_link\">",
"      Regorafenib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_16_32007="Etiology of atrioventricular block";
var content_f31_16_32007=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology of atrioventricular block",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32007/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32007/contributors\">",
"     William H Sauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32007/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32007/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32007/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32007/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/16/32007/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular (AV) block is defined as a delay or interruption in the transmission of an impulse from the atria to the ventricles due to an anatomical or functional impairment in the conduction system. The conduction disturbance can be transient or permanent, and it can have many causes (",
"    <a class=\"graphic graphic_table graphicRef62885 \" href=\"UTD.htm?30/27/31163\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The conduction can be delayed, intermittent, or absent. The commonly used terminology includes first degree (slowed conduction without loss of atrioventricular synchrony), second degree (intermittent loss of atrioventricular conduction, often in a regular pattern, eg, 2:1, 3:2, or higher degrees of block), and third degree or complete AV block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17749?source=see_link\">",
"     \"ECG tutorial: Atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology of AV block will be reviewed here. The management of the specific types of AV block is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41574?source=see_link\">",
"     \"First degree atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=see_link\">",
"     \"Third degree (complete) atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC AND PATHOPHYSIOLOGIC AV BLOCK",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Increased vagal tone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhanced vagal tone due to sleep, athletic training, pain, carotid sinus massage, or hypersensitive carotid sinus syndrome can result in slowing of the sinus rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the development of AV block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=see_link\">",
"     \"Arrhythmia in athletes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"     \"Manifestations and causes of the sick sinus syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10598?source=see_link\">",
"     \"Carotid sinus hypersensitivity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Idiopathic progressive cardiac conduction disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrosis and sclerosis of the conduction system accounts for about one-half of cases of AV block and may be induced by several different conditions which often cannot be distinguished clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/1\">",
"     1",
"    </a>",
"    ]. Progressive cardiac conduction defects, referred to as Lenegre's or Lev's disease, are characterized by progressive impairment of the conduction system:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term Lenegre's disease has been traditionally used to describe a progressive, fibrotic, sclerodegenerative affliction of the conduction system in younger individuals. It is frequently associated with slow progression to complete heart block and may be hereditary. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Familial disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Lev's disease has referred to \"sclerosis of the left side of the cardiac skeleton\" in older patients, such as that associated with calcific involvement of the aortic and mitral rings [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]. It is caused by fibrosis or calcification extending from any of the fibrous structures adjacent to the conduction system into the conduction system [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fibrosis of the top of the muscular septum is a common cause of right bundle branch block (RBBB) with left anterior fascicular block in the elderly patient. Involvement of the mitral ring or the central fibrous body, for example, may be the most common cause of complete heart block with a narrow QRS complex in the elderly. Aortic valve calcification, on the other hand, can invade the bundle of His, the right",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left bundle branch as well as the left anterior fascicle. Thus, the QRS complex may be prolonged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ischemic heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic disease accounts for about 40 percent of cases of AV block [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/1\">",
"     1",
"    </a>",
"    ]. Conduction can be disturbed with either chronic ischemic disease or during an acute myocardial infarction (MI) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. It is estimated that approximately 20 percent of patients with an acute MI develop AV block: 8 percent with first degree; 5 percent with second degree; and 6 percent with third degree [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraventricular conduction disturbances (IVCDs), including bundle and fascicular blocks, also occur in 10 to 20 percent of cases of acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/10-16\">",
"     10-16",
"    </a>",
"    ]. Left bundle branch block (LBBB) and RBBB with left anterior fascicle block are most common, each occurring in about one-third of patients with an IVCD [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/14\">",
"     14",
"    </a>",
"    ]. RBBB with or without left posterior fascicular block and RBBB alternating with LBBB are less frequently seen, while isolated left anterior or posterior fascicle block is most unusual. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=see_link\">",
"     \"Conduction abnormalities after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cardiomyopathy and myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV block can be seen in patients with cardiomyopathies, including hypertrophic obstructive cardiomyopathy and infiltrative processes such as amyloidosis and sarcoidosis, and in patients with myocarditis due to a variety of causes including rheumatic fever, Lyme disease, diphtheria, viruses, systemic lupus erythematosus, toxoplasmosis, bacterial endocarditis, and syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/3,4,17-28\">",
"     3,4,17-28",
"    </a>",
"    ]. The development of AV block in myocarditis is often a poor prognostic sign. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=see_link&amp;anchor=H4#H4\">",
"     \"Lyme carditis\", section on 'Atrioventricular conduction abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Congenital heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital complete heart block may be an isolated lesion or may be associated with other types of congenital heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link\">",
"     \"Congenital third degree (complete) atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Familial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial AV conduction block, characterized by a progression in the degree of block in association with a variable apparent site of block, may be transmitted as an autosomal dominant trait. One form of AV conduction block has been mapped to a genetic locus at chromosome 19q13 and the other to chromosome 3p21, where the cardiac sodium channel, SCN5A, is encoded [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/29\">",
"     29",
"    </a>",
"    ]. Several SCN5A mutations have been associated with AV conduction block [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/30-33\">",
"     30-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of these mutations produce AV block in childhood, while others present in middle-age and have been called hereditary Lenegre's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/30,31,33\">",
"     30,31,33",
"    </a>",
"    ]. In the latter setting, it has been proposed that haploinsufficiency combined with aging leads to a progressive decline in conduction. Consistent with this hypothesis is the observation in a mouse model of SCN5A-linked hereditary Lenegre's disease of progressive impairment of atrial and ventricular conduction with aging in association with myocardial fibrosis; these changes occurred without a change in left ventricular systolic or diastolic function [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some families with SCN5A mutations, AV block or other conduction abnormalities are present with or without associated dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link\">",
"     \"Genetics of dilated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Different SCN5A mutations are associated with other cardiac abnormalities including congenital long QT syndrome type 3, the Brugada syndrome, familial sick sinus syndrome, and familial dilated cardiomyopathy with conduction defects and susceptibility to atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link\">",
"     \"Genetics of congenital and acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"     \"Manifestations and causes of the sick sinus syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link\">",
"     \"Genetics of dilated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other genetic forms of familial AV block have been described, including a progressive form mapped to a locus on chromosome 19q13 and a form associated with congenital heart disease for which a point mutation has been identified in the cardiac transcription factor",
"    <span class=\"nowrap\">",
"     CSX/NKX2-5",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Targeted deletion of the NKX.2-5 gene in mice causes hypoplasia of the cardiac conduction system and progressive heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Congenital heart disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV block can also occur in a variety of other disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperkalemia, usually when the plasma potassium concentration is above 6.3",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/43-45\">",
"       43-45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infiltrative malignancies, such as Hodgkin lymphoma and other lymphomas, and multiple myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hereditary neuromuscular heredodegenerative disease such as myotonic dystrophy, Kearns-Sayre syndrome, and Erb's dystrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/46-48\">",
"       46-48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=see_link\">",
"       \"Inherited syndromes associated with cardiac disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rheumatologic disorders including dermatomyositis and Paget disease [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/2-4\">",
"       2-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperthyroidism, myxedema, and thyrotoxic periodic paralysis [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/3,4,49\">",
"       3,4,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac tumors, cysts, myocardial bridging, and trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/2-4,50-52\">",
"       2-4,50-52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neonatal lupus syndrome, which results from transplacental passage of",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       anti-La/SSB",
"      </span>",
"      antibodies from the mother. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link\">",
"       \"Neonatal lupus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     IATROGENIC AV BLOCK",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of drugs can impair AV conduction, occasionally resulting in AV block. Examples include digitalis, calcium channel blockers (especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and to a lesser extent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , adenosine, and beta-blockers. In comparison, antiarrhythmic drugs that modulate the sodium channel, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    , can produce block in the more distal His-Purkinje system.",
"   </p>",
"   <p>",
"    Most patients with AV block who are taking drugs that can impair conduction probably have underlying conduction system disease. This was suggested by a study of 169 patients with second or third degree AV block not related to acute MI, digitalis toxicity, or vasovagal syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/53\">",
"     53",
"    </a>",
"    ]. Of these, 92 (54 percent) were receiving beta blockers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    . Drug discontinuation resulted in resolution of AV block in 32 of 79 cases; however, AV block later recurred in the absence of therapy in 18 of these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV block may be associated with replacement of a calcified aortic or mitral valve, closure of a ventricular septal defect, or other surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/4,54-58\">",
"     4,54-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Catheter ablation for arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV block is a potential complication of catheter ablation of reentrant arrhythmias when the reentrant pathway lies within or near the AV node. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link&amp;anchor=H9#H9\">",
"     \"Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Transcatheter closure of VSD",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of devices have been used to close muscular ventricular septal defects (VSDs), both congenital and those that occur after myocardial infarction. The Amplatzer ventricular septal defect occluder, for example, completely occluded 28 of 30 VSDs in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/59\">",
"     59",
"    </a>",
"    ]. One patient with complete left bundle branch block after the procedure progressed to complete heart block at one year. The presumed mechanism is that the right ventricular retention disk overlaps the ventricular conduction system as it passes above or anterosuperiorly to the defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Alcohol (ethanol) septal ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous transluminal septal myocardial ablation, also called alcohol (ethanol) septal ablation, transcoronary ablation of septal hypertrophy, and nonsurgical septal reduction therapy, is a nonsurgical treatment for obstructive hypertrophic cardiomyopathy. This intervention consists of infarction and thinning of the proximal interventricular septum via infusion of alcohol into the first septal perforating branch of the left anterior descending coronary artery through an angioplasty catheter. Complete heart block is seen in 14 to 22 percent of patients after this procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link&amp;anchor=H16#H16\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\", section on 'Alcohol (ethanol) septal ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3285435079\">",
"    <span class=\"h2\">",
"     Transcatheter aortic valve implantation (TAVI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A very high rate of AV block can be seen after percutaneous TAVI, with up to one-third of patients requiring a permanent pacemaker within 30 days of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Pre-existing disturbances of cardiac conduction, a narrow left ventricular outflow tract, and the severity of mitral annular calcification appear to be predictors of this complication. There may also be a higher rate of heart block observed with self-expanding implanted aortic valves compared with balloon expandable versions [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32007/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/26/44449?source=see_link\">",
"       \"Patient information: Heart block in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177218\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrioventricular (AV) block is defined as a delay or interruption in the transmission of an impulse from the atria to the ventricles due to an anatomical or functional impairment in the conduction system. The conduction disturbance can be transient or permanent, and it can have many causes (",
"      <a class=\"graphic graphic_table graphicRef62885 \" href=\"UTD.htm?30/27/31163\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fibrosis and sclerosis of the conduction system accounts for about 50 percent of cases of AV block and may be induced by several different conditions that often cannot be distinguished clinically. When fibrosis and sclerosis of the conduction system are present, they are frequently progressive and may ultimately progress to complete heart block. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Idiopathic progressive cardiac conduction disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ischemic disease accounts for about 40 percent of cases of AV block. Conduction disturbances ranging from first degree AV block to complete heart block may occur with either chronic ischemic disease or during an acute myocardial infarction. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Ischemic heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Familial AV conduction block, characterized by a progression in the degree of block in association with a variable apparent site of block, may be transmitted as an autosomal dominant trait. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Familial disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link&amp;anchor=H2#H2\">",
"       \"Congenital third degree (complete) atrioventricular block\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A variety of drugs, including digitalis, calcium channel blockers (especially",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , adenosine, and beta-blockers, can impair AV conduction, occasionally resulting in AV block. In most cases, the resulting AV block is at least partially reversible following withdrawal of the offending medication(s). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of procedures performed on the heart may result in AV block, including valve replacement, catheter ablation of arrhythmias, transcatheter closure of a ventricular septal defect, alcohol septal ablation, and transcatheter aortic valve implantation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Iatrogenic AV block'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/1\">",
"      ZOOB M, SMITH KS. THE AETIOLOGY OF COMPLETE HEART-BLOCK. Br Med J 1963; 2:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/2\">",
"      LENEGRE J. ETIOLOGY AND PATHOLOGY OF BILATERAL BUNDLE BRANCH BLOCK IN RELATION TO COMPLETE HEART BLOCK. Prog Cardiovasc Dis 1964; 6:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/3\">",
"      LEV M. ANATOMIC BASIS FOR ATRIOVENTRICULAR BLOCK. Am J Med 1964; 37:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/4\">",
"      LEV M. THE PATHOLOGY OF COMPLETE ATRIOVENTRICULAR BLOCK. Prog Cardiovasc Dis 1964; 6:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/5\">",
"      Begg FR, Magovern GJ, Cushing WJ, et al. Selective cine coronary arteriography in patients with complete heart block. J Thorac Cardiovasc Surg 1969; 57:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/6\">",
"      Simon AB, Zloto AE. Atrioventricular block: natural history after permanent ventricular pacing. Am J Cardiol 1978; 41:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/7\">",
"      LEVINE SA, MILLER H, PENTON GB. Some clinical features of complete heart block. Circulation 1956; 13:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/8\">",
"      HEJTMANCIK MR, HERRMANN GR, SHIELDS AH, WRIGHT JC. A clinical study of complete heart block. Am Heart J 1956; 52:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/9\">",
"      ROWE JC, WHITE PD. Complete heart block: a follow-up study. Ann Intern Med 1958; 49:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/10\">",
"      Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/11\">",
"      Godman MJ, Lassers BW, Julian DG. Complete bundle-branch block complicating acute myocardial infarction. N Engl J Med 1970; 282:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/12\">",
"      Sugiura T, Iwasaka T, Hasegawa T, et al. Factors associated with persistent and transient fascicular blocks in anterior wall acute myocardial infarction. Am J Cardiol 1989; 63:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/13\">",
"      Mullins CB, Atkins JM. Prognoses and management of venticular conduction blocks in acute myocardial infarction. Mod Concepts Cardiovasc Dis 1976; 45:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/14\">",
"      Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating acute myocardial infarction. 1. Clinical characteristics, hospital mortality, and one-year follow-up. Circulation 1978; 58:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/15\">",
"      Scheinman MM, Gonzalez RP. Fascicular block and acute myocardial infarction. JAMA 1980; 244:2646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/16\">",
"      Dubois C, Pi&eacute;rard LA, Smeets JP, et al. Short- and long-term prognostic importance of complete bundle-branch block complicating acute myocardial infarction. Clin Cardiol 1988; 11:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/17\">",
"      Harris A, Davies M, Redwood D, et al. Aetiology of chronic heart block. A clinico-pathological correlation in 65 cases. Br Heart J 1969; 31:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/18\">",
"      Bernstein M. Auriculoventricular dissociation following scarlet fever: Report of a case. Am Heart J 1938; 16:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/19\">",
"      Rantz LA, Spink WW, Boisvert PJ. Abnormalities in the electrocardiogram following hemolytic streptococcus sore throat. Arch Intern Med 1946; 77:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/20\">",
"      Lev M, Bharati S, Hoffman FG, Leight L. The conduction system in rheumatoid arthritis with complete atrioventricular block. Am Heart J 1975; 90:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/21\">",
"      CLARK NS. Complete heart block in children; report of three cases possibly attributable to measles. Arch Dis Child 1948; 23:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/22\">",
"      Rosenberg DH. Electrocardiographic changes in epidemic parotitis (mumps). Proc Soc Exp Biol Med 1945; 58:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/23\">",
"      ENGLE MA. Recovery from complete heart block in diphtheria. Pediatrics 1949; 3:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/24\">",
"      Menon TB, Rao CK. Tuberculosis of the Myocardium Causing Complete Heart Block. Am J Pathol 1945; 21:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/25\">",
"      SHEE JC. STOKES-ADAMS ATTACKS DUE TO TOXOPLASMA MYOCARDITIS. Br Heart J 1964; 26:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/26\">",
"      Lim CH, Toh CC, Chia BL, Low LP. Stokes-Adams attacks due to acute nonspecific myocarditis. Am Heart J 1975; 90:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/27\">",
"      Wray R, Iveson M. Complete heart block and systemic lupus erythematosus. Br Heart J 1975; 37:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/28\">",
"      Kleid JJ, Kim ES, Brand B, et al. Heart block complicating acute bacterial endocarditis. Chest 1972; 61:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/29\">",
"      Schott JJ, Alshinawi C, Kyndt F, et al. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet 1999; 23:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/30\">",
"      Tan HL, Bink-Boelkens MT, Bezzina CR, et al. A sodium-channel mutation causes isolated cardiac conduction disease. Nature 2001; 409:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/31\">",
"      Wang DW, Viswanathan PC, Balser JR, et al. Clinical, genetic, and biophysical characterization of SCN5A mutations associated with atrioventricular conduction block. Circulation 2002; 105:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/32\">",
"      Herfst LJ, Potet F, Bezzina CR, et al. Na+ channel mutation leading to loss of function and non-progressive cardiac conduction defects. J Mol Cell Cardiol 2003; 35:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/33\">",
"      Probst V, Kyndt F, Potet F, et al. Haploinsufficiency in combination with aging causes SCN5A-linked hereditary Len&egrave;gre disease. J Am Coll Cardiol 2003; 41:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/34\">",
"      Royer A, van Veen TA, Le Bouter S, et al. Mouse model of SCN5A-linked hereditary Len&egrave;gre's disease: age-related conduction slowing and myocardial fibrosis. Circulation 2005; 111:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/35\">",
"      McNair WP, Ku L, Taylor MR, et al. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation 2004; 110:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/36\">",
"      Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 2005; 293:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/37\">",
"      Makiyama T, Akao M, Tsuji K, et al. High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations. J Am Coll Cardiol 2005; 46:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/38\">",
"      Brink PA, Ferreira A, Moolman JC, et al. Gene for progressive familial heart block type I maps to chromosome 19q13. Circulation 1995; 91:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/39\">",
"      Schott JJ, Benson DW, Basson CT, et al. Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science 1998; 281:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/40\">",
"      Ikeda Y, Hiroi Y, Hosoda T, et al. Novel point mutation in the cardiac transcription factor CSX/NKX2.5 associated with congenital heart disease. Circ J 2002; 66:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/41\">",
"      Jay PY, Harris BS, Maguire CT, et al. Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. J Clin Invest 2004; 113:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/42\">",
"      Pashmforoush M, Lu JT, Chen H, et al. Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block. Cell 2004; 117:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/43\">",
"      Arnsdorf MF, Schreiner E, Gambetta M, et al. Electrophysiological changes in the canine atrium and ventricle during progressive hyperkalaemia: electrocardiographical correlates and the in vivo validation of in vitro predictions. Cardiovasc Res 1977; 11:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/44\">",
"      Surawicz B. Relationship between electrocardiogram and electrolytes. Am Heart J 1967; 73:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/45\">",
"      Fisch C. Relation of electrolyte disturbances to cardiac arrhythmias. Circulation 1973; 47:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/46\">",
"      Roberts NK, Perloff JK, Kark RA. Cardiac conduction in the Kearns-Sayre syndrome (a neuromuscular disorder associated with progressive external ophthalmoplegia and pigmentary retinopathy). Report of 2 cases and review of 17 published cases. Am J Cardiol 1979; 44:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/47\">",
"      Sanyal SK, Johnson WW. Cardiac conduction abnormalities in children with Duchenne's progressive muscular dystrophy: electrocardiographic features and morphologic correlates. Circulation 1982; 66:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/48\">",
"      Komajda M, Frank R, Vedel J, et al. Intracardiac conduction defects in dystrophia myotonica. Electrophysiological study of 12 cases. Br Heart J 1980; 43:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/49\">",
"      Hsu YJ, Lin YF, Chau T, et al. Electrocardiographic manifestations in patients with thyrotoxic periodic paralysis. Am J Med Sci 2003; 326:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/50\">",
"      James TN, Carson DJ, Marshall TK. De subitaneis mortibus. I. Fibroma compressing His bundle. Circulation 1973; 48:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/51\">",
"      den Dulk K, Brugada P, Braat S, et al. Myocardial bridging as a cause of paroxysmal atrioventricular block. J Am Coll Cardiol 1983; 1:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/52\">",
"      Rosen KM, Heller R, Ehsani A, Rahimtoola SH. Localization of site of traumatic heart block with His bundle recordings: electrophysiologic observations regarding the nature of \"split\" H potentials. Am J Cardiol 1972; 30:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/53\">",
"      Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. J Am Coll Cardiol 2004; 44:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/54\">",
"      Sanoudos G, Reed GE. Late heart block in aortic valve replacement. J Cardiovasc Surg (Torino) 1974; 15:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/55\">",
"      Rosen KM, Mehta A, Rahimtoola SH, Miller RA. Sites of congenital and surgical heart block as defined by His bundle electrocardiography. Circulation 1971; 44:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/56\">",
"      Furman S, Young D. Cardiac pacing in children and adolescents. Am J Cardiol 1977; 39:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/57\">",
"      Hofschire PJ, Nicoloff DM, Moller JH. Postoperative complete heart block in 64 children treated with and without cardiac pacing. Am J Cardiol 1977; 39:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/58\">",
"      Berdajs D, Schurr UP, Wagner A, et al. Incidence and pathophysiology of atrioventricular block following mitral valve replacement and ring annuloplasty. Eur J Cardiothorac Surg 2008; 34:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/59\">",
"      Thanopoulos BD, Rigby ML. Outcome of transcatheter closure of muscular ventricular septal defects with the Amplatzer ventricular septal defect occluder. Heart 2005; 91:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/60\">",
"      Khawaja MZ, Rajani R, Cook A, et al. Permanent pacemaker insertion after CoreValve transcatheter aortic valve implantation: incidence and contributing factors (the UK CoreValve Collaborative). Circulation 2011; 123:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/61\">",
"      Eltchaninoff H, Prat A, Gilard M, et al. Transcatheter aortic valve implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards) registry. Eur Heart J 2011; 32:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/62\">",
"      Baan J Jr, Yong ZY, Koch KT, et al. Factors associated with cardiac conduction disorders and permanent pacemaker implantation after percutaneous aortic valve implantation with the CoreValve prosthesis. Am Heart J 2010; 159:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32007/abstract/63\">",
"      Roten L, Wenaweser P, Delacr&eacute;taz E, et al. Incidence and predictors of atrioventricular conduction impairment after transcatheter aortic valve implantation. Am J Cardiol 2010; 106:1473.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 907 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-DF771C1915-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32007=[""].join("\n");
var outline_f31_16_32007=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H177218\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGIC AND PATHOPHYSIOLOGIC AV BLOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Increased vagal tone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Idiopathic progressive cardiac conduction disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cardiomyopathy and myocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Familial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      IATROGENIC AV BLOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Catheter ablation for arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Transcatheter closure of VSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Alcohol (ethanol) septal ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3285435079\">",
"      Transcatheter aortic valve implantation (TAVI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H177218\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/907\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/907|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/27/31163\" title=\"table 1\">",
"      Etiology AV block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=related_link\">",
"      Arrhythmia in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10598?source=related_link\">",
"      Carotid sinus hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=related_link\">",
"      Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=related_link\">",
"      Conduction abnormalities after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=related_link\">",
"      Congenital third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17749?source=related_link\">",
"      ECG tutorial: Atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41574?source=related_link\">",
"      First degree atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=related_link\">",
"      Inherited syndromes associated with cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=related_link\">",
"      Lyme carditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=related_link\">",
"      Manifestations and causes of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=related_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/26/44449?source=related_link\">",
"      Patient information: Heart block in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=related_link\">",
"      Third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_16_32008="Hospice: Philosophy of care and appropriate utilization in the United States";
var content_f31_16_32008=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hospice: Philosophy of care and appropriate utilization in the United States",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32008/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32008/contributors\">",
"     Diane E Meier, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32008/contributors\">",
"     Elizabeth McCormick, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32008/contributors\">",
"     Ruth Lagman, MD, MPH, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32008/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32008/contributors\">",
"     Robert M Arnold, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32008/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32008/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/16/32008/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of hospice started during the middle ages when hospices were set up as places of rest for pilgrims and other travelers. At the end of the 19th century, hospices were designated specifically to care for the dying, first in Ireland and later in England. St. Christopher's Hospice in London opened in 1967 under the direction of Dr. Cicely Saunders. A nurse, social worker, and a physician, Saunders developed and advanced the modern hospice movement to reflect her commitment to patient-centered care, pain management, research, and education. The philosophy and practice of the St. Christopher's program has since spread to all countries in the developed world and to many developing areas.",
"   </p>",
"   <p>",
"    Hospice services are designed to provide comprehensive interdisciplinary team-based palliative care for patients with life-limiting illness with a prognosis of six months or less if the disease follows its natural course. Hospice services in the United States are an insurance benefit reimbursed by Medicare, Medicaid, and other payers.",
"   </p>",
"   <p>",
"    In the United States, hospice was initially a grass roots and volunteer response to bring attention to the needs of the dying, with the goal of providing patient-centered care and avoiding unnecessary medical intervention. In 1982, the Medicare hospice benefit was authorized under part A of the Medicare program [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specialty of palliative medicine arose as a direct result of the hospice movement. Palliative medicine incorporates the holistic care developed by hospice, focusing on symptom management, support and assistance with communication, and providing such care to a wider group of patients including those who are not dying or who cannot receive or choose not to receive hospice services.",
"    <br/>",
"   </p>",
"   <p>",
"    The past two decades have seen a dramatic increase in the number of hospice programs, and number of persons served by hospice in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As of 2010, there were 5150 hospice provider programs serving approximately 1.58 million Americans.",
"     </li>",
"     <li>",
"      In 2009, over 40 percent of Medicare decedents utilized hospice at some point in their care, an increase from 23 percent in 2000.",
"     </li>",
"     <li>",
"      Approximately 41.9 percent of all deaths in the United States in 2010 were under the care of a hospice program. This reflects a change from one in 12 deaths of Medicare beneficiaries in 1992 to two in five deaths in 2009 [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the majority of hospices have fewer than 100 patients and are non-profit, the number of for-profit hospices increased by 300 percent from 1992 to 1998; at the same time, the number of non-profit hospices increased by only 43 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/5\">",
"     5",
"    </a>",
"    ]. Large hospice programs serving more than 500 patients daily also tripled over this time period.",
"   </p>",
"   <p>",
"    In tandem with the maturing of the hospice movement and aging of the US population, there has been evolution in the patterns of diagnosis among patients receiving hospice. Death from cancer accounted for 53 percent of hospice patients in the 1990s whereas in 2010, only 35.6 percent of hospice patients had cancer and 64.4 percent died from chronic debilitating diseases (eg, frailty, atherosclerotic, and respiratory disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/3\">",
"     3",
"    </a>",
"    ]. These shifts in diagnoses reflect the correlation of hospice utilization with changes in the leading causes of death (cancer accounts for fewer than 25 percent of deaths in the United States in 2010).",
"   </p>",
"   <p>",
"    This topic will discuss the hospice model of care and utilization of hospice programs in the United States. An overview of palliative care services is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51426050\">",
"    <span class=\"h1\">",
"     THE HOSPICE MODEL OF CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospice care provides medical care and support to a patient with life-limiting illness and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    family with a focus on quality of life rather than life prolongation or cure. The hospice philosophy embraces the general principle of a comfortable death with dignity. The care and treatment provided are based on the patient&rsquo;s and family&rsquo;s goals and values.",
"   </p>",
"   <p>",
"    The key concept of hospice, referred to as &ldquo;total pain&rdquo; by Cecily Saunders, identifies that suffering in the dying patient derives from a combination of symptoms and impairments that disrupt physical, psychological, spiritual, and social equilibrium. The hospice model is one of interdisciplinary team care that provides comprehensive care addressing all aspects of suffering [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients facing unrelieved suffering often experience demoralization and existential angst (questioning the meaning of life, loss of freedom, loss of dignity, grief, and fear of dying); these consequences of suffering must be addressed in the context of care provided by the physician and the hospice interdisciplinary team [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/7\">",
"     7",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The interdisciplinary hospice team is available to provide services, either directly or by phone accessibility, seven days per week and 24 hours per day. Hospice is most often provided in the patient&rsquo;s place of residence (private home, 41.1 percent; nursing home, 18 percent; or assisted living facility, 7.3 percent), but can also be provided in a dedicated facility. Hospice facilities may be freestanding inpatient units, or may be housed within a nursing home or hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103949484\">",
"    <span class=\"h2\">",
"     Distinction between hospice and palliative care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative care focuses on preventing and relieving suffering and on supporting the best possible quality of life for patients and their families facing serious illness.&nbsp;The primary tenets of palliative care are symptom management; establishing goals of care that are in keeping with the patient&rsquo;s values and preferences; consistent and sustained communication between the patient and all those involved in his or her care; and psychosocial, spiritual, and practical support both to patients and their family caregivers with coordination across sites of care. Palliative care aims to relieve suffering in all stages of disease and is not limited to end of life care. Within an integrated model of medical care, palliative care is provided at the same time as curative or life-prolonging treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hospice is a model of palliative care that is offered to patients at the end of life when curative or life-prolonging therapy is no longer indicated. While all care that is delivered by hospices can be considered palliative care, not all palliative care is delivered in hospices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51426077\">",
"    <span class=\"h2\">",
"     The hospice interdisciplinary team",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under the Medicaid Hospice Benefit, patients and families are cared for by an interdisciplinary team which may include the following members [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/9\">",
"     9",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H691082\">",
"     'The US Medicare hospice benefit'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The registered nurse is the primary case manager and is responsible for skilled nursing care and coordination of other members of the interdisciplinary team. Hospice nurses visit patients regularly, from daily to weekly based on need.",
"     </li>",
"     <li>",
"      The hospice physician plays both a medical and administrative role. Some hospice physicians visit patients regularly, particularly if the patient does not have a primary attending physician. In addition, the hospice physician acts as a liaison to the primary attending clinicians and can assist with symptom management.",
"     </li>",
"     <li>",
"      The primary attending physician is encouraged to remain involved in the care of patients referred to hospice. The primary attending physician may work directly with the primary nurse and also in collaboration with the hospice medical director to monitor symptoms and order interventions such as medications or skilled nursing care.",
"     </li>",
"     <li>",
"      The social worker provides psychosocial and practical support for patients and families, including counseling, bereavement support,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      referrals to other support systems. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29769?source=see_link\">",
"       \"Psychosocial issues at the end of life\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The chaplain oversees the spiritual needs of patients and families. Spiritual care is offered to patients with both structured and unstructured religious beliefs. For patients with a structured religious background, chaplains can act as liaisons to clergy or other religious figures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=see_link\">",
"       \"Religion, spirituality, and end of life care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Home health aides and attendants provide assistance to the patient and caregivers in the home, including personal care, food preparation, and shopping.",
"     </li>",
"     <li>",
"      Volunteers provide extra support for patients and families such as reading to patients, visiting, and assisting with errands.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355801997\">",
"    <span class=\"h2\">",
"     Who is a candidate for hospice?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospice becomes appropriate when patients and their families decide to forego curative therapies in order to focus on maximizing comfort and quality of life, when curative treatments are no longer beneficial, when the burdens of these treatments outweigh their benefits, or when patients are entering the last weeks to months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/4,10,11\">",
"     4,10,11",
"    </a>",
"    ]. Hospice supports the patient and family caregivers during the illness and provides bereavement services to family members for 12 months after the death of the patient.",
"   </p>",
"   <p>",
"    Medicare hospice coverage depends on certification by two physicians that a patient&rsquo;s prognosis is six months or less if the terminal illness runs its normal course. For patients with a non-cancer terminal illness, it may be difficult to identify a population with a survival prognosis of six months or less. Clinicians should err on the side of making the referral for chronically ill patients with decreased functional status, poor quality of life, physical and psychological distress, family caregiver burden and stress under circumstances where the goals of care are comfort, being at home, and staying in control.",
"   </p>",
"   <p>",
"    A variety of prognostic tools have been developed to help clinicians in prognostic assessment. Additionally, two systematic reviews provide guidance for identifying patients with end stage illness [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The systematic reviews, based on a literature search of over 1000 articles, have identified patient presentations associated with median survival of six months or less for patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/13\">",
"     13",
"    </a>",
"    ] or six noncancer illnesses (heart failure, chronic obstructive pulmonary disease, dementia, geriatric failure to thrive, cirrhosis, and end stage renal failure) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/12\">",
"     12",
"    </a>",
"    ]. These sample presentations may identify patients in whom aggressive treatment is unlikely to prolong survival and for whom discussion of hospice services may be appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19735?source=see_link&amp;anchor=H11773296#H11773296\">",
"     \"Communication of prognosis in palliative care\", section on 'The science of estimating prognosis'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Specific Medicare eligibility requirements for hospice are discussed below. (See",
"    <a class=\"local\" href=\"#H691104\">",
"     'Eligibility'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10984940\">",
"    <span class=\"h3\">",
"     Common questions and potential misperceptions about hospice eligibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients, families, and clinicians may have mistaken understandings about hospice care. The following common questions frequently arise about hospice eligibility:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is hospice a place?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hospice is a model of care, not a physical location, and may be provided in the patient&rsquo;s home, nursing home, or in an institution.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What type of treatments can patients receive while being cared for by a hospice program?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Under hospice services, patients receive treatments and interventions that achieve the goal of maximizing comfort and quality of life. In some cases, patients may continue to receive the same treatments they received prior to hospice referral, such as palliative chemotherapy, radiation, and heart failure treatments. In addition, patients can come and go from hospice at any time, if it is not meeting needs or if a new treatment becomes available that is not able to be covered by hospice. Once patients leave hospice, they may return to the program at any time, as long as they continue to meet the eligibility criteria (including a prognosis of under six months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do patients have to be actively dying to receive hospice services?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No. Patients do not have to be actively dying to receive hospice care. Patients must show a functional decline and have an estimated prognosis of six months or less to receive hospice services. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do patients have to be DNR to receive hospice?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients are not required to be categorized as &ldquo;Do not resuscitate&rdquo; (DNR) to receive hospice care",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H690304\">",
"    <span class=\"h2\">",
"     Services",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H690257\">",
"    <span class=\"h3\">",
"     Symptom control",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key component to effective hospice care is symptom control in advanced illness. Patients at the end of life often experience a variety of symptoms, which may include pain, dyspnea,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    anorexia, fatigue, agitation, anxiety, and depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=see_link\">",
"     \"Overview of managing common non-pain symptoms in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link\">",
"     \"Assessment and management of depression in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12890?source=see_link\">",
"     \"Pain assessment and management in the last weeks of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link\">",
"     \"Approach to symptom assessment in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Effective symptom assessment and control requires close collaboration between the nurse case manager and the attending physician. Ideally, to increase the timeliness of care, the attending physician should feel comfortable in extending the ability to adjust medications, within certain parameters, to the case manager. Most hospices use standing orders to facilitate this approach. The attending physician signs approval at the time that the patient is admitted to hospice. As an example, titration of analgesics or other drugs may be specified within predetermined parameters, which can then be adjusted by the nurse without having to constantly refer back to the attending physician for new orders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H690264\">",
"    <span class=\"h3\">",
"     Psychosocial and spiritual care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial and spiritual care is of great importance in patients with advanced incurable disease. A humanistic approach, sensitivity to cultural issues, and openness to differing religious and spiritual beliefs are all important. An important concept is to extend similar consideration to the patient's family or caregivers who carry a considerable burden during this time. Support of the family and caregivers is a priority of good hospice care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=see_link\">",
"     \"Religion, spirituality, and end of life care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29769?source=see_link\">",
"     \"Psychosocial issues at the end of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H690271\">",
"    <span class=\"h3\">",
"     Nursing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hospice nurse works with the patient, family, and interdisciplinary team to develop a plan of care to assess symptoms and care needs.",
"   </p>",
"   <p>",
"    The primary responsibility for day to day care typically falls on one or more family members or other identified caregivers which may include friends, as well as privately paid aides. The hospice team supplements the family caregiver, on whom a considerable burden is placed. Delivery of hospice care necessitates effective education and ongoing support of the family and other caregivers given the limited time the hospice aides or nurses are able to spend in the home. Family caregivers who report emotional strain have a significantly increased risk of serious illness and death, and support from the hospice team is essential to reducing this burden and stress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103949625\">",
"    <span class=\"h3\">",
"     Short-term intensified services",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, the patient care needs can increase. This may come about, for example, due to extensive wound care requirements, poorly controlled symptoms, complicated psychosocial issues, or need for extra support during the active phase of dying. In order to address these needs, the Medicare Hospice benefit includes additional levels of nursing care available to patients and their caregivers for short periods. Possible short-term arrangements may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Admission to a general inpatient hospice service in a variety of settings, including a hospice facility, hospital, or skilled nursing facility. This short term care is available to address acute pain and other symptoms that cannot be managed in the home and is typically appropriate for patient care that requires skilled nursing.",
"     </li>",
"     <li>",
"      24 hour support or continuous care services in the home for management of acute symptoms, to facilitate keeping the patient at home.",
"     </li>",
"     <li>",
"      Temporary respite care in a local nursing home or in&ndash;patient hospice facility to give the caregiver a rest from caregiving responsibilities. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H690285\">",
"    <span class=\"h3\">",
"     Bereavement care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bereavement care of the family and caregivers is a central component of hospice care. Grief and bereavement are associated with significant morbidity and mortality. Bereavement care is required to be available for a year after the patient&rsquo;s death. The precise nature of bereavement services varies. In most cases, there is a process to identify persons at high risk of difficult bereavement (eg, unexpected deaths, multiple deaths in a family in a short space of time, or family or caregivers with poor social support systems). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31190?source=see_link\">",
"     \"Grief and bereavement\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691082\">",
"    <span class=\"h1\">",
"     THE US MEDICARE HOSPICE BENEFIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, home hospice care for patients over 65 years of age, or for those who have been disabled for longer than two years, is covered through Medicare. Established as a permanent benefit in 1986, the Medicare hospice benefit model is used by many private insurers and health maintenance organizations (HMOs) for their hospice programs. Most states also cover hospice for their Medicaid beneficiaries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24679?source=see_link\">",
"     \"Medicare\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691104\">",
"    <span class=\"h2\">",
"     Eligibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four criteria for enrollment in the Medicare hospice benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eligibility for Medicare part A (hospital insurance)",
"     </li>",
"     <li>",
"      Medicare-approved hospice",
"     </li>",
"     <li>",
"      A statement signed by the patient indicating that they are choosing hospice care instead of regular Medicare for care associated with their hospice diagnosis. However, Medicare regulations allow for regular Medicare reimbursement for incidental medical expenses that are unrelated to the terminal illness (eg, acute myocardial infarction in a patient with advanced cancer).",
"     </li>",
"     <li>",
"      Certification by both the patient's personal physician and the hospice medical director that the patient has a terminal illness and is likely to have less than six months to live if the disease follows its usual course. In addition, the patient must be willing to forego life-sustaining treatment related to their hospice admitting diagnosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Limitations'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prognosis in patients with a cancer diagnosis is more readily determined than with many other serious illnesses. A six-month prognosis for the end stage cancer patient is suggested when there is obvious progression of disease, leading to a decline in performance status, and the patient requires assistance from another person to accomplish activities of daily living. (See",
"    <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=see_link\">",
"     \"Survival estimates in advanced terminal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the clinical course for non-cancer diagnoses can vary tremendously both within and between patients, and clinical prediction criteria often are ineffective in identifying a population with a survival prognosis of six months or less [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients with serious chronic illness can now live for years with high levels of functional dependency, symptom distress, caregiver burden, and vulnerability to a fragmented and complex health care system. In general, experts suggest erring on the side of making a referral to hospice despite prognostic uncertainty in a patient with significant palliative care needs who is unlikely to benefit from further disease modifying treatment.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.cms.gov/medicare-coverage-database/shared/handlers/highwire.ashx?url=file://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx@@@LCDId$$$32015***ContrId$$$236***ver$$$11***ContrVer$$$2***CntrctrSelected$$$236*2***Cntrctr$$$236***name$$$CGS+Administrators,+LLC+(15004,+HHH+MAC)***LCntrctr$$$236*2***bc$$$AgACAAIAQAAA***&amp;session=a2qgjyiqqk1bgt454ny2dr55&amp;kq=1056876468\">",
"     Guidelines from Medicare",
"    </a>",
"    are available to help in the determination of terminal status for hospice qualification. A table indicates criteria to determine if a patient meets guidelines for decline in clinical status, indicating a life expectancy of six months or less (",
"    <a class=\"graphic graphic_table graphicRef87320 \" href=\"UTD.htm?0/5/87\">",
"     table 1",
"    </a>",
"    ). It is important to point out that determination of decline presumes an assessment of patients over time; therefore it is important that evaluation for hospice services include both report of baseline status, current status, and changes that have occurred over time [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/15\">",
"     15",
"    </a>",
"    ]. Alternatively, patients could be qualified for hospice services by meeting criteria from non-disease specific baseline guidelines (",
"    <a class=\"graphic graphic_table graphicRef87321 \" href=\"UTD.htm?29/35/30268\">",
"     table 2",
"    </a>",
"    ) and disease-specific guidelines (",
"    <a class=\"graphic graphic_table graphicRef61282 \" href=\"UTD.htm?18/51/19262\">",
"     table 3",
"    </a>",
"    ). Individual prognostication remains difficult even with such guidelines.",
"   </p>",
"   <p>",
"    Many hospice organizations no longer require that a patient have a \"do not resuscitate\" (DNR) order.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691111\">",
"    <span class=\"h2\">",
"     Structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Medicare hospice benefit will pay for a comprehensive array of services related to the terminal condition. Medicare-certified hospice programs provide home-based care including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skilled nursing care, such as symptom assessment and monitoring, wound care, and education of family members",
"     </li>",
"     <li>",
"      Medical equipment and supplies",
"     </li>",
"     <li>",
"      Medications related to the terminal condition",
"     </li>",
"     <li>",
"      Psychosocial care, particularly by social workers and chaplains",
"     </li>",
"     <li>",
"      Limited hours of home health aide or attendant care in the home",
"     </li>",
"     <li>",
"      Bereavement support for family and caregivers",
"     </li>",
"     <li>",
"      Short-term respite care is available for five days every 30 days when caregivers are overwhelmed at home",
"     </li>",
"     <li>",
"      Short-term inpatient care for difficult to control symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Medicare hospice benefit is divided into a number of certification periods. The patient is first eligible for two 90-day periods. These are followed by unlimited periods of 60 days. For each certification period, the attending physician must recertify that the patient is terminally ill. In theory, a patient who continues to show decline can continue to be eligible for hospice care even if he or she has survived longer than the specified six-month period; approximately 10 percent of hospice patients fall into this category of more than six month survival [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For some patients, home hospice care either is not feasible or not desired, and inpatient residential hospice facilities may be considered. The Medicare hospice benefit and most private insurers (see below) do not cover the cost of room and board at these facilities. These expenses can be significant, often $150 to $250 per day. In some states, Medicaid will cover these costs. Acute in-patient hospice facilities are available for short periods (usually under a week) either for complex symptom management that cannot be adequately addressed at home, or during the active dying phase, and is included in the Medicare Hospice Benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     BENEFITS AND LIMITATIONS OF HOSPICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hospice philosophy embraces the general principle of a comfortable death with dignity. There are both advantages and limitations of the hospice approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dying at home with hospice care is associated with significantly better quality of life for patients and families, reduced &ldquo;aggressiveness&rdquo; of care at the end of life, and markedly reduced risk of posttraumatic stress disorder and prolonged grief disorder among bereaved family members as compared to outcomes among those dying in a hospital or intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Care provided in a hospice program offers patients and family many benefits, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comprehensive interdisciplinary care",
"     </li>",
"     <li>",
"      24-hour phone access to on-call nurses and clinicians, seven days per week",
"     </li>",
"     <li>",
"      Reduction in out-of-pocket expenses for related medical costs, including medications and durable medical equipment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The National Hospice Study was the largest study to compare the dying experience with and without hospice. Initial results showed that patients&rsquo; quality of life was similar in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/18\">",
"     18",
"    </a>",
"    ]; however, secondary analysis revealed an improved quality of death in patients receiving hospice care [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/19\">",
"     19",
"    </a>",
"    ]. In a mortality follow-back survey, family members of patients who died in hospice were significantly more satisfied with the care than those of patients who died while receiving care in hospitals, nursing homes, or home health agencies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/20\">",
"     20",
"    </a>",
"    ]. Family survivors are less likely to experience posttraumatic stress disorder and prolonged grief disorder after hospice care as compared to those whose loved ones died in a hospital or intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/17\">",
"     17",
"    </a>",
"    ]. Several studies have also demonstrated a survival advantage (of as long as 100 days in heart failure) among hospice beneficiaries as compared to comparably ill patients who do not receive hospice [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing evidence suggests that hospice is associated with decreased direct (billed services) costs, particularly for patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary limitation of hospice is restriction of insurance coverage for life-prolonging treatments (including specific anticancer and palliative cancer treatments). Under the Medicare Hospice Benefit, Medicare provides a fixed sum of money, paid on a per diem basis, from which all provided medical care must be paid. The following difficulties result:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical expenses for imaging or laboratory studies, and costly treatments such as transfusions or high-priced symptom medications, which the attending physician feels are indicated to provide optimal care of the terminal illness, become the financial responsibility of the hospice under the per diem rate. Larger hospices serving at least 100 persons per day typically have the economies of scale necessary to cover such costs but smaller hospices may be unable or unwilling to absorb them.",
"     </li>",
"     <li>",
"      Hospitalizations are usually avoided once a patient is enrolled in a hospice program. The hospice benefit allows admissions to the hospital for short-term treatment of symptoms that cannot be managed at home. Hospices vary in their use of this aspect of the continuum of hospice care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of these issues, patients who may benefit from the comprehensive care that hospice provides but who can realistically benefit from continued and simultaneous life-prolonging treatments are not eligible for the Medicare Hospice benefit. In part as a result, hospice is underutilized, with over one-third of patients utilizing hospice for less than one week [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/16,25-29\">",
"     16,25-29",
"    </a>",
"    ] and 10 percent for less than 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/3\">",
"     3",
"    </a>",
"    ]. Late referral to hospice is associated with lower family satisfaction and bereavement outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25007289\">",
"    <span class=\"h1\">",
"     DISCUSSING HOSPICE WITH PATIENTS AND FAMILIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main barrier to hospice referral relates to the eligibility requirements that patients must have a prognosis of six months or less and forgo curative treatment. Another barrier to hospice referral is physicians&rsquo; comfort level in talking with patients and families about limitations in prognosis and treatment options. Communication can be particularly difficult when a patient has a limited life expectancy but wants aggressive treatment. Early discussions of hospice as a care option that also include an acknowledgement of the serious and fatal nature of the patient&rsquo;s underlying disease can increase the likelihood of future hospice enrollment [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A table outlines useful language for discussing hospice services and recommending a hospice referral to patients and families (",
"    <a class=\"graphic graphic_table graphicRef87287 \" href=\"UTD.htm?24/23/24957\">",
"     table 4",
"    </a>",
"    ). This outline provides a step-based guide for discussions similar to that used to communicate bad news. The initial discussion should focus on working to define patient and family goals and needs; if appropriate, hospice services are then recommended as a way of achieving these goals.",
"   </p>",
"   <p>",
"    This stepwise approach begins with establishing the medical facts and setting a time to meet with the patient and other decision makers. During this meeting, the provider should work to assess the patient&rsquo;s understanding of their illness and prognosis, define the patient&rsquo;s goals of care, identify patient and family care needs, and, finally, make a recommendation based on the patient&rsquo;s goals and care needs [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32008/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A website maintained by the",
"    <a class=\"external\" href=\"file://www.eperc.mcw.edu/EPERC/FastFactsIndex/ff_038.htm\">",
"     End of Life/Palliative Education Resource Center (EPERC)",
"    </a>",
"    , from the Medical College of Wisconsin, provides additional advice for discussing hospice. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=see_link\">",
"       \"Patient information: Medical care during advanced illness (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=see_link\">",
"       \"Patient information: Advance directives (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4568091\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospice care provides medical care and support services to a patient with a terminal illness where the focus is on quality of life rather than life prolongation or cure. The hospice philosophy embraces the general principle of a comfortable death with dignity: the care and treatment provided are based on the patient and family&rsquo;s goals and values. The hospice model is one of interdisciplinary team care that provides comprehensive care by addressing the physical, psychological, social, and spiritual aspects of suffering. Hospice care can be provided in hospitals, nursing homes, and freestanding hospice inpatient facilities. (See",
"      <a class=\"local\" href=\"#H51426050\">",
"       'The hospice model of care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Palliative care focuses on preventing and relieving suffering and on supporting the best possible quality of life for patients and their families facing serious illness.&nbsp;Within an integrated model of medical care, palliative care is provided at the same time as curative or life-prolonging care. Hospice is a model of palliative care that is offered to patients at the end of life when curative or life-prolonging therapy is no longer indicated. While all care that is delivered by hospices can be considered palliative care, not all palliative care is delivered through hospice programs. (See",
"      <a class=\"local\" href=\"#H103949484\">",
"       'Distinction between hospice and palliative care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hospice services become appropriate when patients and their families decide to forego curative therapies in order to focus on maximizing comfort and quality of life, when curative treatments are no longer beneficial, when the burdens of these treatments outweigh their benefits, or when patients are entering the last weeks to months of life. For patients with a non-cancer terminal illness, it may be difficult to identify a population with a survival prognosis of six months or less. Clinicians should err on the side of making the referral for chronically ill patients with decreased functional status, poor quality of life, physical and psychological distress, family caregiver burden and stress under circumstances where the goals of care are comfort, being at home, and staying in control. (See",
"      <a class=\"local\" href=\"#H355801997\">",
"       'Who is a candidate for hospice?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While symptom control is one of the most important services provided by hospice, other services include nursing care and support at home, psychosocial and spiritual care, respite care, and bereavement care. (See",
"      <a class=\"local\" href=\"#H690304\">",
"       'Services'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the US, home hospice care for patients over 65 years of age or for those who have been disabled for longer than two years is covered through Medicare. Medicaid and most private insurers also cover hospice care. Eligibility for hospice under the Medicare program requires the following (see",
"      <a class=\"local\" href=\"#H691082\">",
"       'The US Medicare hospice benefit'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Eligibility for Medicare part A (hospital insurance)",
"     </li>",
"     <li>",
"      Medicare-approved hospice",
"     </li>",
"     <li>",
"      The patient must sign a statement choosing hospice care instead of regular Medicare.",
"     </li>",
"     <li>",
"      The patient's personal physician and the hospice medical director both must certify that the patient has a terminal illness and is likely to live for fewer than six months if the disease follows its usual course.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The advantages of hospice care include comprehensive interdisciplinary care, support to care for dying patients in the home (including 24-hour phone access to on-call nurses and clinicians, seven days per week), and reduction in out-of-pocket expenses for related medical costs, including medications and durable medical equipment. Some limitations include reliance on family or private pay caregivers to help attend to daily needs of patients and the restriction of insurance coverage for some life-prolonging or expensive palliative treatments including specific anticancer treatments. However, patients may leave and return to the hospice program at any time, as long as they continue to meet the eligibility criteria (including a prognosis of under six months). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Benefits and limitations of hospice'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies have shown that early discussions of hospice as a care option, which also include acknowledgment of the serious and fatal nature of the patient&rsquo;s underlying disease, can increase the likelihood of future hospice enrollment. A table provides some guidance about how to discuss hospice with patients (",
"      <a class=\"graphic graphic_table graphicRef87287 \" href=\"UTD.htm?24/23/24957\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25007289\">",
"       'Discussing hospice with patients and families'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Hospice and Palliative Care Organization: History of Hospice Care file://www.nhpco.org/i4a/pages/index.cfm?pageid=3285 (Accessed on March 17, 2011).",
"    </li>",
"    <li>",
"     MedPAC. Report to the Congress: Medicare Payment Policies (March 2010) 2010:148.",
"    </li>",
"    <li>",
"     NHPCO Facts and Figures: Hospice Care in America 2011 Edition file://www.nhpco.org (Accessed on September 09, 2012).",
"    </li>",
"    <li>",
"     National Consensus Project for Quality Palliative Care. Clinical Practice Guidelines for Quality Palliative Care. National Quality Forum; New York, NY 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/5\">",
"      Carlson MD, Gallo WT, Bradley EH. Ownership status and patterns of care in hospice: results from the National Home and Hospice Care Survey. Med Care 2004; 42:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/6\">",
"      Higginson IJ, Edmonds P. Services, costs and appropriate outcomes in end of life care. Ann Oncol 1999; 10:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/7\">",
"      Kissane DW. The relief of existential suffering. Arch Intern Med 2012; 172:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/8\">",
"      Teno JM, Connor SR. Referring a patient and family to high-quality palliative care at the close of life: \"We met a new personality... with this level of compassion and empathy\". JAMA 2009; 301:651.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Medicare and Medicaid Services. Medicare hospice benefit, US Government publlication 02154. Booklet available online at file://www.medicare.gov/publications/pubs/pdf/02154.pdf (Accessed on January 13, 2011).",
"    </li>",
"    <li>",
"     A National Framework and Preferred Practices for Palliative and Hospice Care Quality. National Quality Forum; Washington, DC 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/11\">",
"      Morrison RS, Meier DE. Clinical practice. Palliative care. N Engl J Med 2004; 350:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/12\">",
"      Salpeter SR, Luo EJ, Malter DS, Stuart B. Systematic review of noncancer presentations with a median survival of 6 months or less. Am J Med 2012; 125:512.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/13\">",
"      Salpeter SR, Malter DS, Luo EJ, et al. Systematic review of cancer presentations with a median survival of six months or less. J Palliat Med 2012; 15:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/14\">",
"      Fox E, Landrum-McNiff K, Zhong Z, et al. Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. JAMA 1999; 282:1638.",
"     </a>",
"    </li>",
"    <li>",
"     Local Coverage Determination (LCD) for Hospice Determining Terminal Status, 2002-2011. Available at file://vergehomecare.com/yahoo_site_admin/assets/docs/lcd-LiverDisease.16795545.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/16\">",
"      McCarthy EP, Burns RB, Ngo-Metzger Q, et al. Hospice use among Medicare managed care and fee-for-service patients dying with cancer. JAMA 2003; 289:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/17\">",
"      Wright AA, Keating NL, Balboni TA, et al. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. J Clin Oncol 2010; 28:4457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/18\">",
"      Greer DS, Mor V, Morris JN, et al. An alternative in terminal care: results of the National Hospice Study. J Chronic Dis 1986; 39:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/19\">",
"      Wallston KA, Burger C, Smith RA, Baugher RJ. Comparing the quality of death for hospice and non-hospice cancer patients. Med Care 1988; 26:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/20\">",
"      Teno JM, Clarridge BR, Casey V, et al. Family perspectives on end-of-life care at the last place of care. JAMA 2004; 291:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/21\">",
"      Connor SR, Pyenson B, Fitch K, et al. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manage 2007; 33:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/22\">",
"      Saito AM, Landrum MB, Neville BA, et al. Hospice care and survival among elderly patients with lung cancer. J Palliat Med 2011; 14:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/23\">",
"      Taylor DH Jr, Ostermann J, Van Houtven CH, et al. What length of hospice use maximizes reduction in medical expenditures near death in the US Medicare program? Soc Sci Med 2007; 65:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/24\">",
"      Brumley R, Enguidanos S, Jamison P, et al. Increased satisfaction with care and lower costs: results of a randomized trial of in-home palliative care. J Am Geriatr Soc 2007; 55:993.",
"     </a>",
"    </li>",
"    <li>",
"     More beneficiaries use hospice; many factors contribute to shorter periods of use. HEHS-00-182; United States General Accounting Office, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/26\">",
"      Han B, Remsburg RE, McAuley WJ, et al. National trends in adult hospice use: 1991-1992 to 1999-2000. Health Aff (Millwood) 2006; 25:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/27\">",
"      Earle CC, Neville BA, Landrum MB, et al. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004; 22:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/28\">",
"      Christakis NA, Iwashyna TJ. Impact of individual and market factors on the timing of initiation of hospice terminal care. Med Care 2000; 38:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/29\">",
"      Younis T, Milch R, Abul-Khoudoud N, et al. Length of survival in hospice for cancer patients referred from a comprehensive cancer center. Am J Hosp Palliat Care 2009; 26:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/30\">",
"      Schockett ER, Teno JM, Miller SC, Stuart B. Late referral to hospice and bereaved family member perception of quality of end-of-life care. J Pain Symptom Manage 2005; 30:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/31\">",
"      Casarett D, Van Ness PH, O'Leary JR, Fried TR. Are patient preferences for life-sustaining treatment really a barrier to hospice enrollment for older adults with serious illness? J Am Geriatr Soc 2006; 54:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32008/abstract/32\">",
"      Casarett DJ, Quill TE. \"I'm not ready for hospice\": strategies for timely and effective hospice discussions. Ann Intern Med 2007; 146:443.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2200 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-C006335B05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32008=[""].join("\n");
var outline_f31_16_32008=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4568091\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51426050\">",
"      THE HOSPICE MODEL OF CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H103949484\">",
"      Distinction between hospice and palliative care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51426077\">",
"      The hospice interdisciplinary team",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H355801997\">",
"      Who is a candidate for hospice?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10984940\">",
"      - Common questions and potential misperceptions about hospice eligibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H690304\">",
"      Services",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H690257\">",
"      - Symptom control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H690264\">",
"      - Psychosocial and spiritual care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H690271\">",
"      - Nursing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103949625\">",
"      - Short-term intensified services",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H690285\">",
"      - Bereavement care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H691082\">",
"      THE US MEDICARE HOSPICE BENEFIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H691104\">",
"      Eligibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H691111\">",
"      Structure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      BENEFITS AND LIMITATIONS OF HOSPICE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25007289\">",
"      DISCUSSING HOSPICE WITH PATIENTS AND FAMILIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4568091\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2200\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2200|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/5/87\" title=\"table 1\">",
"      Documenting decline for hospice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/35/30268\" title=\"table 2\">",
"      Non-disease specific baseline guidelines for hospice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/51/19262\" title=\"table 3\">",
"      Disease specific guidelines for hospice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/23/24957\" title=\"table 4\">",
"      Discussing hospice care",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=related_link\">",
"      Approach to symptom assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=related_link\">",
"      Assessment and management of depression in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19735?source=related_link\">",
"      Communication of prognosis in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31190?source=related_link\">",
"      Grief and bereavement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24679?source=related_link\">",
"      Medicare",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12890?source=related_link\">",
"      Pain assessment and management in the last weeks of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29769?source=related_link\">",
"      Psychosocial issues at the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=related_link\">",
"      Religion, spirituality, and end of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=related_link\">",
"      Survival estimates in advanced terminal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_16_32009="Pantoprazole: Drug information";
var content_f31_16_32009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pantoprazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/40/13957?source=see_link\">",
"    see \"Pantoprazole: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/45/22231?source=see_link\">",
"    see \"Pantoprazole: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16572471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Bone Fracture Risk with Proton Pump Inhibitors: Health Canada Issues Alert",
"     </span>",
"     <span class=\"collapsible-date\">",
"      April 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has informed healthcare professionals that proton pump inhibitors (PPIs) may increase the risk of bone fractures. The risk of fracture was observed to be higher in patients receiving multiple daily doses for &ge;1 year; age, gender, and concomitant health conditions may also be a factor. Patients with risk factors for osteoporosis should be closely monitored and should receive a PPI at the lowest effective dose and for the shortest duration of therapy appropriate for the condition.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26523a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Protonix&reg;;",
"     </li>",
"     <li>",
"      Protonix&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pantoprazole&reg;;",
"     </li>",
"     <li>",
"      Ava-Pantoprazole;",
"     </li>",
"     <li>",
"      CO Pantoprazole;",
"     </li>",
"     <li>",
"      Mylan-Pantoprazole;",
"     </li>",
"     <li>",
"      Pantoloc&reg;;",
"     </li>",
"     <li>",
"      Pantoprazole for Injection;",
"     </li>",
"     <li>",
"      Panto&trade; I.V.;",
"     </li>",
"     <li>",
"      PMS-Pantoprazole;",
"     </li>",
"     <li>",
"      Q-Pantoprazole;",
"     </li>",
"     <li>",
"      RAN&trade;-Pantoprazole;",
"     </li>",
"     <li>",
"      ratio-Pantoprazole;",
"     </li>",
"     <li>",
"      Riva-Pantoprazole;",
"     </li>",
"     <li>",
"      Sandoz-Pantoprazole;",
"     </li>",
"     <li>",
"      Tecta&reg;;",
"     </li>",
"     <li>",
"      Teva-Pantoprazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F206284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Proton Pump Inhibitor;",
"     </li>",
"     <li>",
"      Substituted Benzimidazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F206244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Erosive esophagitis associated with GERD:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: 40 mg once daily for up to 8 weeks; an additional 8 weeks may be used in patients who have not healed after an 8-week course.",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling recommends initial treatment for up to 4 weeks and an additional 4 weeks in patients who have not healed after the initial 4-week course. Lower doses (20 mg once daily) have been used successfully in mild GERD treatment (Dettmer, 1998).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance of healing: 40 mg once daily (U.S. labeling) or 20-40 mg once daily (Canadian labeling); 20 mg once daily has been used successfully in maintenance of healing (Escourrou, 1999).",
"     <b>",
"      Note:",
"     </b>",
"     Has not been studied beyond 12 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     40 mg once daily for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypersecretory disorders (including Zollinger-Ellison):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: 40 mg twice daily; adjust dose based on patient needs; doses up to 240 mg daily have been administered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     80 mg every 12 hours; adjust dose based on acid output measurements; 160-240 mg daily in divided doses has been used for a limited period (up to 7 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of rebleeding in peptic ulcer bleed (unlabeled use) (Barkun, 2010; Zargar, 2006):",
"     </b>",
"     I.V.: 80 mg, followed by 8 mg/hour infusion for 72 hours.",
"     <b>",
"      Note:",
"     </b>",
"     A daily infusion of 40 mg does not raise gastric pH sufficiently to enhance coagulation in active GI bleeds.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"     </b>",
"     <b>",
"      eradication (unlabeled use in U.S.):",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     American College of Gastroenterology guidelines (Chey, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nonpenicillin allergy: 40 mg twice daily administered with amoxicillin 1000 mg",
"     <i>",
"      and",
"     </i>",
"     clarithromycin 500 mg twice daily for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Penicillin allergy: 40 mg twice daily administered with clarithromycin 500 mg",
"     <i>",
"      and",
"     </i>",
"     metronidazole 500 mg twice daily for 10-14 days",
"     <b>",
"      or",
"     </b>",
"     40 mg once or twice daily administered with bismuth subsalicylate 525 mg",
"     <i>",
"      and",
"     </i>",
"     metronidazole 250 mg",
"     <i>",
"      plus",
"     </i>",
"     tetracycline 500 mg 4 times daily for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling: 40 mg twice daily administered with clarithromycin 500 mg twice daily",
"     <i>",
"      and",
"     </i>",
"     either metronidazole 500 mg",
"     <b>",
"      or",
"     </b>",
"     amoxicillin 1000 mg twice daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Peptic ulcer disease (Canadian labeling):",
"     </b>",
"     Oral: Treatment: 40 mg once daily for 2 weeks (duodenal ulcer) or 4 weeks (gastric ulcer); may extend therapy for an additional 2 or 4 weeks (based on indication) for inadequate healing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of GI lesions associated with NSAID use (Canadian labeling):",
"     </b>",
"     Oral: 20 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Symptomatic GERD (Canadian labeling):",
"     </b>",
"     Oral: Treatment: 40 mg once daily for up to 4 weeks; failure to achieve adequate symptom relief after the initial 4 weeks of therapy warrants further evaluation",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5707304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/45/22231?source=see_link\">",
"      see \"Pantoprazole: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Erosive esophagitis associated with GERD:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &lt;5 years: Dosage not established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;5 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;15 to &lt;40 kg: 20 mg once daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;40 kg: 40 mg once daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Dosage not established",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F206245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F206246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary; pantoprazole is not removed by hemodialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F206247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     U.S. labeling: No dosage adjustment necessary; doses &gt;40 mg daily have not been evaluated in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-moderate impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment: I.V., Oral: Manufacturer labeling suggests a maximum dose of 20 mg daily.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for suspension, delayed release, enteric coated, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protonix&reg;: 40 mg/packet (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protonix&reg; I.V.: 40 mg [contains edetate disodium]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, oral: 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protonix&reg;: 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Strength expressed as base",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Tablet, enteric coated, as magnesium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tecta&reg;: 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes granules for suspension",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15386979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Protonix&reg; granules for oral suspension, delayed release tablets:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM324058.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM324058.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F206213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Flush I.V. line before and after administration. In-line filter not required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-minute infusion: The volume of reconstituted solution (4 mg/mL) to be injected may be administered intravenously over at least 2 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-minute infusion: Infuse over 15 minutes at a rate not to exceed 7 mL/minute (3 mg/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: Should be swallowed whole, do not crush or chew. Best if taken before breakfast.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delayed-release oral suspension: Should only be administered in apple juice or applesauce and taken ~30 minutes before a meal. Do not administer with any other liquid (eg, water) or foods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral administration in",
"     <b>",
"      applesauce",
"     </b>",
"     : Sprinkle intact granules on 1 tablespoon of applesauce and swallow within 10 minutes of preparation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral administration in",
"     <b>",
"      apple juice",
"     </b>",
"     : Empty intact granules into 5 mL of apple juice, stir for 5 seconds, and swallow immediately after preparation. Rinse container once or twice with apple juice and swallow immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nasogastric tube administration: Separate the plunger from the barrel of a 60 mL catheter tip syringe and connect to a &ge;16 French nasogastric tube. Holding the syringe attached to the tubing as high as possible, empty the contents of the packet into barrel of the syringe, add 10 mL of apple juice and gently tap/shake the barrel of the syringe to help empty the syringe. Add an additional 10 mL of apple juice and gently tap/shake the barrel to help rinse. Repeat rinse with at least 2-10 mL aliquots of apple juice. No granules should remain in the syringe.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14473039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     80 mg in 100 mL (concentration: 0.8 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F206292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetazolamide, alprostadil, aminophylline, ampicillin, anidulafungin, cefazolin, dimenhydrinate, dopamine, doripenem, furosemide, ketorolac, penicillin G potassium, potassium chloride, procainamide, telavancin, ticarcillin/clavulanate, vasopressin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, amikacin, amiodarone, amphotericin B, atropine, caffeine citrate, cefotaxime, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, ciprofloxacin, clindamycin, cloxacillin, cyclosporine, dexamethasone sodium phosphate, diazepam, digoxin, diphenhydramine, enalaprilat, esmolol, estrogens (conjugated), fluconazole, hydralazine, hydrocortisone sodium succinate, hydromorphone, indomethacin, isoproterenol, labetalol, levofloxacin, lidocaine, lorazepam, mannitol, meropenem, metoclopramide, moxifloxacin, multiple vitamins, naloxone, nitroprusside, norepinephrine, oxytocin, pancuronium, phenobarbital, piperacillin/tazobactam, potassium phosphate, prochlorperazine edisylate, propofol, propranolol, ranitidine,  thiopental, tobramycin, trimethoprim/sulfamethoxazole, vecuronium, verapamil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Calcium chloride, calcium gluconate, caspofungin, cefazolin, ceftriaxone, dimenhydrinate, dobutamine, dopamine, epinephrine, fentanyl, furosemide, gentamicin, heparin, insulin (regular), magnesium sulfate, meperidine, methylprednisolone sodium succinate, metronidazole, midazolam, morphine, nitroglycerin, norepinephrine, octreotide, phenytoin, sodium bicarbonate, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Acetazolamide, alprostadil, aminophylline, ampicillin, penicillin G sodium, piperacillin, potassium chloride, procainamide, ticarcillin/clavulanate, vancomycin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, amikacin, amiodarone, amphotericin B, atropine, caffeine citrate, calcium chloride, calcium gluconate, cefazolin, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, chlorpromazine, ciprofloxacin, clindamycin, cloxacillin, cyclosporine, dexamethasone sodium phosphate, diazepam, digoxin, dimenhydrinate, diphenhydramine, dobutamine, dopamine, enalaprilat, epinephrine, estrogens (conjugated), fentanyl, fluconazole, furosemide, gentamicin, heparin, hydralazine, hydrocortisone sodium succinate, hydromorphone, indomethacin, insulin (regular), isoproterenol, labetalol, lidocaine, lorazepam, magnesium sulfate, meperidine, meropenem, methylprednisolone sodium succinate, metoclopramide, midazolam, morphine, naloxone, nitroglycerin, nitroprusside, norepinephrine, octreotide, oxytocin, pancuronium, phenobarbital, phenytoin, piperacillin/tazobactam, potassium phosphate, prochlorperazine edisylate, propranolol, ranitidine, sodium bicarbonate, thiopental, tobramycin, trimethoprim/sulfamethoxazole, vecuronium, verapamil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Propofol.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F206212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Short-term (up to 8 weeks) treatment and maintenance of healing of erosive esophagitis associated with GERD; reduction in relapse rates of daytime and nighttime heartburn symptoms in GERD; hypersecretory disorders associated with Zollinger-Ellison syndrome or other GI hypersecretory disorders",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Short-term treatment (7-10 days) of patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis; hypersecretory disorders associated with Zollinger-Ellison syndrome or other GI hypersecretory disorders",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Canadian labeling: Additional use (not in U.S. labeling): Oral: Peptic ulcer disease (eg, duodenal or gastric ulcer); adjunct treatment with antibiotics for",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     eradication; prevention of GI lesions in patients receiving prolonged NSAID therapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F206280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Peptic ulcer disease, active ulcer bleeding (parenteral formulation); adjunct treatment with antibiotics for",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     eradication; stress-ulcer prophylaxis in the critically-ill",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F206294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pantoprazole may be confused with ARIPiprazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Protonix&reg; may be confused with Lotronex&reg;, Lovenox&reg;, protamine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vials containing Protonix&reg; I.V. for injection are not recommended for use with spiked I.V. system adaptors. Nurses and pharmacists have reported breakage of the glass vials during attempts to connect spiked I.V. system adaptors, which may potentially result in injury to healthcare professionals.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Protonix [U.S., Canada] may be confused with Pretanix brand name for indapamide [Hungary]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F206282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (adults 12%; children &gt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Facial edema (&le;4%), generalized edema (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (&le;4%), vertigo (&le;4%), depression (&le;2%), fever (adults &le;2%; children &gt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (adults &le;2%; children &gt;4%), urticaria (&le;4%), photosensitivity (&le;2%), pruritus (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Triglycerides increased (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (&le;9%), abdominal pain (children &gt;4%), vomiting (&ge;4%), constipation (&le;4%), flatulence (children &le;4%), nausea (children &le;4%), xerostomia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Leukopenia (&le;2%), thrombocytopenia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Liver function tests abnormal (&le;4%), hepatitis (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reaction (thrombophlebitis &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (&le;4%), myalgia (&le;4%), CPK increased (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (children &gt;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Allergic reaction (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Albuminuria, alkaline phosphatase increased, anaphylaxis (including anaphylactic shock), anemia, angioedema, angina pectoris, aphthous stomatitis, arrhythmia, asthma exacerbation, atrial fibrillation/flutter, atrophic gastritis, biliary pain, bone pain, breast pain, bursitis, cataract, CHF, cholecystitis, cholelithiasis,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associate diarrhea (CDAD), colitis, contact dermatitis, creatinine increased, cystitis, deafness, dehydration, diabetes mellitus, diplopia, duodenitis, dysarthria, dysmenorrhea, dysphagia, dysuria, ecchymosis, ECG abnormality, eosinophilia, epididymitis, epistaxis, erythema multiforme, esophagitis, extraocular palsy, fatigue, fracture, fungal dermatitis, gastrointestinal carcinoma, gastrointestinal hemorrhage, gastrointestinal moniliasis, GGT increased, gingivitis, glaucoma, glossitis, glycosuria, goiter, gout, hallucinations, hematemesis, hematuria, hemorrhage, hepatic failure, hernia, hyperbilirubinemia, hyperesthesia, hyper-/hypotension, hyperkinesia, hyperuricemia, hypokinesia, hypomagnesemia, hyponatremia, impotence, interstitial nephritis, jaundice, kidney calculus, kidney pain,  leukocytosis, lichenoid dermatitis, maculopapular rash, melena, mouth ulceration, myocardial infarction, myocardial ischemia, neoplasm, neuralgia, neuritis, optic neuropathy (including anterior ischemic), palpitation, pancreatitis, pancytopenia, paresthesia, periodontitis, pneumonia, pyelonephritis, rectal hemorrhage, retinal vascular disorder, rhabdomyolysis, scrotal edema, seizure, Stevens-Johnson syndrome, stomach ulcer, stomatitis, syncope, tachycardia, tenosynovitis, thrombosis, tinnitus, tongue discoloration, toxic epidermal necrolysis, tremor, urethritis, vision abnormal",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F206217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pantoprazole, substituted benzimidazole proton pump inhibitors, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F206199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrophic gastritis: Long-term pantoprazole therapy (especially in patients who were",
"     <i>",
"      H. pylori",
"     </i>",
"     positive) has caused biopsy-proven atrophic gastritis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carcinoma: Benign and malignant neoplasia has been observed in long-term rodent studies; while not reported in humans, the relevance of these findings in regards to tumorigenicity in humans is not known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy. Patients on high-dose or long-term therapy (&ge;1 year) should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypomagnesemia: Reported rarely, usually with prolonged PPI use of &gt;3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter.  Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of pantoprazole may be necessary; magnesium levels typically return to normal within 2 weeks of stopping.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion related reactions: Thrombophlebitis and hypersensitivity reactions including anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported with I.V.  administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     malabsorption: Prolonged treatment (typically &gt;3 years) may lead to vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     malabsorption and subsequent deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal infection (eg,",
"     <i>",
"      Salmonella, Campylobacter",
"     </i>",
"     ): Use of proton pump inhibitors may increase risk of these infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel. Of the PPIs, pantoprazole has the lowest degree of CYP2C19 inhibition",
"     <i>",
"      in vitro",
"     </i>",
"     (Li, 2004) and has been shown to have less effect on conversion of clopidogrel to its active metabolite compared to omeprazole (Angiolillo, 2011).  In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically-significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham, 2010; Levine, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for other interactions : Concomitant use of pantoprazole with some drugs may require cautious use, may not be recommended, or may require dosage adjustments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edetate sodium (EDTA): Intravenous preparation contains edetate sodium; use caution in patients who are at risk for zinc deficiency if other EDTA-containing solutions are coadministered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     eradication: Short-term combination therapy (&le;7 days) has been associated with a higher incidence of treatment failure. The American College of Gastroenterology recommends 10-14 days of therapy (triple or quadruple) for eradication of",
"     <i>",
"      H. pylori",
"     </i>",
"     (Chey, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F206277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     BCRP, CYP2C19 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Proton Pump Inhibitors may increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Pantoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Proton Pump Inhibitors may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.  Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F206235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may cause gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Prolonged treatment (typically &gt;3 years) may lead to vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     malabsorption and subsequent deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F206220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. Use in pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F206251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F206221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended due to carcinogenicity in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F206222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be taken with or without food; best if taken before breakfast.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Due to EDTA in preparation, zinc supplementation may be needed in patients prone to zinc deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F206219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Protonix Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (1): $7.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Pantoprazole Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (1): $5.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Protonix Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (1): $6.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Pantoprazole Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $368.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (90): $368.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Protonix Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $688.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (90): $688.52",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F206209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersecretory disorders: Acid output measurements, target level &lt;10 mEq/hour (&lt;5 mEq/hour if prior gastric acid-reducing surgery)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F206223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acernix (PH);",
"     </li>",
"     <li>",
"      Anagastra (ES);",
"     </li>",
"     <li>",
"      Anxel (EE);",
"     </li>",
"     <li>",
"      Apton (PT);",
"     </li>",
"     <li>",
"      Azidex (AT);",
"     </li>",
"     <li>",
"      Branzol (UY);",
"     </li>",
"     <li>",
"      Caprol (ID);",
"     </li>",
"     <li>",
"      Ciproton (MX);",
"     </li>",
"     <li>",
"      Conpanzole (MY);",
"     </li>",
"     <li>",
"      Controloc (BG, CZ, EE, EG, HR, HU, IL, IR, JO, MY, PK, PL, RU, SE, SG, TH, ZA);",
"     </li>",
"     <li>",
"      Eumac (IN);",
"     </li>",
"     <li>",
"      Eupantol (FR);",
"     </li>",
"     <li>",
"      Extreme (KP);",
"     </li>",
"     <li>",
"      Fozole (IN);",
"     </li>",
"     <li>",
"      Gastroloc (TW);",
"     </li>",
"     <li>",
"      Gastromax (AR);",
"     </li>",
"     <li>",
"      Inipomp (FR);",
"     </li>",
"     <li>",
"      Kaiji (CL);",
"     </li>",
"     <li>",
"      Kuppam (MX);",
"     </li>",
"     <li>",
"      Leminter (MX);",
"     </li>",
"     <li>",
"      Luoxu (CL);",
"     </li>",
"     <li>",
"      Noacid (BG);",
"     </li>",
"     <li>",
"      Nolpaza (EE);",
"     </li>",
"     <li>",
"      Ozpan (AU);",
"     </li>",
"     <li>",
"      Panloc (ID);",
"     </li>",
"     <li>",
"      Panprax (CH);",
"     </li>",
"     <li>",
"      Panrazol (HK);",
"     </li>",
"     <li>",
"      Pantazol (PH);",
"     </li>",
"     <li>",
"      Pantec (IN);",
"     </li>",
"     <li>",
"      Pantecta (CR, DO, ES, GT, HN, IT, NI, NL, PA, SV);",
"     </li>",
"     <li>",
"      Panteon (KP);",
"     </li>",
"     <li>",
"      Panto (TR);",
"     </li>",
"     <li>",
"      Panto-Byk (LU);",
"     </li>",
"     <li>",
"      Pantoavenir IV (IL);",
"     </li>",
"     <li>",
"      Pantoc (PT);",
"     </li>",
"     <li>",
"      Pantocar (PH);",
"     </li>",
"     <li>",
"      Pantocid (NZ, TH, ZA);",
"     </li>",
"     <li>",
"      Pantodac (IN);",
"     </li>",
"     <li>",
"      Pantodar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Pantoloc (AT, AU, CL, DK, FR, HK, KP, PH, SE, TW);",
"     </li>",
"     <li>",
"      Pantomed (KP);",
"     </li>",
"     <li>",
"      Pantop (AR, PK, VE);",
"     </li>",
"     <li>",
"      Pantopan (IN, IT);",
"     </li>",
"     <li>",
"      Pantoprix (PH);",
"     </li>",
"     <li>",
"      Pantor (PH);",
"     </li>",
"     <li>",
"      Pantostac (KP);",
"     </li>",
"     <li>",
"      Pantozol (AE, BE, BH, CH, CY, DE, EG, ID, IQ, IR, JO, KW, LB, LU, LY, MX, NL, OM, PH, QA, SA, SE, SY, YE);",
"     </li>",
"     <li>",
"      Pantul (EE);",
"     </li>",
"     <li>",
"      Panzole (SG);",
"     </li>",
"     <li>",
"      Panzor (FI);",
"     </li>",
"     <li>",
"      Pauly (MX);",
"     </li>",
"     <li>",
"      Peptazol (AR, SG);",
"     </li>",
"     <li>",
"      Pepticus (PY);",
"     </li>",
"     <li>",
"      Pepzol (ID);",
"     </li>",
"     <li>",
"      Peucetol (MX);",
"     </li>",
"     <li>",
"      Pozola (TW);",
"     </li>",
"     <li>",
"      Protium (GB, IE);",
"     </li>",
"     <li>",
"      Protopan (PY);",
"     </li>",
"     <li>",
"      Prozolan (MX);",
"     </li>",
"     <li>",
"      Pulcet (BG);",
"     </li>",
"     <li>",
"      Regad (MX);",
"     </li>",
"     <li>",
"      Rifun 40 (DE);",
"     </li>",
"     <li>",
"      Salpraz (AU);",
"     </li>",
"     <li>",
"      Segregam (CO);",
"     </li>",
"     <li>",
"      Somac (AU, CZ, FI, NO, NZ);",
"     </li>",
"     <li>",
"      Sunpraz (RU);",
"     </li>",
"     <li>",
"      Tecta (BR, CO, CR, DO, EC, GT, HN, MX, NI, PA, SV);",
"     </li>",
"     <li>",
"      Tonval (PE);",
"     </li>",
"     <li>",
"      Topazol (ID);",
"     </li>",
"     <li>",
"      Toprazol (KP);",
"     </li>",
"     <li>",
"      Toprazole (MY);",
"     </li>",
"     <li>",
"      Ulcemex (CN, PY);",
"     </li>",
"     <li>",
"      Ulcepraz (PH);",
"     </li>",
"     <li>",
"      Ulprix (BG);",
"     </li>",
"     <li>",
"      Unigastrozol (MX);",
"     </li>",
"     <li>",
"      Vomizole (ID);",
"     </li>",
"     <li>",
"      Xotepic (PL);",
"     </li>",
"     <li>",
"      Ziprol (BR);",
"     </li>",
"     <li>",
"      Zolpra (MX);",
"     </li>",
"     <li>",
"      Zoltum (CR, EC, GT, HN, NI, PA, PE, SV);",
"     </li>",
"     <li>",
"      Zurcal (AT, BR, CH, CN, CO, EC, MX, PE, PT);",
"     </li>",
"     <li>",
"      Zurcale (BE);",
"     </li>",
"     <li>",
"      Zurcamed (BE);",
"     </li>",
"     <li>",
"      Zurcazol (GR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F206198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppresses gastric acid secretion by inhibiting the parietal cell H",
"     <sup>",
"      +",
"     </sup>",
"     /K",
"     <sup>",
"      +",
"     </sup>",
"     ATP pump",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F206216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid, well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 11-24 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic; CYP2C19 (demethylation), CYP3A4; no evidence that metabolites have pharmacologic activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~77%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1 hour; increased to 3.5-10 hours with CYP2C19 deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (71%); feces (18%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abraham NS, Hlatky MA, Antman EM, et al, &ldquo;ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(24):2619-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/21060077/pubmed\" id=\"21060077\" target=\"_blank\">",
"        21060077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Angiolillo DJ, Gibson CM, Cheng S, et al, &ldquo;Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2011, 89(1):65-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/20844485/pubmed\" id=\"20844485\" target=\"_blank\">",
"        20844485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bardhan KD, Dillon J, Axon AT, et al, &ldquo;Triple Therapy for",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Eradication: A Comparison of Pantoprazole Once Versus Twice Daily,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2000, 14(1):59-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/10632646/pubmed\" id=\"10632646\" target=\"_blank\">",
"        10632646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barkun AN, Bardou M, Kulpers EJ, et al, &ldquo;International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2010, 152(2):101-113.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/20083829/pubmed\" id=\"20083829\" target=\"_blank\">",
"        20083829",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brunner G, Luna P, Hartmann M, et al, &ldquo;Optimizing the Intragastric pH as a Supportive Therapy in Upper GI Bleeding,&rdquo;",
"      <i>",
"       Yale J Biol Med",
"      </i>",
"      , 1996, 69(3):225-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/9165691/pubmed\" id=\"9165691\" target=\"_blank\">",
"        9165691",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD, Wong BC, et al, &ldquo;American College of Gastroenterology Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       Am J Gastroent",
"      </i>",
"      , 2007, 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cockayne SE, Glet RJ, Gawkrodger DJ, et al, &ldquo;Severe Erythrodermic Reactions to the Proton Pump Inhibitors Omeprazole and Lansoprazole,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      ,1999, 141(1):173-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/10417548/pubmed\" id=\"10417548\" target=\"_blank\">",
"        10417548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Jager CP, Wever PC, Gemen EF, et al, &ldquo;Proton Pump Inhibitor Therapy Predisposes to Community-Acquired",
"      <i>",
"       Streptococcus pneumoniae",
"      </i>",
"      Pneumonia,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2012, 36(10):941-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/23034135/pubmed\" id=\"23034135\" target=\"_blank\">",
"        23034135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo; [published correction appears in",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1394-6],",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(1):296-327.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/18158437/pubmed\" id=\"18158437\" target=\"_blank\">",
"        18158437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dettmer A, Vogt R, Sielaff F, et al, &ldquo;Pantoprazole 20 mg is Effective for Relief of Symptoms and Healing of Lesions in Mild Reflux Oesophagitis,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 1998, 12(9): 865-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/9768529/pubmed\" id=\"9768529\" target=\"_blank\">",
"        9768529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Escourrou J, Deprez P, Saggioro A, et al, &ldquo;Maintenance Therapy With Pantoprazole 20 mg Prevents Relapse of Reflux Oesophagitis,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 1999, 13(11):1481-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/10571605/pubmed\" id=\"10571605\" target=\"_blank\">",
"        10571605",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson CE, &ldquo;Stability of Pantoprazole in 0.9% Sodium Chloride Injection in Polypropylene Syringes,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2005, 62(22):2410-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/16278334/pubmed\" id=\"16278334\" target=\"_blank\">",
"        16278334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jung R and MacLaren R, &ldquo;Proton-Pump Inhibitors for Stress Ulcer Prophylaxis in Critically Ill Patients,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(12):1929-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/12452757/pubmed\" id=\"12452757\" target=\"_blank\">",
"        12452757",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2008, 135(4):1383-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/18789939/pubmed\" id=\"18789939\" target=\"_blank\">",
"        18789939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lanza FL, Chan FK, and Quigley EM, &ldquo;Guidelines for Prevention of NSAID-Related Ulcer Complications,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 140(3):728-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/19240698/pubmed\" id=\"19240698\" target=\"_blank\">",
"        19240698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau JY, Leung WK, Wu JC, et al, &ldquo;Omeprazole Before Endoscopy in Patients With Gastrointestinal Bleeding,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(16):1631-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/17442905/pubmed\" id=\"17442905\" target=\"_blank\">",
"        17442905",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau JY, Sung JJ, Lee KK, et al, &ldquo;Effect of Intravenous Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(5):310-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/10922420/pubmed\" id=\"10922420\" target=\"_blank\">",
"        10922420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lew EA, Pisegna JR, Starr JA, et al, &ldquo;Intravenous Pantoprazole Rapidly Controls Gastric Acid Hypersecretion in Patients With Zollinger-Ellison Syndrome,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2000, 118(4):696-704.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/10734021/pubmed\" id=\"10734021\" target=\"_blank\">",
"        10734021",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lin HJ, Lo WC, Lee FY, et al, &ldquo;A Prospective Randomized Comparative Trial Showing That Omeprazole Prevents Rebleeding in Patients With Bleeding Peptic Ulcer After Successful Endoscopic Therapy,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(1):54-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/9437379/pubmed\" id=\"9437379\" target=\"_blank\">",
"        9437379",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li X-Q, Anderson TB, Ahlstrom M, et al, &ldquo;Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,&rdquo;",
"      <i>",
"       Drug Metab Disp",
"      </i>",
"      , 2004, 32(8):821-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Madrazo-de la Garza A, Dibildox M, Vargas A, et al, &ldquo;Efficacy and Safety of Oral Pantoprazole 20 mg Given Once Daily for Reflux Esophagitis in Children,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2003, 36(2):261-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/12548064/pubmed\" id=\"12548064\" target=\"_blank\">",
"        12548064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan D, &ldquo;Intravenous Proton-Pump Inhibitors in the Critical Care Setting,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(6 Suppl):369-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/12072664/pubmed\" id=\"12072664\" target=\"_blank\">",
"        12072664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Natsch S, Vinks MH, Voogt AK, et al, &ldquo;Anaphylactic Reactions to Proton-Pump Inhibitors,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(4):474-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/10772433/pubmed\" id=\"10772433\" target=\"_blank\">",
"        10772433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paoluzi P, Iacopini F, Crispino P, et al, &ldquo;2-Week Triple Therapy for",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection is Better Than 1-Week in Clinical Practice: a Large Prospective Single-Center Randomized Study,&rdquo;",
"      <i>",
"       Helicobacter",
"      </i>",
"      , 2006, 11(6):562-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/17083378/pubmed\" id=\"17083378\" target=\"_blank\">",
"        17083378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perri F, Festa V, Clemente R, et al, &ldquo;Randomized Study of Two &ldquo;Rescue&rdquo; Therapies for",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      -infected Patients After Failure of Standard Triple Therapies,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2001, 96(1):58-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/11197288/pubmed\" id=\"11197288\" target=\"_blank\">",
"        11197288",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poole P, &ldquo;Pantoprazole,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2001, 58:999-1008.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/11402494/pubmed\" id=\"11402494\" target=\"_blank\">",
"        11402494",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sung JJ, Barkun A, Kuipers EJ, et al, &ldquo;Intravenous Esomeprazole for Prevention of Recurrent Peptic Ulcer Bleeding: A Randomized Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2009, 150(7):455-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/19221370/pubmed\" id=\"19221370\" target=\"_blank\">",
"        19221370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2005, 100(10):2324-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/16181387/pubmed\" id=\"16181387\" target=\"_blank\">",
"        16181387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tolia V, Bishop PR, Tsou VM, et al, &ldquo;Multicenter, Randomized, Double-Blind Study Comparing 10, 20 and 40 mg Pantoprazole in Children (5-11 Years) With Symptomatic Gastroesophageal Reflux Disease,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2006, 42(4):384-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/16641576/pubmed\" id=\"16641576\" target=\"_blank\">",
"        16641576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tsou VM, Baker R, Book L, et al, &ldquo;Multicenter, Randomized, Double-Blind Study Comparing 20 and 40 mg of Pantoprazole for Symptom Relief in Adolescents (12 to 16 Years of Age) With Gastroesophageal Refulx Disease (GERD),&rdquo;",
"      <i>",
"       Clin Pediatr",
"      </i>",
"      , 2006, 45(8):741-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/16968960/pubmed\" id=\"16968960\" target=\"_blank\">",
"        16968960",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vcev A, Stimac D, Ivandic A, et al, &ldquo;Pantoprazole, Amoxycillin, and Either Azithromycin or Clarithromycin for Eradication of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      in Duodenal Ulcer,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2000, 14(1):69-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/10632647/pubmed\" id=\"10632647\" target=\"_blank\">",
"        10632647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolfe MM and Sachs G, &ldquo;Acid Suppression: Optimizing Therapy for Gastroduodenal Ulcer Healing, Gastroesophageal Reflux Disease, and Stress-Related Erosive Syndrome,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2000,118(2 Suppl 1):9-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/10868896/pubmed\" id=\"10868896\" target=\"_blank\">",
"        10868896",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zargar SA, Javid G, Khan BA, et al, &ldquo;Pantoprazole Infusion as Adjuvant Therapy to Endoscopic Treatment In Patients With Peptic Ulcer Bleeding: Prospective Randomized Controlled Trial,&rdquo;",
"      <i>",
"       J Gastroenterol Hepatol",
"      </i>",
"      , 2006, 21(4):716-21",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/16/32009/abstract-text/16677158/pubmed\" id=\"16677158\" target=\"_blank\">",
"        16677158",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9474 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32009=[""].join("\n");
var outline_f31_16_32009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16572471\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206239\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206240\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206284\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206244\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5707304\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206245\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206246\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206247\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206211\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950137\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206195\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15386979\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206213\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473039\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206292\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206212\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206280\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206294\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206282\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206217\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206199\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206277\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206204\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206235\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206207\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206220\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206251\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206221\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206222\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206219\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206209\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206223\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206198\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206216\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9474\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9474|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/40/13957?source=related_link\">",
"      Pantoprazole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/45/22231?source=related_link\">",
"      Pantoprazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_16_32010="Clinical features and diagnosis of abdominal aortic aneurysm";
var content_f31_16_32010=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of abdominal aortic aneurysm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32010/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32010/contributors\">",
"     Jeffrey Jim, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32010/contributors\">",
"     Robert W Thompson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32010/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32010/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32010/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32010/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/16/32010/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/16/32010/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/16/32010/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H135236269\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal aortic aneurysm (AAA), which is an abnormal focal dilation of the abdominal aorta, is relatively common and has the potential for significant morbidity and mortality. Most patients with AAA are asymptomatic but come to medical attention by finding of a pulsatile mass on physical examination, as the result of other abdominal imaging studies, or through ultrasound screening programs for AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/1\">",
"     1",
"    </a>",
"    ]. When symptoms do occur, patients commonly present with abdominal, back, or flank pain, but thromboembolism can also occur leading to symptoms of limb ischemia. Aneurysms that produce symptoms are at an increased risk for rupture, which is associated with high mortality rates.",
"   </p>",
"   <p>",
"    A diagnosis of AAA generally requires imaging confirmation that an aneurysm is present, which is most often accomplished using abdominal ultrasound. However, in symptomatic patients, computed tomography of the abdomen provides additional information that can determine if the aneurysm has ruptured, is expanding rapidly, and for those without signs of rupture, whether or not symptoms are likely to be related to the aneurysm or due to other abdominal pathology.",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of AAA will be reviewed here. The management of nonruptured and ruptured AAA are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H611107773#H611107773\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Introduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11225?source=see_link&amp;anchor=H53322839#H53322839\">",
"     \"Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22314302\">",
"    <span class=\"h1\">",
"     ANEURYSM DEFINITION AND ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An aneurysm is defined as a segmental, full-thickness dilation of a blood vessel 50 percent greater than its normal diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Although &ldquo;normal&rdquo; diameter varies with age, gender, and body habitus, the average diameter of the human infrarenal aorta is about 2.0 cm; the upper limit of normal is typically &lt;3.0 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, for the majority of patients, an infrarenal aorta with a maximum diameter &ge;3.0 cm is aneurysmal [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. The normal diameter of the suprarenal aorta tends to be about 0.5 cm larger than the infrarenal aorta.",
"   </p>",
"   <p>",
"    The aorta dilates with age and the normal aortic diameter in older patients tends to be larger. In a population-based study using magnetic resonance imaging to obtain aortic diameters at various levels in 70-year-old patients, the average diameters were [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Above the celiac artery &ndash; Men: 3.0 cm, Women: 2.7 cm",
"     </li>",
"     <li>",
"      Above the renal arteries &ndash; Men: 3.8 cm, Women: 2.7 cm",
"     </li>",
"     <li>",
"      Just below the renal arteries &ndash; Men: 2.4 cm, Women: 2.2 cm",
"     </li>",
"     <li>",
"      At aortic bifurcation &ndash; Men: 2.3 cm, Women: 2.0 cm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The abdominal aorta (",
"    <a class=\"graphic graphic_figure graphicRef60682 \" href=\"UTD.htm?9/29/9683\">",
"     figure 1",
"    </a>",
"    ) is the most common anatomic site of arterial aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/3\">",
"     3",
"    </a>",
"    ]. Abdominal aortic aneurysms (AAAs) are described relative to the involvement of the renal or visceral vessels.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infrarenal &ndash; The aneurysm originates below the renal arteries (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87329 \" href=\"UTD.htm?26/26/27044\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87331 \" href=\"UTD.htm?42/38/43622\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Juxtarenal &ndash; The aneurysm originates at the level of the renal arteries but the aorta at the renal arteries is normal.",
"     </li>",
"     <li>",
"      Pararenal &ndash; The aneurysm involves the aorta at the level of the renal arteries, ie, the renal artery originates from an aneurysmal aorta (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87567 \" href=\"UTD.htm?36/57/37782\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Suprarenal (visceral) &ndash; The aneurysm originates above the renal arteries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most AAAs are infrarenal (",
"    <a class=\"graphic graphic_figure graphicRef51087 \" href=\"UTD.htm?42/14/43234\">",
"     figure 2",
"    </a>",
"    ). About 15 percent are juxtarenal [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/7\">",
"     7",
"    </a>",
"    ]. Suprarenal aneurysms not also affecting the infrarenal, juxtarenal, or thoracic aorta are uncommon, but may develop late following AAA repair [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1382371318\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors associated with AAA are listed here and are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11450?source=see_link\">",
"     \"Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are associated with an increased risk of developing AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/3,9-11\">",
"     3,9-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Smoking",
"     </li>",
"     <li>",
"      Male gender",
"     </li>",
"     <li>",
"      Advancing age",
"     </li>",
"     <li>",
"      Caucasian race",
"     </li>",
"     <li>",
"      Atherosclerosis",
"     </li>",
"     <li>",
"      Family history of AAA",
"     </li>",
"     <li>",
"      Other peripheral artery aneurysm (iliac, femoral, popliteal)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of aneurysm rupture is increased with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large initial aneurysm diameter (&gt;5.5 cm)",
"     </li>",
"     <li>",
"      Current smoking",
"     </li>",
"     <li>",
"      Elevated blood pressure",
"     </li>",
"     <li>",
"      Greater aortic expansion rate (&gt;0.5",
"      <span class=\"nowrap\">",
"       cm/year)",
"      </span>",
"     </li>",
"     <li>",
"      Female gender",
"     </li>",
"     <li>",
"      Symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Non-Caucasian race and diabetes are associated with a decreased risk for AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/11\">",
"     11",
"    </a>",
"    ]. Although a smaller percentage of women have aneurysms (approximately 20 percent of all AAA diagnoses), women present with rupture more often than men [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15830649\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal aortic aneurysm presents clinically in a variety of ways. Most individuals with AAA have no symptoms. When symptoms do occur, pain is the most common complaint. Pain may or may not be associated with AAA rupture or other associated symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15830656\">",
"    <span class=\"h2\">",
"     Asymptomatic AAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;An asymptomatic (occult) AAA may be discovered as a result of screening, on routine physical examination, or on imaging studies obtained to evaluate an unrelated condition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening for AAA &ndash; Screening for AAA is performed in defined populations based upon risk (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87330 \" href=\"UTD.htm?2/18/2337\">",
"       image 4",
"      </a>",
"      ). In some, but not all countries, screening programs for AAA appear to have contributed to a reduced incidence of ruptured AAA [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/1,13,14\">",
"       1,13,14",
"      </a>",
"      ]. Screening for AAA is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24488?source=see_link\">",
"       \"Screening for abdominal aortic aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulsatile abdominal mass &ndash; Approximately 30 percent of asymptomatic AAAs may be suspected when a pulsatile abdominal mass is palpated on routine physical examination [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/15\">",
"       15",
"      </a>",
"      ]. The ability to palpate and estimate the aortic diameter depends upon the patient&rsquo;s body habitus, the size of the aneurysm, and the clinical experience of the practitioner. (See",
"      <a class=\"local\" href=\"#H181174645\">",
"       'Abdominal palpation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Incidental finding on radiography &ndash; AAA is frequently detected as an incidental finding on imaging studies performed for other purposes [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/16-19\">",
"       16-19",
"      </a>",
"      ]. It is important to note that this information is often",
"      <strong>",
"       not",
"      </strong>",
"      passed on to the referring physician, and up to one-third of patients with aneurysms detected incidentally underwent no subsequent monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/16,20-22\">",
"       16,20-22",
"      </a>",
"      ]. The following findings are illustrative: [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One review study identified AAA in 1 percent of 79,121 abdominal imaging studies including computed tomography of the abdomen, ultrasound, and magnetic resonance imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/16\">",
"       16",
"      </a>",
"      ]. The mean aortic diameter was 4.0 cm. The presence of AAA was communicated to the family physician in only 15 percent of patients.",
"     </li>",
"     <li>",
"      Another review identified delayed recognition or delayed communication of incidental findings on computed tomography in nearly two-thirds of patients, including eight patients who had AAA &gt;5.5 cm, which represented 9 percent of newly diagnosed aortic dilations [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Associated arterial disease &ndash; AAA may also be detected during the clinical examination or work-up for lower extremity symptoms (eg, claudication) thought to be due to peripheral artery disease, or evaluation related to another peripheral aneurysm (iliac, femoral, popliteal) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87339 \" href=\"UTD.htm?40/30/41447\">",
"       image 5",
"      </a>",
"      ). Iliac aneurysm commonly occurs in association with AAA. In a retrospective review of 10,038 patients with iliac aneurysm, 89 percent had a coexistent AAA [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/23\">",
"       23",
"      </a>",
"      ]. Another study found a 14 percent incidence of femoral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      popliteal artery aneurysms in association with AAA [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3065?source=see_link\">",
"       \"Popliteal artery aneurysm\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29304?source=see_link\">",
"       \"Iliac artery aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15830889\">",
"    <span class=\"h2\">",
"     Symptomatic (nonruptured) AAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic AAA refers to any of a number of symptoms that can be attributed to the aneurysm. In surgical series, between 5 and 22 percent of AAA are symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/25-30\">",
"     25-30",
"    </a>",
"    ]. Because symptoms in association with a diagnosis of AAA increase the risk for rupture, symptoms that are not obviously attributable to another cause (eg, diverticulitis), should be presumed to be due to the aneurysm, until proven otherwise. (See",
"    <a class=\"local\" href=\"#H181175753\">",
"     'Symptoms'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H1191820574#H1191820574\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Aneurysm repair versus conservative management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AAA can also present initially as a complication of instrumentation of the aorta (eg, arteriography, cardiac catheterization). As catheters are passed through the aorta, thrombus or atherosclerotic debris associated with the aneurysm can dislodge and embolize distally. Thromboembolism from thrombus within AAA has also been reported following abdominal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H181175588\">",
"     'Limb ischemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15830929\">",
"    <span class=\"h2\">",
"     Ruptured AAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic rupture is due to the weakening of the aortic wall to the extent that it can no longer support the forces imposed upon it leading to a full-thickness tissue loss that results in escape of blood outside the confines of the aorta. Whether aortic rupture is due to AAA or to another disease process (eg, penetrating aortic ulcer, aortic dissection) can only be ascertained though aortic imaging.",
"   </p>",
"   <p>",
"    The incidence of ruptured AAA in hospitalized patients underestimates the overall incidence of ruptured AAA because only about half of patients with ruptured abdominal aortic aneurysm survive long enough for treatment, and not all patients with sudden death undergo autopsy to confirm the cause of death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11450?source=see_link\">",
"     \"Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AAA can present initially with rupture with no intervening symptoms. Although the signs and symptoms of rAAA may be obvious, some presentations make ruptured AAA difficult to recognize.&nbsp;Patients with rupture into the retroperitoneum may attribute their symptoms to other causes, and delay seeking medical attention. Even after presenting to a physician, a misdiagnosis of rAAA as renal colic, perforated viscus, diverticulitis, gastrointestinal hemorrhage, and ischemic bowel occurs about 30 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/32\">",
"     32",
"    </a>",
"    ]. An unsuspected AAA rupture can also be diagnosed on imaging studies obtained to evaluate symptoms presumed to be due to another diagnosis, or a diagnosis of ruptured AAA may only be learned upon autopsy after the patient&rsquo;s demise.",
"   </p>",
"   <p>",
"    The clinical presentation of ruptured AAA in patients who have undergone prior endovascular repair is similar to de novo rupture. Post-EVAR rupture is due to unresolved endoleak re-pressurizing the aneurysm sac and is most commonly seen in patients who have undergone EVAR with less than ideal anatomy or in those who have not been compliant with post-EVAR follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25626?source=see_link&amp;anchor=H1191826906#H1191826906\">",
"     \"Complications of endovascular abdominal aortic repair\", section on 'Endoleak'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22317736\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1382371370\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history is useful for determining the patient&rsquo;s risk for developing AAA, and if AAA is present, the potential for rupture. (See",
"    <a class=\"local\" href=\"#H1382371318\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to assessing risk factors, the patient and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    guardian should be asked:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whether a diagnosis of AAA has been established in the past. Values of aortic diameter from prior imaging studies should be obtained for comparison. Whenever serial imaging studies are available, prior rates of aortic expansion",
"      <span class=\"nowrap\">",
"       (cm/year)",
"      </span>",
"      should be obtained (or calculated) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87327 \" href=\"UTD.htm?15/30/15848\">",
"       image 6",
"      </a>",
"      ). This can be accomplished by taking the maximal aortic diameter from one year and subtracting the diameter from the prior year and dividing by the number of intervening years. As an example, if the aneurysm measured 3.5 cm one year and 5.25 cm two years later, the expansion rate is (5.25 cm - 3.5",
"      <span class=\"nowrap\">",
"       cm)/2",
"      </span>",
"      years or 0.875",
"      <span class=\"nowrap\">",
"       cm/year,",
"      </span>",
"      which exceeds the average expansion rate of 0.5",
"      <span class=\"nowrap\">",
"       cm/year",
"      </span>",
"      and may increase the risk for rupture. (See",
"      <a class=\"local\" href=\"#H22314616\">",
"       'Are symptoms related to AAA?'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11450?source=see_link&amp;anchor=H91206665#H91206665\">",
"       \"Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm\", section on 'Aortic expansion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Whether prior AAA repair has been undertaken. Dilation of the suprarenal abdominal aorta can occur after open or endovascular AAA repair [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/34\">",
"       34",
"      </a>",
"      ], or in the case of prior endovascular repair, mechanical problems can lead to endoleak, which can pressurize the residual infrarenal aortic sac and potentially lead to rupture [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/35\">",
"       35",
"      </a>",
"      ]. Following open AAA repair, late anastomotic failures can occur at the proximal or distal anastomosis with or without associated graft infection, leading to pseudoaneurysm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25626?source=see_link&amp;anchor=H1191826906#H1191826906\">",
"       \"Complications of endovascular abdominal aortic repair\", section on 'Endoleak'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H22314616\">",
"       'Are symptoms related to AAA?'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient may or may not be aware of a diagnosis of AAA prior to clinical manifestations of rupture. Only 20 to 30 percent of patients who present to an emergency department with rupture have a known history of AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who present with symptoms, the history should also seek known disease processes that can cause",
"    <span class=\"nowrap\">",
"     abdominal/back",
"    </span>",
"    or flank pain, as well as to identify prior abdominal surgeries (eg, cholecystectomy, appendectomy). (See",
"    <a class=\"local\" href=\"#H1382370816\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181175753\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals with AAA have no symptoms. Younger patients with AAA may be more likely to have symptoms compared with older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/38\">",
"     38",
"    </a>",
"    ]. When symptoms do occur, pain located in the abdomen, back, or flank is the most common clinical manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/3\">",
"     3",
"    </a>",
"    ]. AAA can also present with limb ischemia, or with systemic manifestations related to an infected aneurysm or inflammatory aneurysm. These symptoms and other clinical manifestations may or may not be related to AAA rupture. The classic triad of severe acute pain, a pulsatile abdominal mass, and hypotension occurs in about 50 percent of patients with ruptured AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms potentially related to AAA can mimic many other diseases; however, in patients known to have, or subsequently shown to have AAA, symptoms are presumed to be due to the aneurysm until unequivocally proven otherwise. (See",
"    <a class=\"local\" href=\"#H1382370816\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22314616\">",
"     'Are symptoms related to AAA?'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181174707\">",
"    <span class=\"h3\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patterns of pain referable to AAA vary widely related to the diameter and position of the aneurysm, whether the aneurysm is ruptured, and if ruptured, the nature (contained or free) and the location of the rupture (proximal or distal aorta). However, a complaint of abdominal pain is relatively nonspecific and can be due to a variety of other conditions. The general approach and evaluation of patients with abdominal pain is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pain related to AAA is typically located in the abdomen, but back or flank pain, pelvic pain, or pain radiating to the groin or thigh are also described [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/42\">",
"     42",
"    </a>",
"    ]. One retrospective review of 66 ruptured AAAs reported pain as a presenting symptom in 75 percent of patients; 45 percent had abdominal pain, 17 percent had",
"    <span class=\"nowrap\">",
"     flank/back",
"    </span>",
"    pain, and 14 percent had both [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/41\">",
"     41",
"    </a>",
"    ]. Abdominal pain was associated with nausea in 20 percent and syncope or a faint feeling in about 30 percent of patients.",
"   </p>",
"   <p>",
"    The location of the pain can usually be related to the position of the aneurysm, with aneurysms positioned more proximally producing upper",
"    <span class=\"nowrap\">",
"     abdominal/back",
"    </span>",
"    pain and distal aneurysms producing lower",
"    <span class=\"nowrap\">",
"     abdominal/pelvic",
"    </span>",
"    pain or radiculopathy. The pain is typically unaffected by position or movement.",
"   </p>",
"   <p>",
"    Physiologically, the pain associated with AAA is related to [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compression",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      erosion of the aneurysm into surrounding structures (eg, spine), which typically does not occur unless the aneurysm is large (&gt;5.5 cm).",
"     </li>",
"     <li>",
"      Rapid expansion of the aneurysm (&gt;0.5",
"      <span class=\"nowrap\">",
"       cm/year),",
"      </span>",
"      which can produce vague, nonspecific, abdominal discomfort or more focal pain.",
"     </li>",
"     <li>",
"      Inflammation or infection of the aortic wall (eg, inflammatory aneurysm, infected aneurysm), which produces vague, nonspecific abdominal pain that may be associated with constitutional symptoms (eg, fever, weight loss).",
"     </li>",
"     <li>",
"      Aneurysm rupture, which produces sudden onset, severe pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An indolent onset of pain that is vague and nonspecific is more typical of nonruptured AAA. The time course from the onset of pain to seeking medical attention is highly variable.",
"   </p>",
"   <p>",
"    AAA rupture typically produces acute, severe abdominal pain and other manifestations that are determined by the location of the rupture, and whether the rupture is contained, ruptures freely into the peritoneum, or ruptures into an adjacent venous structure causing a fistula (eg, aortocaval, aortoiliac) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/42\">",
"     42",
"    </a>",
"    ]. Autopsy studies have found that abdominal aortic aneurysm rupture occurs most commonly in the posterior aorta, which correlates to the levels of highest stress in mechanical modeling studies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proximal aortic rupture near the renal arteries leads to severe",
"      <span class=\"nowrap\">",
"       back/flank",
"      </span>",
"      pain, whereas distal rupture near the iliac bifurcation causes low",
"      <span class=\"nowrap\">",
"       abdominal/pelvic",
"      </span>",
"      pain and may cause pain that radiates to the groin or thigh due to lumbar nerve irritation.",
"     </li>",
"     <li>",
"      Posterior aortic wall rupture is likely to be initially contained within the retroperitoneum leading to retroperitoneal hematoma. The initial rupture is associated with a severe, often focal pain. If the hematoma stabilizes, the pain may subside. Patients with posterior rupture may attribute the initial pain to another cause, and delay seeking medical attention.",
"     </li>",
"     <li>",
"      Rupture of the anterior aortic wall may be contained for a brief period of time. The initial clinical manifestation will be abdominal pain, but rupture is likely to progress quickly to free intraperitoneal rupture with profound hemodynamic instability. Many of these patients succumb before they are able to be transported to the hospital.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181175588\">",
"    <span class=\"h3\">",
"     Limb ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;AAA can present initially with symptoms of lower extremity ischemia due to embolism of thrombus or atherosclerotic debris from the aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/31,45\">",
"     31,45",
"    </a>",
"    ]. In association with",
"    <span class=\"nowrap\">",
"     abdominal/back/flank",
"    </span>",
"    pain, distal embolism can be a sign of aneurysm rupture. Rarely, AAA can also present with acute aortic thrombosis leading to bilateral lower extremity ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During AAA formation, thrombus builds up gradually along the wall as the aorta expands over time. This thrombus is typically laminated, well-formed, and adherent to the wall of the aorta, but may become disrupted as a result of more abrupt changes in aortic wall configuration (ie, rapid expansion), instrumentation, or trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/31,45\">",
"     31,45",
"    </a>",
"    ]. In some patients, aortic debris may be more friable and more prone to embolization. During AAA rupture, new thrombus may form in the region of the aortic tear, which can also embolize; however, distal embolization associated with AAA rupture may more often be related to aortic manipulation during open repair, or instrumentation during endovascular repair [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25626?source=see_link&amp;anchor=H1191827380#H1191827380\">",
"     \"Complications of endovascular abdominal aortic repair\", section on 'Extremity ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Distal embolization of atherothrombotic debris from the aneurysm as a source of symptoms of AAA is not well studied. In the available studies, up to one-third of the clinical manifestations associated with symptomatic AAA may be related to embolism, but the incidence varies widely [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/45\">",
"     45",
"    </a>",
"    ]. This variability is likely due to the fact that AAA as the source for lower extremity ischemia is inferred from imaging studies that are typically obtained to evaluate progression of chronic lower extremity symptoms (eg, claudication, ischemic pain). In one retrospective review of 302 patients who underwent repair of AAA, 15 patients presented with distal embolization as the first manifestation of their AAA, which was limb-threatening in 3 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/45\">",
"     45",
"    </a>",
"    ]. In this study, the risk of embolization did not correlate with aneurysm diameter; 13 of 15 of the aneurysms that presented with embolization were &lt;5.0 cm.",
"   </p>",
"   <p>",
"    Thromboemboli from AAA can be single or multiple. The clinical manifestations of distal thromboembolism depend upon the size of the debris, and number of embolic events. Clinical manifestations may not be apparent if smaller vessels are affected and arterial occlusion is well compensated, or the patients may present with chronic symptoms (eg, claudication). Alternatively, embolism may present acutely with painful, blue digits (blue toe syndrome) or with a painful, pulseless, cool extremity. The clinical manifestations of thromboembolic disease are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link&amp;anchor=H6#H6\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cholesterol embolization as a manifestation of AAA is less common, and most often occurs after instrumentation (eg, arteriography, cardiac catheterization) or aneurysm repair (open or endovascular). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link&amp;anchor=H6#H6\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181174722\">",
"    <span class=\"h3\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other manifestations of AAA include constitutional or systemic symptoms that may indicate the presence of an infected or inflammatory aneurysm, disseminated intravascular coagulation, and other more unusual manifestations of AAA rupture.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of fever, malaise, and other vague abdominal symptoms, which are often chronic, may indicate a primary aortic infection with aneurysm formation or secondary infection of an established AAA. The clinical manifestations of infected aneurysms are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=see_link\">",
"       \"Overview of infected (mycotic) arterial aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptoms of chronic abdominal pain and weight loss in association with AAA are suggestive of an inflammatory aneurysm, which affects about 5 to 10 percent of patients with AAA [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/47-50\">",
"       47-50",
"      </a>",
"      ]. When AAA initially presents in this manner, the diagnosis is frequently confounded and delayed. Patients with the inflammatory variant are younger and more often symptomatic than patients with noninflammatory AAA. Patients with inflammatory AAA also have abnormalities of serum inflammatory markers, such as the erythrocyte sedimentation rate. Ureteral displacement or symptoms of ureteral obstruction can also occur due to the retroperitoneal inflammatory reaction (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87337 \" href=\"UTD.htm?0/30/487\">",
"       image 7",
"      </a>",
"      ). The incidence of rupture in patients with inflammatory AAA may be lower than with noninflammatory aneurysm. In a review that included 180 patients, rupture occurred in 4 percent of patients with inflammatory aneurysm compared with 20 percent of those with noninflammatory aneurysms [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Large or extensive AAAs may be associated with clinical manifestations of disseminated intravascular coagulation (DIC) causing hemorrhagic or thrombotic complications. The incidence of DIC is reported to be as high as 4 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other clinical manifestations that can be associated with ruptured AAA but are less commonly considered related include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Myocardial infarction related to acute blood loss, which occurs in up to 25 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Heart failure due to arteriovenous fistula as a result of rupture of the aorta into a surrounding venous structure such as the inferior vena cava (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87338 \" href=\"UTD.htm?29/24/30087\">",
"       image 8",
"      </a>",
"      ), iliac vein, or left renal vein. Hematuria or massive leg swelling and lower extremity cyanosis without distal ischemia can also be signs of aortocaval fistula [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link&amp;anchor=H5#H5\">",
"       \"Evaluation of the patient with suspected heart failure\", section on 'Physical examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Groin pain or the sudden appearance of groin hernia (even incarceration) can occur related to a sudden increase in intraabdominal pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Upper gastrointestinal bleeding may be due to an aortoduodenal fistula (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87328 \" href=\"UTD.htm?17/2/17444\">",
"       image 9",
"      </a>",
"      ) . Although more commonly related to aortic graft repair, aortoduodenal fistula has been reported in primary infected aortic aneurysm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15830547\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with risk factors for and symptoms suggestive of AAA, the physical examination seeks to identify clinical signs that support a diagnosis of AAA, or possibly suggest an alternative diagnosis.",
"   </p>",
"   <p>",
"    Vital signs in symptomatic patients may be normal, demonstrate sinus tachycardia, or moderate to severe hypotension. The degree of hypotension in patients with a posterior aortic wall rupture is likely to be less severe upon initial clinical presentation compared with patients who suffer from anterior aortic wall rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/42\">",
"     42",
"    </a>",
"    ]. Fever associated with AAA may indicate an infected aneurysm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181174645\">",
"    <span class=\"h3\">",
"     Abdominal palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sole use of abdominal palpation cannot be relied upon to diagnose or exclude AAA. Although abdominal examination may reliably diagnose a large AAA (&gt;5.5 cm), AAA is identified on physical examination alone in fewer than 50 percent of asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/56\">",
"     56",
"    </a>",
"    ]. However, in patients with ruptured AAA, a pulsatile abdominal mass is present in at least 60 percent of patients and is an important sign for making a correct initial diagnosis. Most patients with ruptured AAA also have some degree of abdominal distention and tenderness.",
"   </p>",
"   <p>",
"    An abdominal examination focused specifically on the diagnosis of AAA is more likely to identify an aneurysm than a non-focused examination. AAA most often occurs in the segment of aorta below the renal arteries (",
"    <a class=\"graphic graphic_figure graphicRef60682 \" href=\"UTD.htm?9/29/9683\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, with the patient supine on the examination table and garments removed from the abdomen, palpation of the abdominal aorta is performed by gently but deeply palpating the abdomen between the xiphoid and umbilicus, to identify a widened pulse that suggests the presence of an aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/57\">",
"     57",
"    </a>",
"    ]. Many patients will experience mild tenderness with deep palpation of the aneurysm. Patients with inflammatory or infected aneurysms may exhibit a greater degree of tenderness to palpation. This finding should not be used to brand the aneurysm as symptomatic in order to justify treatment. It is important to note that palpation of the abdomen to detect AAA is",
"    <strong>",
"     safe",
"    </strong>",
"    and has never been reported to precipitate aortic rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detection of an AAA by abdominal palpation is more likely when the aneurysm is large and when abdominal girth is small (waist &lt;40 inches). The sensitivity and specificity of abdominal palpation for AAA as related to AAA diameter and girth are illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review evaluated 15 studies involving patients not previously known to have an AAA and who were screened with both abdominal palpation and ultrasound [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/57\">",
"       57",
"      </a>",
"      ]. The sensitivity of abdominal palpation was 29 percent for AAA 3.0 to 3.9 cm in diameter, 50 percent for AAA 4.0 to 4.9 cm, and 76 percent for AAA 5.0 cm or greater.",
"     </li>",
"     <li>",
"      In a later study of 200 patients, the overall sensitivity of abdominal palpation for detecting AAA was 68 percent and the specificity was 75 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/15\">",
"       15",
"      </a>",
"      ]. Sensitivity significantly improved with increasing aneurysm diameter (61 percent, 3.0 to 3.9 cm; 69 percent, 4.0 to 4.9 cm; 72 percent, 4.0 cm or larger; 82 percent &gt;5.0 cm). The patient&rsquo;s abdominal circumference also affected the examination with an overall sensitivity of 91 percent for patients with a waistline &lt;40 inches (100 cm) versus 53 percent for &gt;40 inches (100 cm). For a waistline of &lt;40 inches, abdominal palpation was 100 percent sensitive for detecting AAA &ge;5.0 cm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prominent but normal-sized aorta or a nonvascular mass overlying an easily transmitted, palpable aortic pulse can be mistaken as AAA, particularly in thin patients. Patients with hypertension, a wide pulse pressure, or a tortuous aorta can also have prominent aortic pulsation that may be mistaken for an AAA. For these reasons, it is important to obtain an imaging study to confirm AAA diagnosed on the basis of abdominal palpation. (See",
"    <a class=\"local\" href=\"#H15828721\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1382374653\">",
"    <span class=\"h3\">",
"     Ecchymosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive retroperitoneal hematoma from ruptured AAA may lead to extravasation of blood into the subcutaneous tissues to produce flank ecchymosis (Grey-Turner sign), periumbilical ecchymosis (Cullen&rsquo;s sign), ecchymosis of the proximal thigh (Fox&rsquo;s sign), and in males, discoloration of the scrotum (Bryant&rsquo;s sign) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/58\">",
"     58",
"    </a>",
"    ]. Although these signs are indicative of retroperitoneal hematoma and may suggest ruptured AAA in patients with positive risk factors for AAA and appropriate clinical symptoms and signs, they are not specific [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/58\">",
"     58",
"    </a>",
"    ]. Other pathologies that may lead to ecchymosis at these sites include acute pancreatitis, ruptured ectopic pregnancy, ruptured hepatocellular hematoma, and perinephric hematoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1382372659\">",
"    <span class=\"h3\">",
"     Vascular examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete peripheral arterial examination should be performed looking for evidence of distal embolization or ischemia. The identification of other peripheral artery aneurysms (femoral, popliteal) on physical examination supports a diagnosis of AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On vascular examination, the carotid and radial pulses should be equal; asymmetry suggests aortic pathology in the chest (eg, aortic dissection). Femoral and pedal pulses may or may not be palpable depending upon the patient&rsquo;s blood pressure, the presence of peripheral artery disease, or thromboembolism. If lower extremity pulses are not easily identified, a hand-held continuous wave Doppler can be used to locate them. If palpable or Dopplerable pulses in the feet are identified (dorsalis pedis, posterior tibial), it is helpful to mark the vessels for later comparison.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15828870\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no laboratory studies that identify the presence of AAA with certainty. Although serial D-dimer levels may reflect increasing deposition of thrombus within an aneurysm sac (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87332 \" href=\"UTD.htm?16/28/16835\">",
"     image 10",
"    </a>",
"    ) and have been used to follow patients with known AAA, D-dimer is nonspecific and can be elevated in a variety of other thrombotic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients who present with acute abdominal complaints will undergo initial laboratory testing that includes a complete blood count, electrolytes, blood urea nitrogen and creatinine. Those who present in shock will undergo additional studies including liver function tests, coagulation parameters, fibrinogen, fibrin split products, arterial blood gases, a lactate level, cardiac enzymes, and toxicology studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H22#H22\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia and metabolic acidosis may point toward acute blood loss as the cause of shock related to a ruptured AAA.",
"     </li>",
"     <li>",
"      An elevated white blood cell count may indicate aortic infection or inflammation in patients who present with systemic manifestations (eg, fever, weight loss). Additional studies such as blood cultures and an erythrocyte sedimentation rate may be useful for distinguishing infected or inflammatory AAA from more common aneurysms. The ESR can be markedly elevated in patients with inflammatory AAA.",
"     </li>",
"     <li>",
"      Laboratory evidence of disseminated intravascular coagulation may be related to a large or extensive aneurysm, such as a thoracoabdominal aneurysm [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15828721\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with AAA and their physicians are unaware that an aneurysm is present. Because asymptomatic AAA can progress to rupture without any intervening symptoms, it is important that a diagnosis of AAA is considered in patients with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No symptoms, but with risk factors for AAA. (See",
"      <a class=\"local\" href=\"#H1382371370\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical examination consistent with AAA (eg, pulsatile abdominal mass) or other peripheral artery aneurysm (eg, femoral, popliteal). (See",
"      <a class=\"local\" href=\"#H15830547\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations (eg, abdominal pain, thromboembolism, others) potentially representing a symptomatic AAA (nonruptured or ruptured). (See",
"      <a class=\"local\" href=\"#H181175753\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although AAA may be suspected based upon these clinical features, a definitive diagnosis requires the demonstration of a focal, aortic dilation meeting the criteria for aneurysm (&gt;1.5 times normal diameter) on imaging, or at the time of abdominal exploration. (See",
"    <a class=\"local\" href=\"#H22314302\">",
"     'Aneurysm definition and anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although an imaging diagnosis is desirable, it is not an absolute requirement in the hemodynamically unstable patient with a known AAA who presents with classic symptoms and signs of rupture",
"    <span class=\"nowrap\">",
"     (abdominal/back/flank",
"    </span>",
"    pain, hypotension, pulsatile mass). In this clinical scenario, patients who are candidates for repair are taken to the operating room for immediate management (intraoperative diagnosis) without an intervening diagnostic imaging study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11225?source=see_link&amp;anchor=H53322839#H53322839\">",
"     \"Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although any imaging study that demonstrates the focal dilation can be used to make a diagnosis, abdominal ultrasound and computed tomography (CT) of the abdomen are the most useful. Each modality is sensitive and specific for establishing a diagnosis of AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/61-63\">",
"     61-63",
"    </a>",
"    ], but recommended under differing clinical circumstances (",
"    <a class=\"graphic graphic_algorithm graphicRef86821 \" href=\"UTD.htm?23/4/23631\">",
"     algorithm 1",
"    </a>",
"    ), depending upon the clinical presentation, and the hemodynamic status of the patient. (See",
"    <a class=\"local\" href=\"#H22322286\">",
"     'Imaging asymptomatic patients'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22322988\">",
"     'Imaging symptomatic patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other imaging modalities (eg, magnetic resonance imaging) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87336 \" href=\"UTD.htm?41/13/42193\">",
"     image 11",
"    </a>",
"    ) are less often used in the initial evaluation of AAA but may play a role in selected patients, such as in the patient with known AAA (unrepaired or post-repair) who presents with new symptoms or in patients who cannot receive intravenous contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Conventional arteriography, which demonstrates only the flow in the luminal channel often surrounded by luminal thrombus, is not accurate for determining the diameter of the aorta (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87335 \" href=\"UTD.htm?34/56/35719\">",
"     image 12",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22322286\">",
"    <span class=\"h2\">",
"     Imaging asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For asymptomatic patients in whom a diagnosis of AAA is suspected on the basis of risk factors, abdominal palpation, or a prior imaging study suggesting AAA, abdominal ultrasound is recommended as the initial diagnostic modality (",
"    <a class=\"graphic graphic_algorithm graphicRef86821 \" href=\"UTD.htm?23/4/23631\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Ultrasound is noninvasive, inexpensive, and has a sensitivity of 98 percent and specificity of 99 percent for the diagnosis of AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. In prospective studies, ultrasound has been found to be a cost-effective screening tool for identifying small aneurysms (&lt;4.0 cm) in patients with risk factors for AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24488?source=see_link\">",
"     \"Screening for abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The routine sonographic evaluation of the aorta involves measuring the anteroposterior (AP), longitudinal, and transverse dimensions of the suprarenal, juxtarenal, pararenal and infrarenal aorta (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66473 graphicRef67861 \" href=\"UTD.htm?25/21/25940\">",
"     image 13A-B",
"    </a>",
"    ). Given the correlation between AAA and iliac artery aneurysm, the examination should also include imaging of the iliac arteries. Patients are asked to fast prior to undergoing the examination to reduce the presence of overlying bowel gas that can obscure the aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/68\">",
"     68",
"    </a>",
"    ]. In approximately 1 to 2 percent of cases, the aorta cannot be adequately imaged because of technical difficulties (eg, bowel gas, aortic depth) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main limitation of abdominal ultrasound is that it is technician and equipment-dependent. If the ultrasound probe is not oriented perpendicular to the centerline, the AP diameter of the aorta may be overestimated [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/70\">",
"     70",
"    </a>",
"    ]. At times, ultrasound may not provide an accurate depiction of the iliac arteries, due to overlying loops of bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/69\">",
"     69",
"    </a>",
"    ]. If the ultrasound study is technically inadequate related to these factors, another imaging study should be obtained (typically computed tomography) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87334 \" href=\"UTD.htm?13/59/14265\">",
"     image 14",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In asymptomatic patients who have undergone a screening study or have been diagnosed with AAA incidentally as a result of another imaging study, it is important to determine if the aorta was adequately imaged. Some screening protocols provide only a limited evaluation of the aorta. If the abdominal aorta was not completely imaged, imaging did not include the iliac arteries, or the maximal AP diameter was not measured in a plane perpendicular to blood flow, a repeat study, typically another abdominal ultrasound, should be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22322988\">",
"    <span class=\"h2\">",
"     Imaging symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing a diagnosis of AAA in symptomatic patients is guided by the hemodynamic status of the patient (",
"    <a class=\"graphic graphic_algorithm graphicRef86821 \" href=\"UTD.htm?23/4/23631\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For hemodynamically unstable patients with a suspected rupture of a known AAA, imaging is highly desirable, but is not absolutely required prior to intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11225?source=see_link&amp;anchor=H933041496#H933041496\">",
"     \"Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm\", section on 'Initial management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When ruptured AAA is suspected but the presence of an aneurysm is NOT known for certain, we suggest ultrasonography to confirm that an aneurysm exists, if immediately available. Ultrasound can be performed at the bedside or in the operating room while the patient is being resuscitated without causing an undue delay in care (",
"    <a class=\"graphic graphic_algorithm graphicRef86821 \" href=\"UTD.htm?23/4/23631\">",
"     algorithm 1",
"    </a>",
"    ). With routine use of the Focused Assessment with Sonography in Trauma (FAST) exam, many emergency department physicians are comfortable with the abdominal ultrasound exam and can quickly identify an abnormally enlarged aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/21\">",
"     21",
"    </a>",
"    ]. If the aneurysm is ruptured, retroperitoneal hematoma may also be seen, but the rupture site is not usually identified. When AAA is identified on ultrasound in a patient with hypotension and",
"    <span class=\"nowrap\">",
"     abdominal/flank/back",
"    </span>",
"    pain, a presumptive diagnosis of ruptured AAA can be made.",
"   </p>",
"   <p>",
"    For symptomatic patients suspected of having AAA who are hemodynamically stable, we recommend urgent abdominal CT rather than ultrasound (",
"    <a class=\"graphic graphic_algorithm graphicRef86821 \" href=\"UTD.htm?23/4/23631\">",
"     algorithm 1",
"    </a>",
"    ). Abdominal CT has the advantage of evaluating the abdomen in more detail, which is necessary for differentiating ruptured from nonruptured aneurysm, and CT is better than ultrasound for evaluating suprarenal aneurysms (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87420 \" href=\"UTD.htm?2/49/2839\">",
"     image 15",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. Abdominal CT also readily identifies other abdominal pathologies as a potential cause of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/71\">",
"     71",
"    </a>",
"    ]. Abdominal CT defines the extent of the aneurysm providing important anatomic information by which to plan urgent AAA repair, and determines whether the aneurysm is suited to endovascular aneurysm repair (EVAR) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87333 \" href=\"UTD.htm?31/54/32611\">",
"     image 16",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. Disadvantages of CT compared with ultrasonography are greater cost, the requirement for intravenous contrast (when CT arteriography is required), and the cumulative risk of radiation with repeated scans in patients with known AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous contrast is generally not needed to establish a diagnosis of rAAA [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/75\">",
"     75",
"    </a>",
"    ]. However, many vascular centers use abdominal CT with intravenous contrast or CT angiography with three-dimensional reconstruction for suspected rAAA in anticipation of potential endovascular repair. However, in the setting of volume depletion, the risk for renal dysfunction is increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the presence of AAA is confirmed on CT, aortic anatomy must be carefully evaluated to determine if the aneurysm is ruptured, or has signs of instability that may indicate impending rupture. The maximal aortic diameter should also be determined and compared with prior studies, if available, to identify patients who might have a rapidly expanding aneurysm (0.5",
"    <span class=\"nowrap\">",
"     cm/year).",
"    </span>",
"    In addition, the aortic wall should be evaluated to determine whether the aneurysm appears to be infected or is consistent with an inflammatory aneurysm. Lastly, for symptomatic patients in whom AAA is present but clearly not ruptured, a judgement must be made as to whether the aneurysm is the most likely cause for the symptoms in the context of other pathology that may be present on imaging. These issues are discussed more fully below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181166154\">",
"    <span class=\"h3\">",
"     Ruptured versus nonruptured AAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiating a symptomatic but nonruptured AAA from an aneurysm that is about to rupture or is in the process of rupturing is critical and is accomplished using computed tomography (CT) of the abdomen. Signs on CT associated with ruptured AAA and AAA that may be unstable and at risk for impending rupture are discussed below. Although rupture is unlikely in patients who have none of the features described, symptomatic patients with AAA, particularly in those with moderate to large-sized aneurysm, are typically admitted and observed when another etiology cannot be determined. The AAA should be considered a &ldquo;symptomatic AAA&rdquo;, until proven otherwise. The management of symptomatic, nonruptured AAA is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H611107773#H611107773\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the setting of ruptured AAA, the risk for contrast-induced nephropathy is increased in the setting of volume depletion when intravenous contrast is used. (See",
"    <a class=\"local\" href=\"#H22322286\">",
"     'Imaging asymptomatic patients'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with acute symptoms lasting more than one hour, findings of AAA rupture on CT scan are usually obvious [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/76\">",
"     76",
"    </a>",
"    ]. CT scan findings consistent with ruptured AAA include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Retroperitoneal hematoma (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87665 \" href=\"UTD.htm?0/14/232\">",
"       image 17",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72201 \" href=\"UTD.htm?17/61/18391\">",
"       image 18",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Indistinct aortic wall (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87666 \" href=\"UTD.htm?6/36/6726\">",
"       image 19",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Retroperitoneal stranding (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87666 \" href=\"UTD.htm?6/36/6726\">",
"       image 19",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Loss of the fat plane between the aorta and surrounding tissue",
"     </li>",
"     <li>",
"      Extravasation of intravenous contrast outside the aorta (into retroperitoneum, into a vein, into bowel) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87667 \" href=\"UTD.htm?13/31/13815\">",
"       image 20",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87328 \" href=\"UTD.htm?17/2/17444\">",
"       image 9",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87338 \" href=\"UTD.htm?29/24/30087\">",
"       image 8",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with AAA and abdominal pain have CT scans that fail to show signs of overt aortic rupture. Other findings on abdominal CT that may be associated with potentially unstable aneurysms or possible &ldquo;impending rupture&rdquo; include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/71,77-80\">",
"     71,77-80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A crescent sign of layering hematoma within the aorta (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87324 \" href=\"UTD.htm?35/35/36407\">",
"       image 21",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Breaks in the calcification of the aortic wall (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72201 \" href=\"UTD.htm?17/61/18391\">",
"       image 18",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Localized areas of higher attenuation within mural thrombus",
"     </li>",
"     <li>",
"      Aortic blebs that bulge from the surface of the aorta (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87326 \" href=\"UTD.htm?31/5/31827\">",
"       image 22",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Irregularity of the aortic wall",
"     </li>",
"     <li>",
"      &ldquo;Draping&rdquo; of the aorta over a vertebral body",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These imaging abnormalities were initially described in a retrospective review of patients with ruptured AAA compared with nonruptured AAA. A later prospective study found only a 7 percent positive predictive value for subsequent AAA rupture using these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/77\">",
"     77",
"    </a>",
"    ]. Although there are no specific CT scan findings that definitively predict rupture, these signs of &lsquo;impending rupture&rsquo; in combination with an AAA of &gt;5 cm may indicate an aneurysm that is rapidly changing anatomically [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22314616\">",
"    <span class=\"h3\">",
"     Are symptoms related to AAA?",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with symptomatic but clearly not ruptured AAA, the question always arises as to whether the aneurysm is the source of the symptoms. Imaging that demonstrates a pathology that is more consistent with the patient&rsquo;s symptoms (eg, renal colic) may indicate that the AAA is the incidental finding.",
"   </p>",
"   <p>",
"    However, if the presenting symptoms are not typical for other pathologies identified on CT, or another etiology cannot be clearly determined, and the symptoms are consistent with those associated with AAA, then the patient is regarded as having a symptomatic AAA, until proven otherwise. This determination usually requires admission to the hospital and observation, while undergoing further studies. In some patients with symptomatic, nonruptured AAA in the setting of hypertension, blood pressure control may sometimes alleviate pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H611107773#H611107773\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who present with lower extremity embolism, features of the aorta on CT that suggest that the aneurysm may be the source embolism include an irregular luminal surface, multiple aortic lumens, heterogeneity of the aortic thrombus, calcification within the aortic thrombus, and fissures extending from the lumen into the aortic thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition, the presence of typical features of embolization in the distal vasculature in the absence of atherosclerotic peripheral artery disease in a patient with AAA and no other proximal source for embolus (eg, atrial fibrillation) suggests that the aneurysm is the source.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22323992\">",
"    <span class=\"h3\">",
"     Infected versus inflammatory AAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation is a common component of most aortic aneurysms, but the typical AAA must be distinguished from aneurysms that are infected, as well as a distinct clinical entity called an inflammatory aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/5,48\">",
"     5,48",
"    </a>",
"    ]. The management of these aneurysm subtypes differs from noninfected, noninflammatory AAAs.",
"   </p>",
"   <p>",
"    Although clinical features of nonspecific abdominal pain associated with systemic symptoms (eg, fever, malaise) and a pulsatile abdominal mass may suggest a diagnosis of an infected or inflammatory AAA, specific features on CT imaging make the distinction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary bacterial infection of the aortic wall, which can lead to rapid aortic expansion, is a rare cause of AAA. Pre-existing AAA can also become secondarily infected [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/5,82\">",
"       5,82",
"      </a>",
"      ]. Findings on CT suggestive of an infected aneurysm include the following [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/83-88\">",
"       83-88",
"      </a>",
"      ], while other clinical features and the diagnosis of infected aneurysm is discussed in detail elsewhere (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=see_link\">",
"       \"Overview of infected (mycotic) arterial aneurysm\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Saccular, eccentric, or multilobulated AAA",
"     </li>",
"     <li>",
"      Soft tissue inflammation surrounding the aorta",
"     </li>",
"     <li>",
"      AAA with intramural air, or air collection around the vessel",
"     </li>",
"     <li>",
"      Perivascular fluid collection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory abdominal aortic aneurysm (IAAA), which accounts for 2 to 10 percent of AAAs, is characterized by thickening of the adventitia due to marked inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/47,49,89-91\">",
"       47,49,89-91",
"      </a>",
"      ]. Radiologically, an IAAA is defined as an AAA with a &ge;1 cm thick inflammatory rind surrounding the aorta on abdominal CT [",
"      <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/47\">",
"       47",
"      </a>",
"      ]. The periaortic soft tissue density may enhance when intravenous contrast is administered and the retroperitoneal tissue planes between the aorta and retroperitoneum are indistinct. Other features consistent with IAAA are fibrosis of the adjacent retroperitoneum, adherence of the anterior aspect of the IAAA to adjacent structures (eg, duodenum, ureters), and medial deviation of the ureters (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87337 \" href=\"UTD.htm?0/30/487\">",
"       image 7",
"      </a>",
"      ). Inflammatory aneurysms are",
"      <strong>",
"       not",
"      </strong>",
"      associated with periaortic air or fluid, and although inflamed, these aneurysms are not infected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H611107773#H611107773\">",
"       \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Introduction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1382370816\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic pathologies that can produce symptoms, particularly abdominal or flank pain similar to AAA, include aortic dissection and aortic pseudoaneurysm due to erosion of ulcerated plaque. The pain from aortic dissection is described as searing and often begins in the chest, migrating into the abdomen over time. Aortic dissection may affect other arch vessels leading to other symptoms (cerebral embolism, upper extremity ischemia), that will not be present in patients with AAA. In patients with ulcerated aortic plaque, the symptoms may be indistinguishable from ruptured AAA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/16/37126?source=see_link&amp;anchor=H3#H3\">",
"     \"Aortic intramural hematoma\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aortic imaging will differentiate these etiologies from AAA; however, imaging protocols vary. Thus, if there is any question that aortic pathology may involve the thoracic aorta, simultaneous chest and abdominal imaging should be obtained rather than abdominal imaging alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\", section on 'Imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/16/37126?source=see_link&amp;anchor=H4#H4\">",
"     \"Aortic intramural hematoma\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pain from symptomatic or ruptured AAA can mimic many other conditions such as diverticulitis, pancreatitis, mesenteric ischemia, biliary tract disease, renal colic and coronary ischemia, to name a few. The general approach to abdominal pain and the extensive differential diagnosis of abdominal pain are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with risk factors, abdominal symptoms, or a physical examination that in any way suggests AAA, the most practical approach is expedient abdominal imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/36\">",
"     36",
"    </a>",
"    ], even though the patient may have a history of another medical condition that could account for their symptoms. In a study of 152 patients, ruptured AAA was initially misdiagnosed as renal colic, perforated viscus, diverticulitis, gastrointestinal hemorrhage, or ischemic bowel in 30 percent of the patients, based upon clinical symptoms and signs alone [",
"    <a class=\"abstract\" href=\"UTD.htm?31/16/32010/abstract/32\">",
"     32",
"    </a>",
"    ]. With imaging, the absence of aortic dilation rules out AAA. If AAA is present, but clearly not ruptured, a determination will need to be made whether or not the symptoms are due to the AAA. (See",
"    <a class=\"local\" href=\"#H22314616\">",
"     'Are symptoms related to AAA?'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/39/22130?source=see_link\">",
"       \"Patient information: Abdominal aortic aneurysm (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/62/34787?source=see_link\">",
"       \"Patient information: Abdominal aortic aneurysm (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H478781272\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal aortic aneurysm (AAA) is defined as a focal, full-thickness dilation of the aorta that is more than 50 percent greater than its normal diameter. The abdominal aorta below the renal arteries (infrarenal) is the most common site for aortic aneurysm. In the infrarenal aorta, a maximum diameter &ge;3.0 cm is aneurysmal in the majority of patients. (See",
"      <a class=\"local\" href=\"#H22314302\">",
"       'Aneurysm definition and anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with AAA do not have any symptoms. Asymptomatic AAA may be discovered as a result of screening in patients with risk factors for AAA, on routine physical examination, or on imaging studies to evaluate an unrelated complaint. (See",
"      <a class=\"local\" href=\"#H15830649\">",
"       'Clinical presentations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient&rsquo;s medical history identifies the risk factors for developing AAA, and risk factors associated with rupture. The patient and their family members should be asked whether a diagnosis of AAA has been established in the past or asked if a prior AAA repair has been performed. The history may also help determine if clinical manifestations are likely related to a possible AAA versus another medical condition. Symptoms potentially related to AAA (eg, pain) can mimic many other diseases; however, in patients known to have, or subsequently shown to have AAA, symptoms are presumed to be due to the aneurysm until unequivocally proven otherwise. (See",
"      <a class=\"local\" href=\"#H1382371370\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22314616\">",
"       'Are symptoms related to AAA?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AAA does not typically cause symptoms unless the aneurysm is expanding rapidly, has become large enough to compress surrounding structures, is an inflammatory or infectious aneurysm, or has ruptured. Patients with symptomatic AAA most commonly present with abdominal, back, or flank pain, which may or may not be associated with AAA rupture. The classic triad of acute abdominal pain, abdominal distention, and hemodynamic instability is present in about 50 percent of patients with ruptured AAA. AAA can also present with other clinical manifestations such as limb ischemia (acute or chronic), or other systemic manifestations (fever, malaise). (See",
"      <a class=\"local\" href=\"#H181175753\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The sole use of abdominal palpation cannot be relied upon to diagnose or exclude AAA. Abdominal palpation is about 70 percent sensitive overall for the detection of AAA. The sensitivity of palpation increases with increasing AAA diameter and is affected by the abdominal girth of the patient. For patients with an abdominal circumference &lt;40 inches (100 cm), the sensitivity of abdominal palpation approaches 100 percent for the detection of AAA &ge;5.0 cm. &nbsp;(See",
"      <a class=\"local\" href=\"#H181174645\">",
"       'Abdominal palpation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although AAA may be suspected based upon risk factors, abdominal palpation, or clinical manifestations, a definitive diagnosis requires abdominal imaging studies that demonstrate a focal, aortic dilation meeting the criteria for aneurysm (&gt;1.5 times normal diameter). Abdominal ultrasound and computed tomography of the abdomen are both highly sensitive and specific for diagnosing AAA, but are recommended under differing clinical circumstances (",
"      <a class=\"graphic graphic_algorithm graphicRef86821 \" href=\"UTD.htm?23/4/23631\">",
"       algorithm 1",
"      </a>",
"      ), depending upon the presence of symptoms, and the hemodynamic status of the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For most asymptomatic patients, we recommend abdominal ultrasound as the initial diagnostic modality. Ultrasound is noninvasive and cost-effective for diagnosing AAA in asymptomatic patients. (See",
"      <a class=\"local\" href=\"#H22322286\">",
"       'Imaging asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most symptomatic patients who are hemodynamically stable, we recommend computed tomography of the abdomen as the initial diagnostic modality. Abdominal CT provides additional anatomic detail that identifies ruptured aneurysm, infected aneurysm, inflammatory aneurysm, and other features that are important in the subsequent management of symptomatic AAA. Abdominal CT may also identify other pathologies that may be the source of symptoms. (See",
"      <a class=\"local\" href=\"#H22322988\">",
"       'Imaging symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For hemodynamically unstable patients suspected of having ruptured AAA, where a diagnosis of AAA is NOT previously known, we suggest a focused ultrasonography exam (bedside, operating room) to confirm that an aneurysm exists prior to exploration, provided it is immediately available. Patients with a known AAA, who present with classic symptoms and signs of rupture, are generally taken for repair without preoperative imaging. (See",
"      <a class=\"local\" href=\"#H22322988\">",
"       'Imaging symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/1\">",
"      Shreibati JB, Baker LC, Hlatky MA, Mell MW. Impact of the Screening Abdominal Aortic Aneurysms Very Efficiently (SAAAVE) Act on abdominal ultrasonography use among Medicare beneficiaries. Arch Intern Med 2012; 172:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/2\">",
"      Johnston KW, Rutherford RB, Tilson MD, et al. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg 1991; 13:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/3\">",
"      Chaikof EL, Brewster DC, Dalman RL, et al. The care of patients with an abdominal aortic aneurysm: the Society for Vascular Surgery practice guidelines. J Vasc Surg 2009; 50:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/4\">",
"      Wanhainen A. How to define an abdominal aortic aneurysm--influence on epidemiology and clinical practice. Scand J Surg 2008; 97:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/5\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/6\">",
"      Wanhainen A, Themudo R, Ahlstr&ouml;m H, et al. Thoracic and abdominal aortic dimension in 70-year-old men and women--a population-based whole-body magnetic resonance imaging (MRI) study. J Vasc Surg 2008; 47:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/7\">",
"      Jongkind V, Yeung KK, Akkersdijk GJ, et al. Juxtarenal aortic aneurysm repair. J Vasc Surg 2010; 52:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/8\">",
"      Martin GH, O'Hara PJ, Hertzer NR, et al. Surgical repair of aneurysms involving the suprarenal, visceral, and lower thoracic aortic segments: early results and late outcome. J Vasc Surg 2000; 31:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/9\">",
"      Singh K, B&oslash;naa KH, Jacobsen BK, et al. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study : The Troms&oslash; Study. Am J Epidemiol 2001; 154:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/10\">",
"      Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Troms&oslash; Study, 1994-2001. Circulation 2009; 119:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/11\">",
"      Kent KC, Zwolak RM, Egorova NN, et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg 2010; 52:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/12\">",
"      Dillavou ED, Muluk SC, Makaroun MS. A decade of change in abdominal aortic aneurysm repair in the United States: Have we improved outcomes equally between men and women? J Vasc Surg 2006; 43:230.",
"     </a>",
"    </li>",
"    <li>",
"     file://hcupnet.ahrq.gov/HCUPnet (Accessed on May 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/14\">",
"      Giles KA, Pomposelli F, Hamdan A, et al. Decrease in total aneurysm-related deaths in the era of endovascular aneurysm repair. J Vasc Surg 2009; 49:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/15\">",
"      Fink HA, Lederle FA, Roth CS, et al. The accuracy of physical examination to detect abdominal aortic aneurysm. Arch Intern Med 2000; 160:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/16\">",
"      van Walraven C, Wong J, Morant K, et al. Incidence, follow-up, and outcomes of incidental abdominal aortic aneurysms. J Vasc Surg 2010; 52:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/17\">",
"      van Walraven C, Wong J, Morant K, et al. The influence of incidental abdominal aortic aneurysm monitoring on patient outcomes. J Vasc Surg 2011; 54:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/18\">",
"      Muzaffar R, Kudva G, Nguyen NC, Osman MM. Incidental diagnosis of thrombus within an aneurysm on 18F-FDG PET/CT: frequency in 926 patients. J Nucl Med 2011; 52:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/19\">",
"      Lanitis S, Zacharioudakis C, Zafeiriadou P, et al. Incidental findings in trauma patients during focused assessment with sonography for trauma. Am Surg 2012; 78:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/20\">",
"      Gordon JR, Wahls T, Carlos RC, et al. Failure to recognize newly identified aortic dilations in a health care system with an advanced electronic medical record. Ann Intern Med 2009; 151:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/21\">",
"      Lee SI, Mueller PR, Thrall JH. Re: \"managing incidental findings on abdominal CT: White Paper of the ACR Incidental Findings Committee\". J Am Coll Radiol 2011; 8:e3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/22\">",
"      van Walraven C, Wong J, Morant K, et al. Radiographic monitoring of incidental abdominal aortic aneurysms: a retrospective population-based cohort study. Open Med 2011; 5:e67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/23\">",
"      Lawrence PF, Gazak C, Bhirangi L, et al. The epidemiology of surgically repaired aneurysms in the United States. J Vasc Surg 1999; 30:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/24\">",
"      Diwan A, Sarkar R, Stanley JC, et al. Incidence of femoral and popliteal artery aneurysms in patients with abdominal aortic aneurysms. J Vasc Surg 2000; 31:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/25\">",
"      Sullivan CA, Rohrer MJ, Cutler BS. Clinical management of the symptomatic but unruptured abdominal aortic aneurysm. J Vasc Surg 1990; 11:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/26\">",
"      Nevala T, Per&auml;l&auml; J, Aho P, et al. Outcome of symptomatic, unruptured abdominal aortic aneurysms after endovascular repair with the Zenith stent-graft system. Scand Cardiovasc J 2008; 42:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/27\">",
"      Franks S, Lloyd G, Fishwick G, et al. Endovascular treatment of ruptured and symptomatic abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2006; 31:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/28\">",
"      Antonello M, Lepidi S, Kechagias A, et al. Glasgow aneurysm score predicts the outcome after emergency open repair of symptomatic, unruptured abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2007; 33:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/29\">",
"      Shifrin EG, Pizov R, Perel A, et al. Urgent abdominal aortic aneurysm repair in patients over the age 80. J Cardiovasc Surg (Torino) 1987; 28:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/30\">",
"      Cambria RA, Gloviczki P, Stanson AW, et al. Symptomatic, nonruptured abdominal aortic aneurysms: are emergent operations necessary? Ann Vasc Surg 1994; 8:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/31\">",
"      Nigro G, Giovannacci L, Engelberger S, et al. The challenge of posttraumatic thrombus embolization from abdominal aortic aneurysm causing acute limb ischemia. J Vasc Surg 2011; 54:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/32\">",
"      Marston WA, Ahlquist R, Johnson G Jr, Meyer AA. Misdiagnosis of ruptured abdominal aortic aneurysms. J Vasc Surg 1992; 16:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/33\">",
"      Powell JT, Brown LC, Greenhalgh RM, Thompson SG. The rupture rate of large abdominal aortic aneurysms: is this modified by anatomical suitability for endovascular repair? Ann Surg 2008; 247:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/34\">",
"      Hallett JW Jr, Marshall DM, Petterson TM, et al. Graft-related complications after abdominal aortic aneurysm repair: reassurance from a 36-year population-based experience. J Vasc Surg 1997; 25:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/35\">",
"      Jones JE, Atkins MD, Brewster DC, et al. Persistent type 2 endoleak after endovascular repair of abdominal aortic aneurysm is associated with adverse late outcomes. J Vasc Surg 2007; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/36\">",
"      Akkersdijk GJ, van Bockel JH. Ruptured abdominal aortic aneurysm: initial misdiagnosis and the effect on treatment. Eur J Surg 1998; 164:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/37\">",
"      Gloviczki P, Pairolero PC, Mucha P Jr, et al. Ruptured abdominal aortic aneurysms: repair should not be denied. J Vasc Surg 1992; 15:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/38\">",
"      Muluk SC, Gertler JP, Brewster DC, et al. Presentation and patterns of aortic aneurysms in young patients. J Vasc Surg 1994; 20:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/39\">",
"      Kiell CS, Ernst CB. Advances in management of abdominal aortic aneurysm. Adv Surg 1993; 26:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/40\">",
"      Tsai YW, Blodgett JB, Wilson GS, et al. Ruptured abdominal aortic aneurysm. Pathognomonic triad. Vasc Surg 1973; 7:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/41\">",
"      Rinckenbach S, Albertini JN, Thaveau F, et al. Prehospital treatment of infrarenal ruptured abdominal aortic aneurysms: a multicentric analysis. Ann Vasc Surg 2010; 24:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/42\">",
"      Assar AN, Zarins CK. Ruptured abdominal aortic aneurysm: a surgical emergency with many clinical presentations. Postgrad Med J 2009; 85:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/43\">",
"      Fillinger MF, Marra SP, Raghavan ML, Kennedy FE. Prediction of rupture risk in abdominal aortic aneurysm during observation: wall stress versus diameter. J Vasc Surg 2003; 37:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/44\">",
"      Vorp DA, Raghavan ML, Webster MW. Mechanical wall stress in abdominal aortic aneurysm: influence of diameter and asymmetry. J Vasc Surg 1998; 27:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/45\">",
"      Baxter BT, McGee GS, Flinn WR, et al. Distal embolization as a presenting symptom of aortic aneurysms. Am J Surg 1990; 160:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/46\">",
"      Hirose H, Takagi M, Hashiyada H, et al. Acute occlusion of an abdominal aortic aneurysm--case report and review of the literature. Angiology 2000; 51:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/47\">",
"      Pennell RC, Hollier LH, Lie JT, et al. Inflammatory abdominal aortic aneurysms: a thirty-year review. J Vasc Surg 1985; 2:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/48\">",
"      Rasmussen TE, Hallett JW Jr. Inflammatory aortic aneurysms. A clinical review with new perspectives in pathogenesis. Ann Surg 1997; 225:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/49\">",
"      Cavallaro A, Sapienza P, di Marzo L, et al. [Inflammatory aneurysm of the abdominal aorta. Study of 355 patients with aortic aneurysm]. Recenti Prog Med 2001; 92:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/50\">",
"      Hellmann DB, Grand DJ, Freischlag JA. Inflammatory abdominal aortic aneurysm. JAMA 2007; 297:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/51\">",
"      Lindblad B, Almgren B, Bergqvist D, et al. Abdominal aortic aneurysm with perianeurysmal fibrosis: experience from 11 Swedish vascular centers. J Vasc Surg 1991; 13:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/52\">",
"      Aboulafia DM, Aboulafia ED. Aortic aneurysm-induced disseminated intravascular coagulation. Ann Vasc Surg 1996; 10:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/53\">",
"      Fisher DF Jr, Yawn DH, Crawford ES. Preoperative disseminated intravascular coagulation associated with aortic aneurysms. A prospective study of 76 cases. Arch Surg 1983; 118:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/54\">",
"      Salo JA, Verkkala KA, Ala-Kulju KV, et al. Hematuria is an indication of rupture of an abdominal aortic aneurysm into the vena cava. J Vasc Surg 1990; 12:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/55\">",
"      Khaw H, Sottiurai VS, Craighead CC, Batson RC. Ruptured abdominal aortic aneurysm presenting as symptomatic inguinal mass: report of six cases. J Vasc Surg 1986; 4:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/56\">",
"      Lederle FA, Johnson GR, Wilson SE, et al. Yield of repeated screening for abdominal aortic aneurysm after a 4-year interval. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 2000; 160:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/57\">",
"      Lederle FA, Simel DL. The rational clinical examination. Does this patient have abdominal aortic aneurysm? . JAMA 1999; 281:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/58\">",
"      David M, Pelberg J, Kuntz C. Grey Turner's sign. QJM 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/59\">",
"      Diehm N, Baumgartner I. D-dimer measurement: a useful prognostic marker in surveillance of patients with abdominal aortic aneurysm? Eur Heart J 2011; 32:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/60\">",
"      Golledge J, Muller R, Clancy P, et al. Evaluation of the diagnostic and prognostic value of plasma D-dimer for abdominal aortic aneurysm. Eur Heart J 2011; 32:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/61\">",
"      LaRoy LL, Cormier PJ, Matalon TA, et al. Imaging of abdominal aortic aneurysms. AJR Am J Roentgenol 1989; 152:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/62\">",
"      American College of Cardiology Foundation (ACCF), American College of Radiology (ACR), American Institute of Ultrasound in Medicine (AIUM), et al. ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS 2012 appropriate use criteria for peripheral vascular ultrasound and physiological testing part I: arterial ultrasound and physiological testing: a report of the American College of Cardiology Foundation appropriate use criteria task force, American College of Radiology, American Institute of Ultrasound in Medicine, American Society of Echocardiography, American Society of Nephrology, Intersocietal Commission for the Accreditation of Vascular Laboratories, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. J Am Coll Cardiol 2012; 60:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/63\">",
"      Lederle FA, Johnson GR, Wilson SE, et al. Relationship of age, gender, race, and body size to infrarenal aortic diameter. The Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Investigators. J Vasc Surg 1997; 26:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/64\">",
"      Ernst CB. Abdominal aortic aneurysm. N Engl J Med 1993; 328:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/65\">",
"      Petersen MJ, Cambria RP, Kaufman JA, et al. Magnetic resonance angiography in the preoperative evaluation of abdominal aortic aneurysms. J Vasc Surg 1995; 21:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/66\">",
"      Ashton HA, Buxton MJ, Day NE, et al. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 2002; 360:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/67\">",
"      Lee TY, Korn P, Heller JA, et al. The cost-effectiveness of a \"quick-screen\" program for abdominal aortic aneurysms. Surgery 2002; 132:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/68\">",
"      Scott RA, Ashton HA, Kay DN. Abdominal aortic aneurysm in 4237 screened patients: prevalence, development and management over 6 years. Br J Surg 1991; 78:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/69\">",
"      Beales L, Wolstenhulme S, Evans JA, et al. Reproducibility of ultrasound measurement of the abdominal aorta. Br J Surg 2011; 98:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/70\">",
"      Schermerhorn M. A 66-year-old man with an abdominal aortic aneurysm: review of screening and treatment. JAMA 2009; 302:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/71\">",
"      Siegel CL, Cohan RH, Korobkin M, et al. Abdominal aortic aneurysm morphology: CT features in patients with ruptured and nonruptured aneurysms. AJR Am J Roentgenol 1994; 163:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/72\">",
"      Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation 2005; 111:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/73\">",
"      Litmanovich D, Bankier AA, Cantin L, et al. CT and MRI in diseases of the aorta. AJR Am J Roentgenol 2009; 193:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/74\">",
"      Ten Bosch JA, Teijink JA, Willigendael EM, Prins MH. Endovascular aneurysm repair is superior to open surgery for ruptured abdominal aortic aneurysms in EVAR-suitable patients. J Vasc Surg 2010; 52:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/75\">",
"      Mehta M, Taggert J, Darling RC 3rd, et al. Establishing a protocol for endovascular treatment of ruptured abdominal aortic aneurysms: outcomes of a prospective analysis. J Vasc Surg 2006; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/76\">",
"      Chien DK, Chang WH, Yeh YH. Radiographic findings of a ruptured abdominal aortic aneurysm. Circulation 2010; 122:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/77\">",
"      Boules TN, Compton CN, Stanziale SF, et al. Can computed tomography scan findings predict \"impending'' aneurysm rupture? Vasc Endovascular Surg 2006; 40:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/78\">",
"      Arita T, Matsunaga N, Takano K, et al. Abdominal aortic aneurysm: rupture associated with the high-attenuating crescent sign. Radiology 1997; 204:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/79\">",
"      Mehard WB, Heiken JP, Sicard GA. High-attenuating crescent in abdominal aortic aneurysm wall at CT: a sign of acute or impending rupture. Radiology 1994; 192:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/80\">",
"      Roy J, Labruto F, Beckman MO, et al. Bleeding into the intraluminal thrombus in abdominal aortic aneurysms is associated with rupture. J Vasc Surg 2008; 48:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/81\">",
"      Thammaroj J, Vungtal S, Srinakarin J. Predictive CT features in ruptured abdominal aortic aneurysm. J Med Assoc Thai 2006; 89:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/82\">",
"      Oderich GS, Panneton JM, Bower TC, et al. Infected aortic aneurysms: aggressive presentation, complicated early outcome, but durable results. J Vasc Surg 2001; 34:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/83\">",
"      Vogelzang RL, Sohaey R. Infected aortic aneurysms: CT appearance. J Comput Assist Tomogr 1988; 12:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/84\">",
"      Ou P, Sidi D, Bonnet D, Brunelle F. Infected pulmonary artery aneurysms: CT imaging findings. Eur J Cardiothorac Surg 2006; 29:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/85\">",
"      Gomes MN, Choyke PL. Infected aortic aneurysms: CT diagnosis. J Cardiovasc Surg (Torino) 1992; 33:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/86\">",
"      Lee MH, Chan P, Chiou HJ, Cheung WK. Diagnostic imaging of Salmonella-related mycotic aneurysm of aorta by CT. Clin Imaging 1996; 20:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/87\">",
"      Rozenblit A, Bennett J, Suggs W. Evolution of the infected abdominal aortic aneurysm: CT observation of early aortitis. Abdom Imaging 1996; 21:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/88\">",
"      Lee WK, Mossop PJ, Little AF, et al. Infected (mycotic) aneurysms: spectrum of imaging appearances and management. Radiographics 2008; 28:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/89\">",
"      Paravastu SC, Murray D, Ghosh J, et al. Inflammatory abdominal aortic aneurysms (IAAA): past and present. Vasc Endovascular Surg 2009; 43:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/90\">",
"      Stone WM, Fankhauser GT, Bower TC, et al. Comparison of open and endovascular repair of inflammatory aortic aneurysms. J Vasc Surg 2012; 56:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/16/32010/abstract/91\">",
"      Dalainas I, Nano G, Ranucci M, et al. Inflammatory abdominal aortic aneurysms. A 20-year experience. J Cardiovasc Surg (Torino) 2007; 48:305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15229 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32010=[""].join("\n");
var outline_f31_16_32010=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H478781272\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H135236269\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22314302\">",
"      ANEURYSM DEFINITION AND ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1382371318\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15830649\">",
"      CLINICAL PRESENTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15830656\">",
"      Asymptomatic AAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15830889\">",
"      Symptomatic (nonruptured) AAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15830929\">",
"      Ruptured AAA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22317736\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1382371370\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181175753\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181174707\">",
"      - Pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181175588\">",
"      - Limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181174722\">",
"      - Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15830547\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181174645\">",
"      - Abdominal palpation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1382374653\">",
"      - Ecchymosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1382372659\">",
"      - Vascular examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15828870\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15828721\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22322286\">",
"      Imaging asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22322988\">",
"      Imaging symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181166154\">",
"      - Ruptured versus nonruptured AAA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22314616\">",
"      - Are symptoms related to AAA?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22323992\">",
"      - Infected versus inflammatory AAA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1382370816\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478781272\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15229\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15229|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/4/23631\" title=\"algorithm 1\">",
"      Algorithm for the diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15229|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/26/27044\" title=\"diagnostic image 1\">",
"      Aortogram normal aorta and infrarenal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/38/43622\" title=\"diagnostic image 2\">",
"      CT scan infrarenal aortic aneurysm with thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/57/37782\" title=\"diagnostic image 3\">",
"      Pararenal abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/18/2337\" title=\"diagnostic image 4\">",
"      Ultrasound of normal abdominal aorta and aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/30/41447\" title=\"diagnostic image 5\">",
"      Arteriomegaly and aneurysmal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/30/15848\" title=\"diagnostic image 6\">",
"      Symptomatic abdominal aortic aneurysm with rapid expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/30/487\" title=\"diagnostic image 7\">",
"      Rapid expansion of abdominal aortic aneurysm on ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/24/30087\" title=\"diagnostic image 8\">",
"      Abdominal aortic aneurysm with aortocaval fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/2/17444\" title=\"diagnostic image 9\">",
"      Aortoduodenal fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/28/16835\" title=\"diagnostic image 10\">",
"      CT scan infrarenal aortic aneurysm with eccentric thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/13/42193\" title=\"diagnostic image 11\">",
"      Infrarenal abdominal aortic aneurysm on MRI and CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/56/35719\" title=\"diagnostic image 12\">",
"      Aortogram and CT scan of infrarenal abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/32/8719\" title=\"diagnostic image 13A\">",
"      Abdominal aortic aneurysm on ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/54/7009\" title=\"diagnostic image 13B\">",
"      Abdominal aortic aneurysm long and short axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/59/14265\" title=\"diagnostic image 14\">",
"      Abdominal aortic aneurysm extending to the iliac bifurcation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/49/2839\" title=\"diagnostic image 15\">",
"      Thoracoabdominal aortic aneurysm on axial CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/54/32611\" title=\"diagnostic image 16\">",
"      Abdominal aortic aneurysm on three-dimensional imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/14/232\" title=\"diagnostic image 17\">",
"      Ruptured abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/61/18391\" title=\"diagnostic image 18\">",
"      Ruptured abdominal aortic aneurysm on computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/36/6726\" title=\"diagnostic image 19\">",
"      Large ruptured abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/31/13815\" title=\"diagnostic image 20\">",
"      Ruptured abdominal aortic aneurysm with contrast extravasation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/35/36407\" title=\"diagnostic image 21\">",
"      Abdominal aortic aneurysm with crescent sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/5/31827\" title=\"diagnostic image 22\">",
"      Abdominal aortic aneurysm with bleb",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15229|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/29/9683\" title=\"figure 1\">",
"      Anatomy abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/14/43234\" title=\"figure 2\">",
"      Normal abdominal aorta",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/16/37126?source=related_link\">",
"      Aortic intramural hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25626?source=related_link\">",
"      Complications of endovascular abdominal aortic repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11450?source=related_link\">",
"      Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29304?source=related_link\">",
"      Iliac artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=related_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11225?source=related_link\">",
"      Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=related_link\">",
"      Overview of infected (mycotic) arterial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/62/34787?source=related_link\">",
"      Patient information: Abdominal aortic aneurysm (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/39/22130?source=related_link\">",
"      Patient information: Abdominal aortic aneurysm (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3065?source=related_link\">",
"      Popliteal artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24488?source=related_link\">",
"      Screening for abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_16_32011="Approach high K RAAS blockers";
var content_f31_16_32011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approach to patients at risk for hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Estimate glomerular filtration rate to assess specific risk of hyperkalemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discontinue nonsteroidal antiinflammatory drugs and other drugs that interfere with renal potassium excretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inquire about use of herbal preparations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prescribe a low-potassium diet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inquire about use of potassium-containing salt substitutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prescribe thiazide or loop diuretics to increase potassium excretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prescribe sodium bicarbonate to correct metabolic acidosis if present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When initiating ACE inhibitor, angiotensin receptor blocker, or aldosterone receptor blocker therapy, use low doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measure plasma potassium concentration one week after initiating therapy or after increasing dose of these agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If plasma potassium increases to &le;5.5 mmol/liter, decrease dose of drug and, if combination therapy is being given, discontinue one agent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In plasma potassium increases to &gt;5.5 mmol/liter despite above measures, discontinue these agents",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Palmer BF. Managing hyperkalemia caused by inhibitors of the renin- angiotensin-aldosterone system. N Engl J Med 2004; 351:585.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32011=[""].join("\n");
var outline_f31_16_32011=null;
var title_f31_16_32012="Causes of proteinuria children";
var content_f31_16_32012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of proteinuria in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Transient proteinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Associated with fever, exercise, seizures and/or hypovolemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Orthostatic proteinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Persistent proteinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Glomerular proteinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Primary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Minimal change disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Congenital nephrotic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        \"Finnish-type\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Mesangial sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Focal segmental glomerular sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        IgA nephropathy (Berger's disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Membranoproliferative glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Membranous nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Alport syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Secondary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Acute post-streptococcal glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Henoch-Sch&ouml;nlein purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Tubular proteinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Primary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cystinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Dent's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Wilson's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Lowe's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Polycystic kidney disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mitochondrial disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Secondary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Heavy metal poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Acute tubular necrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tubulointerstitial nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Secondary to obstructive uropathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32012=[""].join("\n");
var outline_f31_16_32012=null;
var title_f31_16_32013="Blood pressure and kidney related mortality in blacks";
var content_f31_16_32013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Blood pressure and kidney related mortality in blacks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 235px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relative risk of death from all causes of renal disease in blacks and whites according to systolic blood pressure in almost 350,000 men screened for the Multiple Risk Factor Intervention Trial. Patients with higher systolic pressures and blacks were at increased risk. A similar trend was seen for increasing diastolic pressures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Flack JM, Neaton JD, Daniels B, et al. Am J Kidney Dis 1993; 21 Suppl 1:31.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32013=[""].join("\n");
var outline_f31_16_32013=null;
var title_f31_16_32014="Number of burns US";
var content_f31_16_32014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Number of burn injuries compared by age and type occurring in the US between 1998 and 2008.",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 353px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The number of fire/flame, scald and contacts burns in the US between 1998 and 2008 are shown by age group. Fire/flame burns are the most common burn injury for all age groups except for children under age five years of age. Scald injuries are the most common burns for children under age five years of age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control. Web-based injury and statistics query and reporting system (WISQARS&trade;) 2009. Available online at: webappa.cdc.gov/sasweb/ncipc/mortrate9.html (Accessed on April 2, 2010).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32014=[""].join("\n");
var outline_f31_16_32014=null;
var title_f31_16_32015="Botulinum toxin injection sites for platysmal bands";
var content_f31_16_32015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Botulinum toxin injection sites for platysmal bands",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Examples of botulinum toxin injection sites for the treatment of platysmal bands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_16_32015=[""].join("\n");
var outline_f31_16_32015=null;
